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Dementia includes a range of neurological disorders characterized by memory loss and cognitive 
impairment. The most common early symptom is difficulties remembering recent events. With the 
development of the disease, symptoms occur such as disorientation, mood swings, confusion, more 
serious memory loss, behavioural changes, difficulties in speaking and swallowing, as well as walking. 
Alzheimer Disease (AD) is the most common form of dementia (50-70% of dementia cases). Increasing 
age is the most important risk factor for AD.  
 
In 2012 and 2015, the World Health Organization (WHO) presented reports suggesting that Alzheimer 
Disease and other dementias (ADOD) should be regarded as a global public health priority 1,2. Similar 
policy declarations have been presented by the European Union 3,  as well as by some individual 
countries. These policy declarations acknowledge trends that sometimes are described in terms of an 
epidemic or a “time-bomb”. In 2015, the number of people affected by dementia worldwide is 
estimated to be almost 47 million and the numbers are expected to reach 75 million by 2030 and 131 
million by 2050, with the greatest increase in low and middle income countries. The main reason for 
the increase is the global aging trend, since dementias are associated with a high age-specific 
prevalence, i.e., increasing prevalence with higher age. The global economic costs of dementia were 
estimated to be more than 600 billion USD in 2010 6 and 818 billion USD in 20155. The direct costs in 
the medical and social care sectors, 487 billion USD, represent 0.65% of the aggregated global gross 
domestic products (GDP), which is an enormous economic impact of a single group of disorders, 
especially considering that 87% of the costs occur in high income countries. Care of people with 
dementia impacts several sectors in the society with the social care (long term care and home services) 
and informal care sectors constituting the greatest proportions – even greater than direct medical care 
6. In cost of illness studies, European cost estimates in 2010 ranged between  238,6 billion USD 6 and 
105,6 billion € 7. 
 
However, the economic and societal burden of ADOD corresponds to the aggregate burden of people 
with dementia and their next of kin. The progressive nature of dementia can influence the whole life 
situation for families over many years. So far, no cure or substantial symptom relieving treatment is 
available for ADOD. Thus, the impact of this terminal disease is already today enormous, and given the 
predictions for the future, ADOD represents an enormous challenge for any society, and particularly to 
the ageing European society.   
Further knowledge is needed regarding the causes of ADOD. A more complete understanding of the 
disease mechanisms is required for new diagnostic and therapeutic strategies. There is also a need to 
establish new cell-based and animal models representing, as far as possible, major clinical components 
of the disease. For some studies, post mortem brain material will be most important, as animal models 
are unfortunately not always relevant. 
The global burden of AD and its economic ramifications coupled with the very slow progress towards 
finding effective treatments, leads to a call for a significantly larger investment in treatment research 
for AD as well as a broad public health approach towards disease prevention.  There is an opportunity 
and need to shift the treatment development paradigm towards ascertaining stronger proof of concept 
before launching very expensive phase 3 trials, to developing multimodal combination treatment 




Today, there exists a considerable heterogeneity in awareness among politicians, family members, 
health care professionals and related stakeholder groups about all different aspects of AD. New 
knowledge from research should be more quickly translated into practice and disseminated broadly. 
In all education programmes, health care professionals should be made aware of best available 
evidence-based care. Our public sector representatives and policy decision makers are ultimately 
responsible for assuring that clinical and basic research advances are effectively implemented into 
public health policy. Such an aim demands that our research agenda should be broad and engage a 
wide range of sectors. Policy decision makers in Europe must support universal access to better 
diagnosis, care planning, and to evidence-based treatment; at the same time, European countries 
should implement disease prevention programmes, and incent the undertaking of drug development 
and clinical trials. 
 
Target reader 
In this Lancet Neurology Commission Paper, we want to inform, guide and stimulate the public debate. 
We have assembled the leading health care professionals representing the areas of health economy, 
epidemiology, genetics, biologics, diagnoses, treatment, care and ethics. They have contributed with 
their experience, knowledge and viewpoints.  One key focus of this article is to inform policy decision 
makers in Europe to provide a firm basis for making proper decisions regarding best care and future 
research strategies for AD. 
 
KEY MESSAGES  [Panel 1] 
Areas of great importance when addressing the increasing problem with AD: 
- Demographic situation and societal costs 
o Increasing prevalence of Alzheimer’s disease will lead to an explosion in care costs 
which risks bankrupting care systems even in wealthy countries 
 
- Universal access to 
o Diagnosis, treatment and care 
o Participation in Clinical Studies 
o Databases, biobanks and data from finished clinical trials for researchers 
 
- Prevention of age-related cognitive impairment and dementia 
o Lifestyle intervention(s) 
 
- Strengthened research efforts to 
o Elucidate origin and mechanisms, and to develop relevant animals models for AD 
o Achieve research breakthroughs in basic AD biology, identify patient subtypes with 
homogenous etiology and prognosis 
 
- Awareness 
o Information to the public society, and need to change perceptions of the disease 




- Ethical considerations regarding 
o Diagnostic standards in the light of lacking disease modifying treatment  
o Risk of false positive diagnoses 
o Revealing genetic status of/to patients 




THE HEALTH ECONOMICS OF ALZHEIMER DISEASE 
 
Summary 
The societal costs of AD will increase dramatically as the global prevalence (ie total number of 
demented persons) of AD is projected to double about every 20 years through 2050. Even though recent 
studies have shown a somewhat decreased incidence, we still see an increased prevalence due to the 
demographic development with people living longer. As opposed to other chronic diseases where direct 
medical costs predominate, only about 16% of AD costs are direct – the majority of costs are indirect, 
including care and societal costs. New approaches to diagnose and treat AD should be evaluated in the 
context of new paradigms for cost-benefit analysis to maximize resource utilization and improve quality 
of life for AD patients. 
 
Current status 
The global economic burden of AD 
AD has considerable economic impact for each person and family affected. A 2011 study based on a 
multinational (Spain, Sweden, United Kingdom and United States) sample of 1222 patients, estimated 
that societal costs amount to about 1,000 GBP per month (14,500 EUR per year) in patients with a high 
level of ADL autonomy living at home, but rises up to 5,000 GBP per month (72,500 EUR per year) in 
patients requiring residential care. 8  The global prevalence of AD has been projected to almost double 
every 20 years, from 35.6 million patients affected globally in 2010 to 65.7 million in 2030 and 115.4 
million in 2050 9. The economic burden of AD is therefore expected to increase dramatically in coming 
decades. The 2010 World Alzheimer Report estimates the global costs of AD at 604 billion USD. In 2014 
the direct cost of AD for payers in the United States alone is estimated to 214 billion USD 
(http://www.alz.org/downloads/facts_figures_2014.pdf). For comparison, the global direct cost 
(resources used for prevention and treatment) and indirect cost (resources lost due to morbidity or 
mortality, such as lost work productivity) due to cancer was estimated to 290 billion USD in 2010, while 
the cost of diabetes was estimated to 472 billion USD, and the cost for all cardiovascular disease 
(including cerebrovascular disease) was estimated to 863 billion USD 10.  
For diabetes the direct costs amount to 80% of the global economic burden of the disease (almost 90% 
in high-income countries). Indirect costs constitute a minority of the costs of diabetes. This result stems 
from the availability of effective medical therapy, both to manage glucose controls and prevent 
complications, and to treat complications when they occur. By contrast, in AD, only 16% of costs were 
direct medical costs, while 41.7% were informal care costs and 42.3% social care costs. Thus the costs 
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of AD are mainly driven by resources spent to compensate for lost function, rather than resources used 
for treatment or prevention. The global market for acetylcholine esterase inhibitors, the mainstay of 
current pharmacological treatment of AD, was just over 4 billion USD in 2011, or less than 1% of the 
total costs of disease 11. This illustrates the absence of effective therapy for AD, but also the 
opportunity for new treatment options to provide benefit by improving health outcome and shifting 
costs from indirect to direct costs.  
 
The costs of diagnosing AD 
Insufficient diagnostic services remain a major barrier to patients with dementia receiving access to 
appropriate care. Although disease-modifying treatments are currently not available, timely and 
correct dementia diagnosis is a prerequisite for accessing important support services (e.g. living 
arrangements) and symptomatic treatment. 
It is estimated that only 20-50% of patients living with dementia have a documented diagnosis in 
primary care, while the figure is substantially lower in low - middle income countries 12. Based on data 
from the Swedish Dementia Registry /SveDem), the average cost of diagnosing a case of AD in primary 
care has been estimated to 753 EUR, while the corresponding cost in specialist care was 1,298 EUR in 
2010 13. 
Table 1 presents an example from Sweden of the costs involved in diagnosing a case with AD and a 
calculation of the cumulative costs as each new diagnostic procedure is added, starting in primary care 
and transitioning to specialist care.  
It should be noted that even though the maximal diagnostic cost (assuming all available diagnostic 
procedures are performed) is over 5,000 EUR, which is high compared to the costs of diagnosing other 
common chronic disorders for which diagnostic biomarkers are available (e.g. diabetes), this cost 
would only be a small fraction of the lifetime costs of care incurred by an AD patient.  
The costs for individuals with dementia remaining undiagnosed are largely borne by caregivers and by 
patients themselves. With the possible future availability of treatment, early identification of AD 
pathology becomes even more important. The cost-effectiveness of treatment will depend on the 
strategy for identifying patients eligible for that treatment.   
Indirect and intangible costs of AD 
Measuring the costs for informal care (care provided by family members and other non-professional 
caregivers) is associated with methodological issues, both for the estimation of the amount of time 
and how this time should be valued. Studies have indicated substantial willingness to pay among 
caregivers for reductions in the time required for caregiving tasks between 59 and 144 GBP per hour 
depending on the country of study 14. 
In addition to the direct and indirect costs of AD, the burden of illness of AD also includes the 
“intangible” cost of reduced quality of life and mortality. In health economic evaluations, this is often 
quantified in terms of quality adjusted life-years (QALYs, see box). 
 
Panel 2: QALYs and DALYs explained 
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One quality-adjusted life-year (QALY) corresponds to a year spent in perfect health. Years spent in less 
than perfect health states (e.g., with Alzheimer’s disease) are assigned a weight (health utility), 
calculated based on preferences for the health state. A weight of 1 signifies perfect health, while a 
weight of zero means the health state is equivalent to death. Weights below zero are also theoretically 
possible, indicating a health state worse than death.  
 
Disability Adjusted Life Years (DALYs) is a construct that like the QALY summarizes morbidity and 
mortality into a single index. The number of DALYs is calculated as 
DALY=YLL+YLD 
YLL (years of life lost) corresponds to the number of deaths multiplied by the standard life expectancy 
at the age at which death occurs. The formula for YLL (without including social preferences), is  
YLL = N x L 
where: 
 N = number of deaths   L = standard life expectancy at age of death in years 
To estimate the years of life with disability (YLD) for a particular disease over a certain time period, the 
incident cases in that period is multiplied by the mean disease duration (until remission or death) and 
a disability weight reflecting the severity of the disease on a scale from 0 (perfect health) to 1 (dead). 
The basic formula for YLD is the following (again, without applying social preferences): 
YLD = I x  DW X L 
where:  
I = number of incident cases   DW = disability weight  L = average duration of disease  
 
Utility weights for disease states with AD have been calculated with the Health Utility Index (HUI) 
ranging from 0.69 in mild disease to 0.14 in terminal disease 11. Using a different instrument, the 
EuroQoL EQ-5D, weights have been estimated ranging from 0.69 in mild dementia to 0.33 in severe 
dementia 15. For comparison, population mean utility weights in the age group 65-74 years is 0.78 and 
the utility weight for legal blindness has been estimated to 0.2616.  The DEMQoL instrument was, unlike 
the HUI and EQ-5D, specifically developed to measure quality of life in dementia, and a tariff linking 
responses on the DEMQoL to health utilities has been developed 17 . Most studies have relied on proxy 
assessments of the health status of AD patients. The agreement between patient and proxy ratings 
with the EQ-5D and DEMQoL have varied in different studies, however agreement is generally poorer 
in severe disease states. The quality of life of caregivers themselves may also be affected; studies have 
indicated an increased prevalence of depression in caregivers to patients with AD 359. However, no 
direct link between caregiver health utilities and the severity dementia in the patient they care for was 
seen, using the EQ-5D 15. More specific and sensitive instruments may be required to measure the 
potential disutility associated with caregiving.  
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WHO has estimated the disability weights for mild dementia: 0.082, moderate dementia: 0.346 and 
severe dementia: 0.438 (ref: WHO methods and data sources for global burden of disease estimates 
2000-2011, (http://www.who.int/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf). On this 
scale, zero (0) equals no disability and one (1) equals complete disability. In 2012, AD and other 
dementias were estimated to cause 18 million DALYs globally. This is just 0.7% of all DALYs, however 
in European women aged 70+, AD causes 6% of DALYs '(WHO health statistics and information systems, 
estimates for 2000-2012, 
http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html).  
Assuming the QALYs lost would be equivalent to the number of DALYs, and valuing each QALY at 3 
times the gross national product (GDP) per capita, the intangible cost of illness of AD and other 
dementias is 550 billion USD (Table 2). Thus the intangible cost of dementia might be almost as high 
as the total direct and indirect costs of care for AD. This is consistent with previous estimates indicating 
that intangible costs for non-communicable diseases may be close to the direct and indirect costs 




Current challenges and future goals 
There is a strong imperative to attempt to reverse current course of increasing incidence and morbidity 
from AD by way of new treatment modalities and strategies for prevention and care. Projections of 
future burden of illness can underestimate the effects of introduction of new medical technology. In 
the case of AD, the main source of technological change over the foreseeable future is expected to 
come from the potential introduction of new treatments.  Clinical trials are currently ongoing with 
several compounds with the objective of demonstrating a reduction in the decline of cognitive function 
and the progression of ADL disability, or the progression from preclinical states to AD dementia.   
As new options for diagnosing and treating AD become available, these will undergo two stages of 
evaluations: the first by regulatory agencies to determine benefit/risk, and the second by Health 
Technology Assessment (HTA) agencies and payer organizations to determine value relative to current 
standard of care and to inform coverage and reimbursement decisions. Tools are needed that allow 
determination of the value of these new technologies with sufficient degree of certainty in order to 
make correct coverage decisions at the time these are introduced. If a new treatment receives 
regulatory approval but faces negative reimbursement decisions due to inadequate demonstration of 
value, uptake of the new treatment will be minimal and patients and caregivers will miss out on the 
potential treatment benefits.  
A major issue in demonstrating the value of new treatments for AD is that the benefits of such 
treatments will largely fall outside of the health care sector, since most of the potentially preventable 
costs of dementia relate to long-term care and burden on informal caregivers. It is common that 
budgeting constraints prevent funds from flowing freely between “silos,” so that for instance savings 
due to reduced need for long-term care could be used to finance increasing costs for drug therapy. It 
is very likely that increasing availability of treatment options for AD will require increasing medical 
expenditures, at least in the short term. Reductions in the need for informal caregiving will benefit 
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caregivers but this does not appear on any budget and cannot easily offset treatment costs. Further, 
funding decisions sometimes adopt a short time horizon or apply discounting (by which the value of 
future costs and effects is decreased to reflect negative time preferences), which reduces the value of 
future costs and benefits. A new therapy with the potential of changing the long term course of 
Alzheimer's disease will likely require substantial upfront investments in diagnosis and drug costs, 
while the full benefits may take years or decades to realize.  
The main value of therapies affecting the long-term course of disease will lie in shortening the time 
spent in the severe stages of dementia. However, this is not an outcome variable that is being studied 
in trials of new drugs. Rather, this value will need to be estimated through forecasting models before 
treatments are even introduced in clinical practice. The accuracy of such models depends on the 
availability of long-term, high-quality data on disease progression rates, costs and health outcomes. 
Several epidemiological studies have followed patients with AD longitudinally from diagnosis until the 
end stages (Swedish National Study on Aging and Care (SNAC), EADC-ICTUS, etc). Much less data are 
available from the very early phases of AD, before the onset of dementia. As new therapies are being 
evaluated in preclinical states of dementia, new data sources are needed to model accurately the long-
term benefits of these treatments. 
The results from economic models are highly contingent on assumptions around long-term treatment 
benefits that will not be immediately available from clinical trials. For instance, the potential impact of 
treatment on overall mortality has important implications for costs of care18. If treatment improves 
survival but prolongs the time spent in with severe dementia, it might only bring marginal health 
benefits for patients but increase care costs substantially. However, if late-stage morbidity is 
compressed and patients spend proportionally more time in less severe states, cost savings can be 
substantial. Thus, the goal of therapy is not merely to slow disease progression, but to minimize the 
time spent in a severe dementia condition and maximize the time with conserved cognitive resources, 
ADL independency and quality of life. 
In addition, patients receiving new therapies will need to be followed in clinical practice, and data 
collected on resource use and health outcomes in order to gain further understanding of the value 
provided by new treatment options as they are being implemented in practice. Few countries have 
infrastructure to follow patients prospectively (e.g., the Swedish National Dementia Registry 18). The 
data collected may not immediately be relevant for other countries due to important international 
differences in dementia care organization and delivery; observational studies collecting data across 
several countries is an important addition; one example is the ICTUS study, organized through the 
European Alzheimer's Disease Consortium (EADC). 
 
RECOMMENDATIONS 
 Economic evaluations of new methods for diagnosing and treating AD should include all 
elements of costs, and adopt a broad measure of outcome that captures full societal benefits 
of treatment.  
 Accurate, reliable and timely diagnosis is a requisite for providing cost-effective care with 
currently available therapies and of key importance for realizing the potential value of novel 
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disease modifying therapies. The cost-effectiveness of new therapies will be uncertain at the 
time they are introduced, since there is limited experience of long-term benefits while up-front 
treatment costs can be substantial.   
 Follow-up with routine data collection in clinical practice on resource utilization and patient-
relevant outcomes will facilitate the evaluation of treatment benefits and cost-effectiveness in 




ALZHEIMER’S DISEASE AND DEMENTIA IN THE POPULATION: EPIDEMIOLOGICAL ASPECTS 
Summary 
Additional epidemiologic surveillance is required to provide a complete picture of the epidemiology of 
dementia in Europe and worldwide. AD accounts for up to 70% of all dementia cases in most studies, 
but more information about stage, clinical progression and risk factors is needed. Temporal and 
geographic studies should be extended. AD is an age related disease developing over time, but it is not 
an inevitable consequence of aging – up to 50% of people reaching age 90 are free of dementia. More 
work is needed to understand why. 
 
As stated in the introduction, dementia is a disabling syndrome characterized by progressive 
deterioration in multiple cognitive domains that is severe enough to interfere with daily functioning, 
including social and professional functioning 19. Thus, dementia has an enormous impact on daily life 
of patients, their families, as well as on the society.  
 
The burden of AD or dementia, which is projected to surge in the coming decades, poses a serious 
threat to the sustainable development of economy and social welfare system of the European society, 
along with continuous increases in the ageing population. Epidemiological studies generate knowledge 
concerning occurrence (e.g., prevalence and incidence), distribution (e.g., demographic, geographic, 
and temporal variations), determinants (e.g., genetic and non-genetic risk or protective factors), health 
economics (e.g., costs of health care and cost-effectiveness of treatment and intervention), and 
intervention strategies (e.g., therapeutic and preventive intervention) of AD and dementia. In the 
European Union (EU) countries there is a rather good knowledge about the number of people with 
dementia, but there are less data on the prevalence of dementia in the Eastern European countries 
(Figure 1). Such knowledge is critical for policy decision makers to cope with the challenges of the 
devastating disorder because it will help design and develop care and social welfare system, and 
appropriately relocate the limited resources for care of people with the disease.  
 
In the past decade, the work of the 10/66 Dementia Research Group has helped to better understand 
the epidemiology of dementia in middle- and low-income countries such as Brazil, India, and China 20-
22. The age-standardized prevalence of dementia for people aged 60 years or over is 5%-7% in most 
regions of the world. Recent systematic reviews and meta-analyses provide more precise global and 
regional estimates of dementia prevalence 3,23,4,24. These analyses also demonstrate rather similar 
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patterns of age-specific prevalence of AD and dementia among worldwide regions, although 
substantial variations are evident among oldest old groups 4,24,25,26 (Figure 2).  
Given the diversity in social service system and economic development across Europe, there is a strong 
need for epidemiological studies on dementia and AD in Eastern and Middle European countries to 
complete the picture 27,28. In addition, higher prevalence and incidence of dementia and AD in women 
than in men, especially among the oldest old, have been reported in numerous studies in Europe and 
Asia, although finding of the gender difference has been less consistent in studies from North America 
29.  
Although AD diagnosed by current clinical criteria contributes to 60-70% of all dementia cases, 
autopsy-verified studies have suggested that mixed dementia owing to cerebral mixed vascular and 
neurodegenerative pathology accounts for the large majority of all dementia cases. In addition, early-
onset AD that occurs before 65 years of age accounts for up to 5% of all AD cases. Early-onset familial 
AD is a rare form of AD caused by mutations in presenilin (PSEN)-1, PSEN-2, and amyloid precursor 
protein (APP) genes 30. Non-familial (sporadic) early-onset AD often has no reliable family history, and 
may have a later onset of AD than familial early-onset AD 31. Late-onset sporadic AD is the most 
common form of AD, accounting for about 90% of all AD cases. Late-onset AD is a multifactorial 
disorder that involves multiple biological mechanisms in which genetic susceptibility (e.g., APOE ε4 
gene), environmental factors (e.g., psychosocial, lifestyle, and biological factors), and their interaction 
over the lifespan contribute to the pathological processes and clinical expression of the disease. 
As mentioned above, the costs of care for patients with dementia largely depend on disease severity32; 
patients with mild dementia have very different medical and social needs than those in more severe 
stages. However, prevalence data of dementia according to severity or stage are scarce. 33,34  
 
Living with dementia 
Numerous population-based studies have suggested that people aged 65 years or above survive an 
average of three to nine years after a diagnosis of dementia, while some live as long as 20 years 35-43. 
Clinical deterioration of people with dementia, and with AD in particular, is progressive, although the 
rate of decline in mental and physical function may vary. According to the WHO, in general, people 
with dementia can be expected to be in the mild or early stage of dementia (e.g., forgetful, some 
difficulty with language, and mood changes) for the first year or two, in the moderate or middle stage 
(e.g., very forgetful, increasing difficulty with speech, and need help with self-care activities) for the 
second to fourth or fifth years, and in the severe or late stage (e.g., serious memory disturbances and 
nearly total dependence and inactivity) for the fifth and more years 23. Data from the Kungsholmen 
Project of community-dwellers aged 75+ years in central Stockholm suggest that people with incident 
dementia spend approximately a few months in the very mild dementia stage, two years in the mild 
phase, one to two years in the moderate, and one year in the severe stage 44. Women with dementia 
live longer than men, owing to a longer survival in the severe stage 44,45. It has been estimated that 
more than 50% of dementia cases reach the severe stage within three years. A population-based study 
of prevalent dementia cases showed an increase in the proportion of severe dementia from 19% at 
baseline to 48% after three years, and to 78% after seven years 46. By contrast, a population-based 
prospective Cache County study of dementia progression found that a significant proportion (40-50%) 
of patients with incident AD deteriorate slowly in cognitive and functional ability (e.g., 1-point decline 
per year on MMSE score and clinical dementia rating sum of boxes) 47.  In spite of numerous studies 
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46,48-51, the effect of cognitive decline on specific tasks of self-care activities of daily living (ADL) (e.g., 
eating, dressing, and toileting) or instrumental ADL (e.g., shopping, cooking, and basic housework) is 
still not completely clarified, owing largely to relatively short periods of follow-up for most studies 52-
54. Furthermore, the knowledge concerning the effect of potential compensatory factors (e.g., social 
engagement, cognitive training, and mentally-stimulating activity) is still very limited.  
 
In many countries, the health care policy aims at avoiding or postponing admission of patients with 
dementia to nursing homes and institutions; informal care (e.g., home care provided by families and 
friends) as compared to formal care (e.g., care provided at nursing homes or institutions) tends to be 
less costly for the social security system55, although this may be not true when the costs are assessed 
from the society perspective 56. In addition to the health and social care policies, the proportion of 
people with dementia living at home varies depending on several factors, mainly linked to 
characteristics of patients (e.g., severity of cognitive and functional disability) and caregivers (e.g., 
perceived burden and coping strategies), and cultural aspects. 
 
Worldwide, the majority of people with AD or dementia are cared for at home, usually by a spouse or 
a daughter. The proportion of people with dementia living at home is higher in low and middle income 
countries than in high income countries, and in rural rather than urban areas. In high income countries, 
the estimated proportion of people with dementia living at home is around 66%, compared to 
approximately 94% in low- and middle-income countries 57. A longitudinal study from Australia found 
that several baseline clinical features of dementia predicted a shorter time period until 
institutionalization, such as lower cognitive and functional ability, more neuropsychiatric symptoms, 
and use of antipsychotic medications 58. Moreover, greater deterioration in these factors within the 
first three months after baseline also predicted faster time until institutionalization, which indicates 
that rate of disease progression is an important factor.  
 
Dying with dementia  
Several follow-up studies have consistently shown that dementia shortens life-expectancy, depending 
on age of dementia onset, gender, and dementia subtypes 45. Data from the UK Medical Research 
Council Cognitive Function and Ageing Study (MRC CFAS) showed that the prevalence of dementia and 
severe cognitive impairment in the period before death rises steeply with age; by the age of 90 years, 
around 60% of people died with dementia or severe cognitive impairment 59,60. Finally, not only does 
dementia shorten life expectancy but a subtle decrement in global cognitive function, even in the 
absence of clinically recognized impairment, is strongly associated with shorter survival 61. 
 
It has been estimated that the potential years of life lost (YLL) due to dementia in subjects over age 75 
varies from three to five years44,45. A Swedish study of people aged 75+ suggested that the impact of 
dementia on lifespan (YLL, 3.41) is similar to that of cardiovascular disease (CVD) (YLL, 3.58), but is 
lower than cancer (YLL, 4.40) (Figure 3)44. The mortality in people with dementia or CVD is two times 
higher than the mortality in subjects without those disorders, whereas people with a diagnosis of 
cancer have a three times higher mortality risk compared with people without cancer 44. Further, the 
estimated years lived with or lost due to one of those disorders is most dependent on the age at 
diagnosis, being higher among the younger old people (75-84 years of age) than in the oldest old group 
(85 years and above). This is supported by a recent study showing that the mortality risk for AD was 
higher for younger old ages than for oldest old people (relative risk 4.30 vs. 2.77, P<0.05)62. 
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AD and other dementias are substantially under-reported on death certificates and medical records, 
although the situation has been improved in the last 2-3 decades, owing to increasing awareness of 
the disease by health professionals and the public. The contribution of dementia to mortality is difficult 
to assess based solely on death certificates because dementia is rarely considered as an immediate or 
an underlying cause of death in death certificates 63. Indeed, older people often experience different 
chronic and acute illnesses that may be related to the dementia process 64 but may be the direct or 
indirect cause of death. A population-based study estimated that the population attributable risk (%) 
of death owing to AD was about 36% for people ages 75+, and that in the US, AD may contribute to 
close to as many deaths as heart disease or cancer 62. Similarly, the US nationwide study estimated 
that among individuals aged 65 years or older, deaths with AD comprised 32% of all deaths in 2010, 
with the proportion being projected to reach 43% by 2050 65. According to the 2013 Alzheimer’s 
Association report, AD was the sixth leading cause of death across all ages, and the fifth leading cause 
of death for people aged 65+ years in the USA 66. In UK, the rank of the age-standardized YLL for AD 
increased from the 24th in 1990 to the 10th in 2010 67. When death with dementia is examined, the 
proportion of deaths attributable to dementia reached approximately one-third in persons aged 
85+ years 68. 
 
Temporal and geographical variations  
Studying the secular trends and geographic variations of dementia occurrence and their determinants 
is crucial for policy development in a world facing a rapid increase in absolute number and proportion 
of older adults in the population. Thus, there has been increasing interest in investigating the time 
trend of dementia occurrence (e.g., incidence and prevalence) (Table 3), as well as possible geographic 
differences of dementia distribution in the past few years. Although findings from various regions 
across the world have not been consistent, several population-based community surveys point to a 
stable or declining age-specific prevalence or incidence of dementia among elderly people in Europe 
and North America 69,70. Identifying temporal and geographical variations in prevalence and incidence 
of dementia may help identify modifiable risk or protective factors for the dementing disorders.  
North America. In North America, a decline in prevalence of dementia and cognitive impairment has 
been reported in a few studies from the US 71-73, and another study suggested a stable age-adjusted 
prevalence of dementia and AD in African American people aged 70+ from 1992 to 2001 74. In addition, 
several population-based studies from the US have also shown a decline (2-3% per annum) in incidence 
of dementia and AD from the 1990s through the 2000s 75,76.  
Europe. In Europe, two population-based surveys in Sweden showed a relatively stable prevalence of 
dementia over the last 2-3 decades 68,77. The repeated cross-sectional surveys conducted in 1988 and 
1994 in Spain suggested a stable prevalence of dementia in women but a decreased prevalence in men 
78. Finally, the large-scale study from the MRC CFAS provided evidence that a cohort effect might exist 
in the age specific prevalence of dementia among the community residents such that later-born 
populations had a lower likelihood of prevalent dementia than those born earlier in the past century, 
whereas the prevalence of dementia among older people living in care settings increased 79. However, 
the MRC CFAS found no evidence of variations in incidence or prevalence of dementia among five 
regions in England and Wales. A systematic review did reveal evidence of geographical variations in 
the prevalence or incidence of dementia and, specifically, a higher risk of AD in rural as opposed to 
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urban areas 25. Studies from the Netherlands, Sweden, and England also are suggestive of a trend of 
declining incidence of dementia in the communities 68,79,80.  
Asia-Pacific region. In mainland China, the prevalence of dementia and AD increased steadily across all 
age groups of people aged 55 years and older from the 1990s to 2010 81, although the trends might be 
partly due to the methodological variations over different time periods (e.g., diagnostic criteria, range 
of age, and sampling methods) 82. The number of people with dementia was estimated to increase by 
63.5% from 2000 to 2010 in China, compared to an average 46.5% increase worldwide during almost 
the same time period 4,24, largely owing to a faster pace of population ageing in China than the 
worldwide trend. The rural and urban difference in prevalence of dementia and AD is supported by a 
large scale study from China 83, suggesting that early experience or exposure to rural living (e.g., low 
education and SES) may contribute to the association between rurality and an increased risk of late-
life dementia and AD. In Hong Kong, China, the systematic review revealed that the prevalence of 
clinically diagnosed dementia among community-dwelling people aged 70 and above increased from 
4.5% in 1995 to 9.3% in 2005-2006 84. In Japan, the population-based Hisayama Study suggested that 
the age-specific prevalence of all-cause dementia and specific AD significantly increased from the early 
1990s to 2005 in a general population of elderly people 85. After all the methodological variations were 
carefully evaluated, the increasing trend in the prevalence of dementia in Japan was confirmed by a 
systematic review 86. This suggests that earlier estimates of dementia burden and long-term trend in 
the world, especially in the Asia-Pacific region, are likely to be underestimated 87. 
 
Given the numerous factors that can affect estimates of the occurrence of dementia, it is not a surprise 
that temporal trends of dementia may vary within and among countries.  For instance, the upward 
trend in prevalence of dementia from the 1990s to 2010 in China is consistent with the time trends of 
prevalence of stroke and ischemic heart disease and related lifestyle and metabolic risk factors (e.g., 
smoking, physical inactivity, obesity and overweight, hypertension, and diabetes) over the similar 
periods, 88 together with a faster pace of population ageing in China. Similarly, a substantial reduction 
in the prevalence of dementia in England from 1991 to 2011 and the suggested reduction of dementia 
risk in the Netherlands and Sweden imply that changes in health behaviours (e.g., smoking cessation 
and physical activity), improved management of cardiovascular risk factors (e.g., hypertension and high 
cholesterol), and a reduced risk of stroke and heart disease have had a great effect in reducing the risk 
of dementia and AD, possibly by reducing number of brain lesions, thus preventing and delaying the 
onset of dementia in the general community 79,89. In support of this notion, the Rotterdam study has 
provided evidence that the suggested decline in dementia incidence over time might be due to less 
brain atrophy and less cerebral small-vessel disease 80. 
The new evidence for the temporal trend of dementia occurrence will affect estimates of worldwide 
and regional future burden of disease because earlier estimates and projections were based on the 
assumption that age-specific prevalence of dementia stayed constant. Even for regions such as Europe 
with evidence of declining prevalence or incidence, future burden of dementia is still likely to increase 




Dementia is not an unavoidable consequence of ageing  
Not all nonagenarians, nor even centenarians develop AD or dementia 90,91, which implies that some 
people are able to reach very advanced ages while escaping severe mental deterioration. 
Neuropathologically, the population-based 90+ Autopsy Study of people aged 90 and older in USA 
found that nearly half of people with dementia did not have sufficient neuropathology in their brain to 
explain their cognitive symptoms 92. On the contrary, intermediate or high Alzheimer pathology was 
present in about one-third of very old people without dementia or cognitive impairment 93. 
Furthermore, the association between pathological hallmarks of AD (e.g., neurofibrillary tangles and 
neuritic plaques) and clinical syndrome of dementia was less strong in oldest old persons than in 
younger old persons 18,94. These findings imply that by providing brain reserve and cognitive reserve, 
certain compensatory factors (e.g., high education, social engagement, and maintenance of 
cardiovascular health) may play a part in allowing people to tolerate a significant amount of Alzheimer 
pathology until very old without manifesting obvious dementia syndrome, even in carriers of the 
susceptibility genes such as APOE ε4 allele 95. 
 
Risk and protective factors  
Dementia, including AD, is a multifactorial disorder that is determined by the interplay of genetic 
susceptibility and environmental factors over the lifespan (Table 4). Older age is the strongest risk 
factor for dementia, and patients developing dementia before age 65 owing to gene mutations account 
for only a very small proportion of all cases (5%). The majority of dementia and AD cases are at least 
partly contributable to cardiovascular risk factors (e.g., hypertension, diabetes, and obesity) and 
psychosocial factors (e.g., education, social engagements, and leisure activities), which represent the 
major modifiable factors that can be targeted for interventions. The qualitative and quantitative effects 
of most of these factors on AD and dementia have been evaluated in numerous systematic reviews 
and meta-analyses. 96,97 
(1) Lifestyle-related cardiovascular risk factors; Smoking is associated with a 50-80% increased risk of 
dementia; even second-hand smoking could increase risk of dementia. Diabetes in middle age or later 
in life increases risk of not only vascular dementia but also AD by about 50%. On the contrary, light-to-
moderate alcohol consumption has been associated with a 30-40% reduced risk for dementia. Likewise, 
regular physical activity, even low-intensity activity such as walking, may reduce dementia risk by 
approximately 40%. Of note, systematic reviews from the life-course perspective have revealed age-
dependent associations of dementia and AD with major cardiometabolic risk factors, such as 
hypertension, high cholesterol, and obesity or overweight, such that having these factors in young 
adulthood or middle age (e.g., age <65), but not necessarily in late life (e.g., age ≥75), is associated with 
an increasing risk of dementia and AD; low levels of these metabolic factors in later life may represent 
part of the prodromal dementia. These findings have significant implications for public health because 
it indicates the optimal time windows (e.g., young or middle ages) for intervention targeting these 
factors in order to be effective in delaying the onset of dementia. More importantly, population-based 
studies have also shown that concurrently having multiple cardiovascular risk factors (e.g., smoking, 
hypertension, diabetes, and hypercholesterolemia) at middle age or several years prior to dementia 
onset incrementally increases the risk for dementia and AD 98. Risk indices at middle age or later life 
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for predicting risk of dementia have been developed and validated, with the accuracy ranging between 
70% to 80%, in which unhealthy lifestyle and cardiometabolic risk factors constitute major part of the 
indices 99-103. This implies that intervention targeting multidomains is likely to be more effective in 
delaying dementia onset.  
(2) Psychosocial factors; High educational achievements in early life have been consistently associated 
with a reduced risk of late-life dementia and AD in numerous studies104 . Cognitive activity or mentally-
stimulating activity (e.g., reading, doing crossword puzzles, and playing games), which may be related 
to early life education, also has shown protective effect against dementia. Rich social network and 
social engagement are associated with a decreased risk of dementia. Finally, the temporal relationship 
between depression and dementia in older people remains debatable, but evidence from long-term 
follow-up studies has emerged that depression may act as a risk factor for dementia and AD105,106.  
 
Potential  pathological mechanisms 
In the last decade, population-based neuroimaging and neuropathological studies have significantly 
contributed to the understanding of pathophysiological mechanisms of cardiovascular risk factors and 
psychosocial factors in AD and dementia. Evidence from the multidisciplinary research supports the 
vascular mechanisms and reserve hypothesis to be involved in the development and clinical 
manifestations of dementia and AD. This has significant implications for preventing or postponing 
onset of dementia because the two pathways can be targeted for intervention.   
Vascular mechanisms. It is well known that major cardiovascular risk factors (e.g., hypertension and 
diabetes) cause cerebrovascular lesions. Recent research also provides evidence that these factors may 
contribute to global and regional brain atrophic lesions and neurodegenerative pathologies107-109. 
Biologically, cerebral atherosclerosis and neurodegeneration may share common mechanisms, such as 
oxidative stress, inflammation, and toxic beta-amyloid peptide (Aβ) deposition. Intracranial 
atherosclerosis could also induce cerebral hypoperfusion and trigger accelerated deposition of Aβ, 
which in turn contributes to cognitive deterioration and dementia110. Furthermore, cerebral macro- 
and microvascular and neurodegenerative pathologies may represent coinciding processes in ageing 
that converge to cause additive brain damage, and thus to promote clinical manifestation of dementia 
syndrome111-114. This is supported by numerous neuroimaging and neuropathological studies, which 
show that the majority of clinically diagnosed dementia and AD cases among older persons living in 
the community are due to mixed vascular and degenerative pathologies in the brain 115-117. 
Reserve hypothesis.  Psychosocial factors, such as social network, social engagement, and cognitive 
activities may postpone the onset of the dementia syndrome by increasing cognitive reserve capacity, 
such that older people with higher cognitive reserve need more pathology in the brain than those with 
lower reserve to express symptoms of AD and dementia. Neuropathological studies have shown that 
education, cognitively-stimulating activity, and social networks modify the association of 
neurodegenerative pathologies to cognitive function, such that cognitive function remains higher in 
subjects with a heavier burden of global neuropathology if they also have high education or rich social 
networks 118-120. These studies illustrate that psychosocial factors, such as high education, mentally-
stimulating activity, and rich social networks, could compensate for the deleterious effects of 




Public health implications 
A 2010 NIH state-of-the-science review concluded that firm conclusions cannot be drawn about the 
association of any modifiable risk factor with cognitive decline or AD 121. Indeed, extant studies have 
been hampered by methodological issues, such as self-reported measurements of exposures, 
inconsistent control of relevant confounders (e.g., depression), and variations in diagnostic procedure 
and criteria of dementia and AD 122,123. However, a different scenario would have emerged if the 
evidence was evaluated from a life-course perspective (i.e., early life, middle age, and later in life) 97. 
For instance, a systematic review of epidemiological studies on seven modifiable risk factors (e.g., low 
education, smoking, diabetes, midlife hypertension, midlife obesity, depression, and physical 
inactivity) suggested that a 10% reduction in exposure to these risk factors could potentially prevent 
up to 1.1 million AD cases worldwide 96. Therefore, the life-course approach should be kept in mind 
when designing any intervention programmes 124. It has been suggested that some intervention 
measures (e.g., pharmacologic control of hypertension), if implemented in middle-aged or young-old 
adults, may be effective in reducing the incidence of dementia125. Thus, although age remains the 
major driving force for dementia development 126, current evidence tends to support the notion that 
interventions targeting multiple modifiable risk factors, if implemented earlier in life, may be more 
promising in reducing the risk or in postponing the onset of dementia 29 , and several intervention 
studies to assess effect on disease onset are ongoing in Europe 127. It has been estimated that delaying 
the onset of dementia by five years would halve prevalence of dementia and substantially decrease 
the number of dementia cases in the community; delaying the onset of dementia by even two years 
also would have significant public health, economic and societal benefits 128 
 
Traumatic brain injury and dementia  
 
A systematic review found no convincing evidence supporting an increased risk of AD or dementia 
following mild traumatic brain injuries129. However, several epidemiological studies have suggested 
that a history of head trauma or traumatic brain injury (mTBI) is associated with an increased risk of 
dementia and results in an earlier age at onset compared to those without a head trauma 130-133. Indeed, 
autopsy studies have reported significant amyloid β (Aβ) deposition in up to 30% of persons who die 
acutely following a brain injury 134,135. In line with greater brain Aβ deposition, studies also suggest that 
brain interstitial fluid levels of the aggregation-prone 42 amino acid long Aβ form, Aβ42, and the axonal 
injury marker tau are higher immediately after severe TBI 136-138. A history of head trauma is associated 
with greater Aβ deposition in patients with MCI 139 and recent data suggest that an important cause of 
dementia in individuals with a lifestyle associated with increased risk of repetitive mTBI (or concussion; 
the terms are used interchangeably) is chronic traumatic encephalopathy (CTE), a neuropathologically 
defined condition previously only described in professional boxers 140. It is now clear that athletes 
engaged in contact sports such as boxing, American football and ice hockey constitute a new group at 
risk for dementia. The molecular mechanisms seem to involve diffuse axonal injury and Aβ and tau 
deposition due to repetitive acceleration-deceleration and rotational forces on the brain tissue140. The 
magnitude of this potential epidemic is currently unknown but worrying data on smaller hippocampus 
volume in American football players, CTE pathology in ice hockey players, American footballers and 
military personnel, and biomarker changes indicating brain injury following subconcussive head blows 







Epidemiology provides powerful tools to illustrate the burden and geographic variations of dementia 
and AD in the society, to understand the natural history as well as risk and protective factors for 
dementia, to identify the populations at an elevated risk for dementia, to monitor the time trends in 
occurrence of dementia, to evaluate the new therapeutic approaches for dementia, and to assess the 
different strategies for intervention against dementia. Indeed, significant progresses have been made 
in many of these epidemiological aspects of dementia and AD in the last 2-3 decades. However, we are 
still far away from developing a cure or efficacious pharmacotherapy for AD and dementia, from 
providing the cost-effective medical and social care for numerous patients affected by dementia, and 
from implementing successful intervention strategies against dementia. From epidemiological 
perspective, implementing the following recommendations is critical to meet the future challenge of 
dementia and AD owing to the increasing ageing population: 
 There is a need in Europe to establish the harmonized international database for existing 
population-based longitudinal studies on ageing and dementia. This will provide powerful 
resources for further understanding the burden (e.g., economic and societal costs), temporal 
trends (e.g., prevalence, incidence, and mortality), nature history (e.g., genetic and clinical 
markers for early detection), and etiopathogenetic hypotheses (e.g., psychosocial stress, 
traumatic brain injury, nutrition, and frailty) for AD and dementia 28,150.  
 There is still limited knowledge regarding certain critical aspects of the impact of dementia at 
the individual and societal levels, such as prevalence stratified by severity, factors linked to 
progression in cognitive and functional disability, and factors linked to institutionalization.  
 Multidisciplinary research projects that integrate epidemiological approaches with genetic, 
neurobiological, neuroimaging, and clinicopathological techniques are critically needed to better 
understand the pathophysiological processes of ageing and dementia. Such knowledge will 
facilitate the development of new therapeutic approaches for dementia in the clinical settings 
and intervention strategies against dementia in the communities. 
 Life-course approaches should be applied to epidemiological studies of AD and dementia. These 
approaches are particularly relevant with regard to understanding the ethology, nature history, 
and intervention strategies for multifactorial chronic diseases, such as dementia. 
 Long-term studies with harmonized methodology will help better understand the temporal 
trends and the possible geographical variations of dementia occurrence within single countries 
and across Europe. In particular, more research is needed to clarify whether and, to what extent, 
the secular trends in cardiovascular risk and dementia occurrence in Europe are causatively 
correlated. 
 A collaborative project in Europe should be initiated to understand the occurrence, non-genetic 




Glossary of Terms Epidemiology  
10/66 Dementia Research Group: A collective of researchers carrying out population-based research 
into dementia, non-communicable diseases, and ageing in low- and middle-income countries. 10/66, 
as part of Alzheimer’s Disease International, refers to the two-thirds (66%) of people with dementia 
living in low- and middle-income countries, where 10% or less of population-based research that has 
been carried out. 
 
Brain reserve: Brain reserve is directly related to brain size, number of neuronal cells or density of 
synapses, such that a large brain or large number of neurons is able to tolerate more pathology before 
it reaches the critical threshold for clinical symptoms to appear. 
 
Cerebral small vessel disease (SVD): The term describes a range of neuroimaging, pathological, and 
associated clinical features. Signs of SVD on conventional MRI include small subcortical infarcts, white 
matter hyperintensities, lacunes, prominent perivascular spaces, and cerebral microbleeds 153. 
 
Cognitive reserve154: Cognitive reserve refers to the brain's ability to adequately perform cognitive 
tasks despite neuropathological damage in the brain. Cognitive reserve represents either an enhanced 
ability to recruit alternative brain networks or a more efficient utilization of brain networks in general. 
Common measures of cognitive reserve include such as high education, leisure activities, mentally-
stimulating activity, and rich social network. 
 
Confounder: A confounder refers to a factor that is related to both an exposure of interest and outcome 
(e.g., a disease). The factor (confounder) may explain all or part of the association between the 
exposure and the outcome. 
 
Early-onset dementia/Alzheimer’s disease: A term refers to dementia/Alzheimer cases diagnosed 
before the age of 65 years. 
 
Life-course approach: In epidemiology, a life-course approach is used to study the biological, physical, 
and social hazards during gestation, childhood, adolescence, young adulthood, and midlife that may 
affect risk of chronic diseases and health outcomes in later life. It aims to identify the underlying 
biological, behavioural, and psychosocial processes that operate across the lifespan. 
 
Population attributable risk (PAR): A proportion of cases that would not occur in a population if the 
factor were completely eliminated from the population. The PAR (%) in a general population depends 
on the prevalence of the risk factor (Pe) and the strength of its association (relative risk) with the 
disease (RRe). The formula is: PAR=Pe (RRe-1)/[1 + Pe (RRe-1)]. It is also called population attributable 
fraction. 
 
Years of life lost (YLL): An estimate of the average years a person would have lived if the person had 
not died prematurely. It is an alternative to death or mortality rates, but gives more weight to deaths 
that occur among younger people. YLL can be estimated from the number of deaths multiplied by a 




PREVENTION OF COGNITIVE IMPAIRMENT AND DEMENTIA 
Summary 
Alzheimer’s disease patology is complex but epidemiological studies have given us knowledge on 
protective factors and modifiable risk factors. Promoting cerebrovascular health and certain life-style 
changes affect the risk profile for AD. A significant challenge is to design dementia prevention programs 
based on firm evidence from well-designed and ethically-sound clinical studies. Modifying 
cardiovascular risk factors, including control of hypertension, diabetes and obesity, and increasing 
physical activity have been shown to reduce also the risk for AD, but more large-scale collaboration and 
multinational intervention trials are needed. 
 
Finding effective preventive strategies is essential for a sustainable society in an aging world. Both the 
WHO (http://www.who.int/mental_health/publications/dementia_report_2012/en/) and the G8 
Dementia Summit (https://www.gov.uk/government/publications/g8-dementia-summit-
agreements/g8-dementia-summit-declaration) have described dementia as a public health priority and 
prevention has been identified as one of the key elements in addressing dementia epidemic, in a similar 
way as it is for other major non-communicable disorders such as cardiovascular disease. It is estimated 
that one third of AD cases worldwide might be attributable to seven modifiable risk factors (low 
education, midlife hypertension, midlife obesity, diabetes, physical inactivity, smoking, depression), 
and a reduction in the prevalence of those risk factors by 10-20% per decade would reduce worldwide 
AD prevalence by 8-15% in 2050 (between 8.8-16.2 million cases155). Even just the possibility to delay 
the clinical expression of dementia would have a significant impact on its prevalence. In fact, it has 
been estimated that postponing the onset of dementia by five years would decrease the number of 
cases in total by up to 50% during 50 years.  This delay would have a major impact on societies.  156,157   
Observational studies in the general population starting already in early adulthood are necessary to 
monitor the distribution of risk and protective factors in different age groups and in different 
generations over long periods of time. Very few such studies are currently available, and data from the 
1960s and 1970s may not be entirely applicable today because of the changes in society, lifestyle, 
pharmacological treatments, and risk factors levels. 158 For instance, in the last few decades there has 
been a widespread and substantial increase in prevalence of obesity and diabetes mellitus, which are 
main risk factors for dementia and AD159 
(http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf (2013). Knowledge about risk factors 
distribution in different populations can help to obtain reliable estimates of the effects of preventive 
interventions on future dementia prevalence, thus aiding health education and community planning. 
Also, randomized controlled trials (RCTs) targeting such risk factors will be crucial to understand if 
reduction or removal of these factors can substantially decrease dementia incidence.  
 
Evidence from observational studies and clinical trials 
During the last 10-15 years, long term observational studies have linked various modifiable risk and 
protective factors to an increased risk of dementia and AD (Table 4). Vascular risk factors at midlife 
(e.g., high blood pressure, cholesterol, obesity, and diabetes) have been linked with an increased risk 
of dementia and AD later in life. On the other hand, lifestyle-related factors including physical, mental 
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and social activities and healthy diet may reduce the risk. Psychosocial factors (e.g., depression, 
loneliness, stress) have also been indicated as possible risk factors. There are complex gene-
environmental interactions and some of the environmental factors may have more pronounced effect 
among the genetically susceptible persons (APOE4 carriers, the most important genetic risk factor for 
AD).  
 
While observational studies have provided information about potential modifiable risk and protective 
factors, large randomized controlled studies (RCTs) are needed to verify that interventions targeting 
those factors can efficiently postpone or prevent cognitive impairment and dementia, and to test 
which interventions are most effective in preventing or delaying onset of dementia in different at-risk 
groups.  
 
Positive results from observational studies have not automatically become successful prevention 
strategies in RCTs. For instance, this has been the case for the hormone replacement therapy (HRT) 
and non-steroidal anti-inflammatory drugs (NSAIDs). For both medications, encouraging data about 
preventive properties from observational studies were not confirmed in RCTs 160-162 An important 
reason is the problematic translation of observational data into intervention design. Trials based on 
the assumption that AD is a mono-dimensional condition (that is, mainly due to a single risk factor or 
cause) have consistently failed to identify effective prevention interventions. Additionally, a variety of 
compounds with different mechanisms of action (e.g., non-steroidal anti-inflammatory drugs, NSAIDs, 
HRT, statins, vitamins, ginkgo biloba extract) were tested in prevention RCTs that were often add-ons 
to trials with other primary outcome designs (e.g., cardiovascular or cerebrovascular events)158. Such 
methodological frameworks could have limited the possibility to detect an effect on cognition or 
dementia risk because of limited statistical power or too short duration of the study. To date, no 
studies have convincingly shown an effective single-drug approach to dementia prevention. Anti-
hypertensive drugs represent the only exception, with some evidence for a protective effect against 
dementia 163. In addition, single lifestyle-related interventions (physical activity, cognitive training) 
have only shown modest or short term positive results 164.  
Prevention RCTs have pointed out several key issues that must be taken into account165. Effective 
interventions depend on proper timing. Starting at the preclinical states of AD, before the onset of 
dementia, may lead to better effects than starting when dementia is already established, and some 
interventions may have critical time windows (e.g., beneficial effects only at midlife or at the pre-
symptomatic phase). Preventive measures need to be adjusted to their intended target groups, and 
larger trials (e.g., several thousand participants instead of hundreds) with longer-term (years instead 
of months) interventions are needed to show any effects in relatively healthy, younger (around 60 
years) individuals. The very definition of ‘effects’ is important, and measuring performance in cognitive 
tests, which can capture subtle decline and entire continuum of cognitive functioning, may be a more 
sensitive outcome than just conversion to dementia. In multifactorial conditions, single-agent 
interventions may not be enough and targeting several risk factors and disease mechanisms 
simultaneously may be needed for optimal preventive effects.   
Some risk or protective factors for dementia and AD have been investigated. The amount and quality 
of available evidence for such factors varies quite a lot. Opinions are also divided about what 
constitutes sufficient evidence for formulating specific prevention recommendations. RCTs are usually 
considered to provide the best evidence that an intervention has clinically meaningful effects. However, 
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conducting traditional RCTs is not always possible. Vascular risk factors cannot be left untreated in the 
placebo group because of ethical reasons (there is already lots of evidence that treating vascular risk 
factors protects against CVD), and strict double-blinding may not be possible with lifestyle-related 
interventions. Vascular risk factors (e.g., high blood pressure, high cholesterol, and obesity) at midlife 
have been linked with an increased risk of dementia and AD 20 to 30 years later in long term 
population-based observational studies 166. However, it is not feasible to conduct such long term RCTs 
to verify these effects. It would also be counterproductive to wait for successful RCTs before 
implementing every prevention strategy. The relation between smoking and lung cancer is a classic 
example of observational studies providing enough evidence for prevention. No RCTs have been 
needed for non-smoking guidelines and recommendations, since this would have been unethical.   
 
As mentioned in the Epidemiology section, recent epidemiological studies in several countries (e.g., US, 
the Netherlands, Sweden, UK) suggest that the incidence or age-specific prevalence of dementia has 
declined in the past 20 years 68,79,80. These findings suggest that dementia risk may be modifiable. 
Possible explanations for the declining dementia incidence include favourable changes in some 
vascular risk factors (better and wider use of medications and changes in behaviour), changes in 
education or employment, and fewer head injuries.    
 
Research in progress 
Several countries have already taken the step from observation to action and initiated large lifestyle-
based multifactorial intervention trials. Table 5 summarizes the major trials conducted/ongoing in 
Europe. This approach includes interventions targeting several risk factors simultaneously in 
individuals who are at increased risk of dementia. Other new approaches are for example selecting at-
risk group for the FINGER study (clinicaltrials.gov NCT01041989; 
https://clinicaltrials.gov/ct2/show/NCT01041989?term=Finnish+FINGER&rank=2) according to the 
CAIDE Dementia Risk Score, the first tool for estimating long term risk of dementia based on risk factors 
present at midlife (Table 6). The risk score has been later validated in a large multi-ethnic population 
in the US 167. The risk score can help to identify individuals who may benefit from intensive lifestyle 
consultations and pharmacological interventions (e.g., target interventions for those most at risk). It 
can also be used as an educational and motivational tool and to distribute easily understandable 
information about risk factors to the general population. In the FINGER RCT, the 2-year multidomain 
intervention consisted of four components: nutritional guidance, physical exercise, cognitive training 
and social activity, and management of vascular risk factors. The first results from this study indicate 
that it is possible to improve lifestyle factors in older adults at risk of dementia, and such changes can 
significantly enhance cognitive performance and reduce the risk for cognitive decline168. Extended 
follow-up of FINGER study participant is currently ongoing to detect differences in dementia and AD 
incidence. 
Another new approach is utilization of technology in dementia prevention. For example, in the HATICE 
trial (ISRCTN register, ISRCTN48151589, http://www.controlled-trials.com/ISRCTN48151589/HATICE), 
an internet-based platform has been developed aiming to motivate and support lifestyle changes and 
improve management of cardiovascular factors. The platform is interactive with readily available 
nurse/coach support and will test if making prevention more easily accessible for elderly persons in 
community can reduce CVD risk factors and dementia.  Finally, between the ongoing multi-domain 
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prevention RCTs in Europe, a data-sharing platform facilitating in-depth joint analyses and 
collaborations between research groups in different countries has been established. This allows 
analyses concerning different target groups and interventions. Differences in health care systems 
across Europe can also be taken into account, which is crucial for planning future multinational 
dementia prevention studies and programmes.   
Increased collaboration between research groups, among governments, public, and private institutions 
is required to create infrastructure for dementia/AD prevention research and to facilitate 
implementation of the results.  Actually, some international large-scale initiatives have already been 
established aiming to increase collaboration, e.g., EU Joint Programme for Neurodegenerative 
Disorders (EU-JPND), Innovatives Medicine Initiative (IMI), G8 Dementia Summit, OECD mapping for 
big data in Alzheimer research. A common theme of these initiatives is to increase coordinate 
investments and collaborations between participating countries, by bringing together academic 
experts, private sectors (the pharmaceutical and other industries) and policy decision makers, and by 
building on existing infrastructures. Main goal is to investigate key research questions about 
neurodegenerative diseases, including AD, and identify effective preventive and therapeutic measures 
that can be implemented in different settings (i.e. general population, clinical settings).  
 
Prevention trials in populations at high risk of dementia 
 
The shift of focus from advanced dementia to earlier, preclinical stages of AD has also brought 
prevention and treatment trials much closer than before, meaning that these trials now target very 
similar groups of people in the preclinical stages of AD. In fact, potential disease-modifying strategies 
(e.g., anti-amyloid drugs) previously tested only in patients with dementia due to AD, are now being 
tested in selected populations of asymptomatic individuals who are at-risk of AD, because of an 
established biomarker burden or a specific genetic profile 169.   There are three ongoing RCTs testing 
safety and efficacy of anti-amyloid drugs as preventive measures in subjects with pre symptomatic (or 
preclinical) AD. The Alzheimer’s Prevention Initiative (API) and the Dominantly Inherited Alzheimer's 
Network (DIAN) studies enrol subjects who carry genetic mutations for dominantly inherited AD: 
mutations in the APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes can cause early-onset 
familial AD that accounts for no more than 5 percent of all cases. Data from the DIAN study have shown 
that different phenotypic changes can be detected several years before the onset of cognitive 
symptoms in individual with autosomal dominant AD: it has been shown that CSF levels of Aβ42 decline 
25 years before expected symptom onset, and brain deposition of Aβ can be detected 15 years before 
170 The DIAN study is an international study involving 210 individuals from North America, Australia and 
Europe (NCT01760005, http://www.dianexr.org/), while the API RCT (NCT01998841) focuses on the 
world largest early-onset AD kindred in Antioquia, Columbia. Of about 5000 individuals in this kindred, 
approximately 1500 carry a mutation in the PSEN1 gene (E280A) causing early onset AD (mean age of 
onset: 45 years)171. Finally, the Anti-Amyloid Treatment of Asymptomatic Alzheimer’s (A4) RTC 
(NCT02008357, http://a4study.org/), aims to prevent sporadic AD and evaluate the effect of an anti-
amyloid compound in older adults with evidence of brain amyloid accumulation at neuroimaging 
evaluation. The A4 study includes also an ethics arm examining the psychological impact of disclosing 
information to individuals about their risk of developing AD172. 
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While Europe has been at the forefront of initiatives promoting lifestyle-based interventions for 
dementia prevention, North America has led the start of RCTs testing anti-AD medications in preclinical 
AD. However, studies on both pharmacological and non-pharmacological interventions for prevention 
of cognitive decline and dementia are being started in several regions of the world. In Europe, the 
recent launch of the European Prevention of Alzheimer’s Dementia Consortium (EPAD, www.ep-
ad.org), within the Innovative Medicines Initiative, is expected to create readiness cohorts and novel 
framework for RCT testing numerous disease-modifying drugs in preclinical stages of AD.   
 
Assessing health economics of dementia prevention 
Evaluating the benefits of dementia prevention or delaying onset from an economic perspective is a 
complex endeavour. AD has a long ‘silent’ phase before the first symptoms appear, and it can also take 
time for milder symptoms to develop into full-blown dementia. Compared to late stages of the 
cognitive disorders, in the early stages there is less need for health care services use and costs are 
lower. Intervention methodology may also be misleading, for example a very broad intervention in 
younger individuals around 40-50y with no symptoms will result in a very low occurrence of dementia 
even if no prevention activities are taking place. This is because dementia incidence is very strongly 
age related and dementia is rare at midlife. Some prevention activities, such as targeting vascular and 
lifestyle factors, can be embedded in an implicit way in daily life and in medical care settings, making 
it difficult to separately estimate their costs. Public health prevention trials outside the medical care 
system are easier to assess than trials embedded in the medical care system since they tend to demand 
some kind of separate infrastructure with associated programme costs. 
Approaches such as economic simulations may be useful for estimating cost-effectiveness. One 
example of an economic simulation is a study where the cost-effectiveness of a potential dementia 
prevention programme using the CAIDE Dementia Risk Score and a Markov model adapted to Swedish 
conditions was evaluated 173. The prevention programme consisted of two main components, a healthy 
lifestyle promotion programme and pharmacological treatment of cardiovascular risk factors. Figures 
of costs (intervention costs, costs of care for people with and without dementia), utilities (health 
utilities expressed as quality adjusted life years, QALYs), and mortality according to age group were 
obtained from literature or databases. The multi-domain preventive intervention was less costly and 
had better dementia-related outcomes compared with ‘usual care,’ supporting cost-effectiveness. This 
is a promising outlook for future research on preventive interventions in dementia. To evaluate the 
cost effectiveness of prevention programmes, it is important to have a multifactorial approach with a 
‘filter’ for selecting at-risk participants, and to have sufficient statistical power in terms of sample size 
and intervention duration.  
 
Ethical aspects of prevention 
Prevention strategies need to consider several ethical issues. In clinical trials, vascular and lifestyle-
related risk factors cannot be left untreated in placebo groups because there is already strong evidence 
that treating vascular risk factors and healthy lifestyle are beneficial for CVD prevention and other 
health outcomes. Dementia risk is the result of interactions between genetic and environmental 
factors (e.g., effects of environmental risk factors are more pronounced among ApoE4 carriers). The 
potential need for genetic counselling or ‘genetic-tailored’ guidance as part of dementia risk 
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assessment in trials, and later in clinical practice, will have to be considered. Another ethical aspect is 
deciding when the evidence is sufficient to start recommending specific prevention strategies, or to 
start informing and educating the general public about modifiable risk factors. Many risk factors cluster 
in groups with lower socioeconomic status (e.g., lower education, smoking, obesity, suboptimal 
treatment of CVD risk factors), and socioeconomic differences are increasing in many countries. Thus, 
how these risk groups can be captured by prevention programmes is an important challenge for the 
future.     
Most importantly, blaming persons with dementia for presumably having had an ‘unhealthy lifestyle’, 
as well as false promises for preventive intervention effects in popular media must be avoided.   Results 
from epidemiological studies are applicable at population level, but translating them to individual level 
is not simple because not all characteristics of an individual can be captured by average characteristics 
of a group.   
 
RECOMMENDATIONS 
Compared to cardiovascular prevention, dementia/AD prevention is a rather young field and much 
work is still needed. However, prevention or delaying onset of dementia/AD seems to be possible since 
many known risk factors are modifiable or amenable to management. There is already enough 
evidence to justify some immediate actions in dementia prevention 174 including for example public 
health policies encouraging middle-aged people to stop smoking; treat high blood pressure; avoid 
becoming obese and diabetic; increase physical activity, and improve education level. At the same time, 
knowledge about modifiable risk factor for dementia/AD needs to be refined and validation of the 
observational studies with large intervention studies is needed.  
 Many modifiable risk factors such as high blood pressure, obesity, physical inactivity and 
unhealthy diet are shared among dementia/AD and other major late-life chronic conditions 
like heart disease and stroke. Public health efforts promoting healthier lifestyles in midlife have 
the potential to improve generally health status in advanced age.  
 
 Population surveillance of risk factors in different age groups and countries is urgently needed 
to better estimate the effects of preventive interventions on future dementia and AD 
prevalence. This can help planning of public health policy.  
 
 Observational studies need to start early in midlife and have a long duration in order to identify 
windows of opportunity for effective interventions. Building on existing infrastructures and 
cohorts developed for other chronic diseases will allow optimizing the use of resources.  
 
 Effective dementia/AD prevention needs tailored intervention strategies for appropriate 
target groups (different ages and contexts). Also, health care system differences between 
countries need to be considered for developing preventive strategies that can be easily 




 Given the multi-factorial etiology of dementia/AD, multi-domain interventions with 
simultaneous management of various risk factors based on lifestyle changes and 
pharmacological treatment may be needed for optimal preventive effects. 
 
 Scientific collaborations among research groups in Europe require the development of 
appropriate infrastructures to facilitate more effective use of existing data, and rapid 
recruitment of participants in multinational intervention trials. Increased collaboration among 




GENETIC RISK OF DEMENTIA: Individual susceptibility 
Summary 
The heritability of AD is estimated to be greater than 60%. Several specific gene mutations cause, or 
contribute to, early-onset (before age 60) AD, but only about 2% of AD cases fall into this category. 
Gene variants that increase the susceptibility for AD have also been identified and large-scale genome-
wide association studies are ongoing. Well-organized biobanks and large collaborative groups that 
share data are essential to advance the understanding of the genetic underpinning of AD pathology 
and risk factors. There is hope that an understanding of inherited early-onset AD might provide insights 
for therapies directed at sporadic, age-related dementias. 
 
The epidemiological evidence summarized earlier helps to understand the relationships between 
lifestyle factors, such as physical activity or smoking, and medical conditions, such as hypertension, at 
midlife and the risk for developing dementia several decades later. The evidence from genetic studies 
of AD, reviewed in this section, explains how genetic variability, present in our DNA from conception, 
contributes to the development of AD later in life. Genetic epidemiology attempts to study how our 
genetic make-up lends resistance or vulnerability to environmental exposures, such as life style and 
medical illnesses. The impact of individual genetic susceptibility in the occurrence of AD is substantial, 
considering that the heritability for AD is usually estimated to be greater than 60% 175. 
The very first genetic determinant of AD discovered in 1991 was a mutation located in the amyloid 
beta (Aβ) precursor protein gene (APP) associated with a familial form of early onset (before 65 years 
of age) AD 176. Indeed, approximately 2% of all AD cases are hereditary explaining about half of the 
early onset AD cases, in which the occurrence of the disease is explained by mutations in one gene 
with a major effect. Most of these monogenic hereditary forms follow a Mendelian autosomal 
dominant transmission, affecting at least one individual in each generation. For the other 98% of AD 
sporadic cases, with an age at onset after 65 years of age, very often, clinicians identify a family history 
of dementia without any specific mode of transmission. However, due to the late age at onset of the 
disease, the precise estimation of this family history is difficult because of both parent survival and 
diagnostic assessment limitations. 
Genetics plays a major role in our current understanding of AD and will play an important role in the 
general prevention and care of the disease in the future. For example, genetic tests can be used to 
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identify and classify individuals with various level of risk of disease, ranging from low to high, before 
symptoms have appeared, so called predictive pre-symptomatic genetic testing, and for early diagnosis 
in preclinical states of dementia. A detailed understanding of the level of AD incidence associated with 
genetic susceptibility will be important in future when efficient treatment has been developed because 
genetic testing may thus be used to identify and treat at risk individuals before symptoms of cognitive 
dysfunction have developed. Genetic discoveries also offer new clues to what pathological processes 
(gene functions) are involved in the development of the disease and thus potential treatment 
approaches can be developed to intervene in these processes.  
Already genetic testing procedures require special ethical considerations since genetic information on 
one family member gives information about other family members indirectly, especially since there is 
no treatment available for Alzheimer disease. Thus, for instance, genetic testing in AD hereditary forms 
should be performed in the context of clinical genetic counselling with strict guidelines for 
communicating genetic information in the context of a lack of treatment. 
 
The progress of AD genomics: the pivotal role of international collaboration and data sharing 
Since the discovery of the mutations in APP, the first gene associated with familial AD in 1991, a second 
major milestone was achieved with the discovery of the first susceptibility gene in sporadic AD, the ɛ4 
allele of the apolipoprotein E gene (APOE) in 1993177,178. In contrast to APP mutations, the 
polymorphism of the APOE ɛ4 allele is frequent in the population, with a co-dominant effect on AD risk. 
The odds ratio (OR) is estimated to be 3.2 and 14.9 for carriers of one or two ɛ4 alleles, respectively, 
with a high attributable fraction in the population (between 20 and 40%)179. Two other genes were 
identified in 1995, Presenilin 1 (PSEN1)180 on chromosome 14 and Presenilin 2 (PSEN2)181 on 
chromosome 1 in familial forms of AD, explaining, together with the APP mutations, almost half of 
these familial forms. Between 1995 and 2009, more than 500 potential new susceptibility genes were 
reported, but none of them could be consistently replicated and confirmed 182. We had to wait for the 
first achievement of the Human Genome Project 183 and the incredible development of nano-genome-
sequencing technologies in biological sciences 184 to stimulate the deciphering of the genetic 
susceptibility of AD. That is, the natural genetic variation in the human population consisting of single 
nucleotide polymorphisms (SNPs) has been mapped across all chromosomes such that it is possible to 
define the unique position (locus) of individual SNPs with respect to the rest of the genome. 
Indeed, the genome wide association study (GWAS) approach that was developed thanks to these new 
technical developments has allowed for the identification of a large part of the genetic susceptibility 
of human diseases. Based on high throughput genomics technologies, GWAS can characterize millions 
of single nucleotide polymorphisms (SNPs) covering the entire genome of one individual and offer a 
comprehensive view of the genomic regions associated with diseases. However, testing millions of 
variables in a case-control study design may lead to the discovery of numerous false positive 
associations. Thus, the AD geneticists had to use very stringent P-value thresholds (<5 10-8) and to 
replicate systematically their discoveries in additional follow-up studies 185. Consequently, they had to 
enlarge the size of their samples from hundreds to thousands of cases and controls to increase their 
statistical power, improving chances to detect frequent polymorphisms with small individual effects 
on the disease risk. The only way to collect very large samples of cases and controls was to create large 
collaborative consortia sharing their clinical data, biobanks and genotypes. In 2009, two such consortia, 
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the European Alzheimer’s Disease Initiative (EADI) 186 and the Genetic and Environmental Risk in AD 
(GERAD) 187 discovered three new AD susceptibility loci; in 2010, another consortium, the Cohort for 
Heart and Ageing Research in Genomic Epidemiology (CHARGE) 188 in collaboration with the two 
previous ones, published two new loci among which one was confirmed; in 2011, another consortium, 
the Alzheimer Disease Genetic Consortium (ADGC) 189 published, back-to-back with a paper from the 
three other consortia 190, five new loci. Thus the total number of susceptibility locus associated with 
late-onset AD was 10 including APOE. These four consortia decided to work together and to give birth 
to the largest and most efficient genomics collaboration in AD ever done, the International Genomics 
Alzheimer’s Project (IGAP) 44,191 that recently discovered 11 new loci clearly confirmed and 13 new 
potential ones. Finally, using different approaches, four other genes were identified. In 2015 the total 
number of confirmed genetic effects is 26, with 14 that still need to be validated, located in 39 different 
loci (Table 7), a significant portion of which have unknown function.  
 
 
Effects and frequencies of genetic variants 
Based on the level of association of the genetic variant with the disease risk (weak or strong) and on 
the frequency of this genetic variant in the general population it is possible to classify the AD associated 
loci into different groups of genetic influence on AD (Table 8). Generally, causal mutations are rare and 
deterministic meaning that they contribute only to a minor fraction of the total number of patients 
with AD (rare mutations) but these mutations have a strong impact on the individual (very strong 
association), being sufficient to cause the disease and are thus classified separately as “disease genes”. 
In contrast, susceptibility genetic variations are usually more common in the population (Single 
nucleotide polymorphisms with a minor allele frequency, MAF >10%) and thus an association may have 
a large impact on the total burden of disease in the population but relatively small impact on the 
individual risk. Susceptibility loci may have a “high impact” or “low impact” depending on how strong 
the association to AD is (OR ≥ or < 2). 
Disease genes were identified using segregation studies in familial forms of AD with a disease 
inheritance supporting the involvement of a single gene mutation as the etiology of the disease. Most 
high impact susceptibility loci have been identified through hypothesis driven candidate gene 
approaches, targeting one or a few specific genes based on their biological function or on systematic 
sequencing approaches associated with functional studies. Finally, the low impact susceptibility loci 
have been identified in GWAS. GWAS approaches are based on the association of SNPs to a disease 
with no a priori hypotheses. These SNPs are usually markers distributed evenly all over the genome in 
order to build the most extensive coverage. Some of the SNPs mark regions of the genome where only 
one gene is present that may be considered as the functional one, while other SNPs are located in 
regions containing several genes with no simple way to identify the responsible one. Thus, in the 
absence of any functional or experimental information, GWAS results refer in general to susceptibility 
loci mostly without any known functional implications to the disease etiology because of their non-
hypothesis-driven approach. 
The first two groups of genes in the first column of Table 8 are the disease genes and the high impact 
susceptibility loci discovered in familial forms of autosomal dominant AD with Mendelian inheritance.  
These diseases are early-onset monogenic forms of AD caused by deterministic mutations in genes 
28 
 
which are at the origin of the amyloid cascade hypothesis: APP, PSEN1 and PSEN2 192. However, these 
three genes are only found in half of the families with autosomal dominant early-onset AD, suggesting 
that other major genes still remain to be discovered. For instance, systematic exome sequencing in 
these autosomal dominant early-onset familial forms has led to the discovery of non-sense and 
missense mutations in SORL1, not detected in large control samples. Following in silico analyses, these 
mutations in the gene that encodes the Sortilin-related receptor LR11/SorLA, a protein involved in the 
control of the amyloid β peptide production, are likely to have a pathogenic effect 193. This reinforces 
the implication of the amyloid cascade hypothesis in the early onset forms. Moreover, common 
polymorphisms of SORL1 are also associated with sporadic AD.  
Concerning sporadic AD with an older age at onset, the very first and only gene to be consistently 
associated was APOE, which constitutes the third group of disease loci with high frequency in the 
population and a high impact on disease risk. APOE was already known to be associated with high levels 
of LDL-cholesterol and myocardial infarction risk 194,195. In AD, the risk effect of the APOE ɛ4 allele was 
discovered in 1993 thanks to candidate gene approaches 177,178. Then more in depth analyses 
demonstrated that another allele of this gene, the APOE ɛ2 allele, was conversely a protective factor 
reducing the risk for AD 196. The strong association between the APOE ɛ4 allele and AD was largely 
confirmed in all populations. In recent studies, lifetime risks for AD, without reference to the APOE 
genotype, at the age of 85 was 11% in males and 14% in females. This lifetime risk was 50% for APOE 
ɛ4 homozygous men and 60% for homozygous women, while for heterozygous APOE ɛ3ɛ4 carriers the 
lifetime risks were 23% and 30% respectively for men and women.  These estimations are consistent 
with a semi-dominant inheritance of a moderately penetrant gene, similar to the effect of BRCA1 
mutations and risk for breast cancer and other major-effect genes with incomplete penetrance in 
Mendelian diseases 197. Despite this major susceptibility impact on AD, the role of APOE on the AD 
pathophysiology remains heavily discussed. 
In 2009, built on the experience of the genomics of other complex diseases, and on the development 
of the GWAS, three new loci were reported by two major consortia 186,187, constituting a fourth group 
of susceptibility loci with high frequency and low impact. These loci were centred within three genes: 
CLU, CR1 and PICALM. The SNPs identified in these loci were frequent (more than 20% MAF) and 
associated with 20% of the risk variation being either protective (the minor allele is more common in 
the control group compared with AD thereby associated with a lower risk for AD) or deleterious (the 
minor allele is more common in AD compared with the control group and is thereby associated to 
increased AD risk). Following a similar approach, the BIN1 locus was identified in a new GWAS and 
replicated 188. Finally, the four research consortia had identified nine AD loci and, as mentioned above, 
decided to come together in a global collaboration called IGAP, sharing their data to increase 
significantly the statistical power of these genetic studies. The combined sample population of  25 580 
AD cases and 48 466 controls in IGAP lead to the discovery and confirmation of 11 new AD loci and to 
the proposition of 13 new potential loci 44. All these loci in this fourth “low impact” group still need to 
be explored to understand their role in the pathophysiological process of AD i.e. through which 
biological disturbances the genetic variants contribute to the development of AD. Some of the 
associated loci point to a specific gene, while others cover larger regions with numerous possible 
candidates. Thus, future research must focus on the identification of the specific genetic variants that 
are responsible for the increased risk of AD and subsequent functional studies will unravel their 
biological relevance in the pathophysiology of AD 198. 
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Thanks to the development of the next generation sequencing (NGS) technologies it is now possible to 
sequence the exomes of a given genome, allowing to characterize all the mutations present in the 
coding regions of patients, and comparing their presence or absence in controls. This sequencing 
approach was successfully used to discover two new AD genes with low frequency mutations (<1%) 
with high effects, almost as high as the one observed for heterozygous APOE ɛ4 allele carriers, outlining 
a fifth group of susceptibility genes. The first gene was TREM2, previously associated with a rare 
disease, the Nasu–Hakola disease presenting with bone cysts and early-onset dementia 199. While 
sequencing TREM2 in a series of AD cases and controls, several low frequency mutations could be 
identified and associated with an increased risk of sporadic AD, increasing the risk more than 4 times 
200. TREM2 was simultaneously discovered in an Icelandic population and similarly extended to sporadic 
AD risk in other populations 201. Recently, a second gene was added to this fifth group, the PLD3 gene 
202. A non-synonymous coding mutation was discovered in a whole exome sequencing study of 14 large 
late-onset AD families with AD in four or more individuals. The mutation segregated with AD in two 
independent families and doubled the risk for AD in a large case-control multicentre study. 
Unfortunately, this observation could not be replicated203Functional experiments suggested that 
TREM2 is related to the immune pathway , a pathway previously implicated in AD pathogenesis.  
Similarly, while searching for rare variants in the APP gene with a significant effect on AD risk, Icelandic 
researchers found a coding mutation (A673T) that potentially protects against AD and cognitive decline 
in the elderly population 204.  
 
Early-onset and late-onset AD genes 
About 200 different mutations have been identified in early-onset AD cases. These mutations are 
usually inherited from an affected parent in autosomal dominant fashion suggesting that new, de novo, 
mutations are rare and the penetrance is generally high, reaching almost a 100% life time risk. There 
have also been two reports on recessive APP mutations in rare cases 205,206. Thus, by screening for 
mutations in APP, PSEN1 and PSEN2 in individuals affected by AD who belong to families with a 
dominant inheritance of the disease, it is possible to identify the causal mutation in almost half of the 
cases. This type of mutation screening in known genes could be applied in clinical practice as a genetic 
diagnostic test.  
If a mutation is identified in an index case from a family, it becomes possible to use genetic testing to 
predict the risk for relatives who are still asymptomatic, a procedure known as presymptomatic genetic 
testing. In research, there is a major opportunity to increase our understanding of AD by studying the 
natural history of the disease in such at-risk subjects who are asymptomatic mutation carriers. Indeed, 
several studies in sporadic forms of early onset AD have demonstrated that the pathophysiological 
process that underlie AD begins several years before definite clinical symptoms appear: in a 
prospective study of subjects aged over 65 and followed-up more than 15 years, the first decline in 
cognitive performances, using, for example, measures of semantic memory, appeared 12 years before 
the dementia diagnosis 207. So being able to identify individuals, very early and with limited 
comorbidities who later will develop AD may help our advancement in tracing the natural history of 
the disease. Thus, the study of at risk individuals from families with early onset AD caused by mutations 
in APP, PSEN1 or PSEN2 may serve to understand also the sporadic disease process 208. Several research 
groups have studied the natural history of early onset AD through prospective examinations of healthy, 
asymptomatic mutation carriers and their healthy non-mutation carrier siblings. These autosomal 
dominant AD cases have pathophysiological changes decades before any cognitive symptoms exists 
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209,210. For instance, concentrations of Aβ42 in the CSF decline 25 years before expected symptom onset; 
Aβ deposition, as measured by positron-emission tomography (PET) is detected fifteen years before, 
as are increased concentrations of tau protein in the CSF and increase in brain atrophy. Given the low 
frequencies of these familial AD forms, a collaborative effort of international AD centres has been 
launched, the Dominantly Inherited Alzheimer Network (DIAN) 211. 
As indicated in Table 7, GWAS has led to the identification of several susceptibility loci in addition to 
APOE whose relative contribution to the total load of AD in the population is relatively high compared 
with the population attributable fraction of risk associated with the rare early onset AD genes. 
However, the use of this susceptibility information in any genetic testing at the individual level remains 
very limited. Thus, there is a consensus agreement not to offer APOE genetic testing, the gene with 
highest attributable fraction in the population, as a predictive test. 
Finally, other unknown genetic susceptibilities may result from interactions with environmental factors 
and other genes and from mechanisms for which we still do not have the tools to uncover.  These other 
potential mechanisms of action include epigenetic modifications of DNA and DNA-binding proteins 
such as cystein-methylation and histone acetylation as well as somatic mutations in the target tissue 
(i.e., nerve cells) 212. There are still not sufficient data on these mechanisms to know if they are at play 
and future research must be engaged in such hypotheses. In order to decipher these underlying 
complex genetic mechanisms, there is a need for increased access to high quality databases of detailed 
electronic health records and biobanks to be able to correlate efficiently genotype to phenotype and 
estimate interactions.  
 
From gene discovery to clinical application 
Much work remains to elucidate disease mechanisms in AD. However, the amount of data already 
accumulated from genomics prompts thinking about the consequences that this information may 
already have for translational research and clinical practice. Indeed, we can outline three major 
consequences in the medium term: risk prediction, clinical trial enrichment and precision medicine. 
The most obvious application of genomics in clinical practice resides in using genetic testing to support 
early and presymptomatic diagnosis. However, the questionable clinical utility associated with 
presymptomatic genetic testing for sporadic AD as long as there are no proven pharmacological 
interventions which can stop or delay the disease also raises ethical concerns. Thus in the current 
circumstances of lack of specific treatments or lifestyle changes with robust proven efficacy, the major 
use of genomics in AD is to increase the scientific knowledge and to help improve translational and 
clinical research. 
However, in cases with a strong family history of early onset AD, clinical genetic testing may be 
requested by patients themselves. In case such requests are put forward, these should be better 
handled in a clinical genetics setting with access to physicians allowing a medical, social and 
psychological continuous support rather than by direct-to-consumer genetic testing companies with 
limited medical follow-up and support. 
 
Before any type of genetic test can be administered, each individual to be tested must have had the 
opportunity to be fully informed about the consequences of these tests: information about the disease 
itself, a priori risk of inheritance and consequences of these genetic tests for other family members. 
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Performing a diagnostic genetic test on a patient diagnosed with AD often has as much consequences 
for the rest of the family as for the patient himself or herself, such as being implicitly able to deduce 
the risk of the other members as a result of Mendelian (mostly autosomal dominant) transmission.  
Although rare, identification of a causal mutation in a patient with AD may result in requests for 
presymptomatic genetic testing in other members of her family. If so, this genetic testing should only 
be performed in the context of genetic counselling provided by teams with experience in the 
neurodegenerative disease field. This request can come from family members with autosomal 
dominant AD, individuals with a family history compatible with a familial AD (the disease occurs in 
more than one individual, and at least two of the affected individuals are third-degree relatives or 
closer), or individuals with an isolated case in a sporadic context.  
When genetic testing is requested by a symptomatic individual, this patient should be accompanied by 
a family member or any declared representative.  If the individual is presymptomatic, a protocol based 
on the International Huntington Association and World Federation of Neurology Research Group on 
Huntington’s Chorea Guidelines is recommended 213. This testing has several limitations. In autosomal 
AD, the search for the causative gene in a family will be performed among the three known ones: APP, 
PSEN1 and PSEN2. However, half of the families do not present any mutations in these three genes. 
Furthermore, due to the heterogeneity of dementia etiology, misdiagnosis of AD in the family must be 
considered. In particular, the most common genetic cause for familial frontotemporal lobe dementia, 
an expansion of the hexanucleotide repeat in C9orf72, has been identified in families misdiagnosed 
with AD 214. Thus, in families with a clear autosomal dominant inheritance pattern, the possibility of 
other causative genes should be considered, allowing an extension of the number of target genes if 
mutation screening has been requested. A neuropathological examination in the family will also help 
to define the clinical diagnosis 215. Finally, in families who request genetic testing but lack mutations in 
the known genes, it may be valuable to store the DNA for future mutation screening in novel genes. 
Beside these three causative genes, the other gene that could be tested is the strongest susceptibility 
gene for AD, APOE. However, despite a relatively high attributable fraction of the APOE ɛ4 allele in 
population (around 20%) and a high lifetime risk in homozygous carriers, the ε4 allele is neither 
necessary nor sufficient to cause AD. Using APOE genotyping for predicting AD risk is not recommended 
because of its low sensitivity and specificity to diagnose AD, the lack of preventive options, and the 
difficulty of estimation of an absolute individual risk.  
As outlined in Table 9, the genetic testing outcome of the presence of a disease mutation in 
deterministic genes such as APP, PSEN1 and PSEN2 in early onset AD is very different from a positive 
test result for a risk gene such as APOE or BIN1 (Table 7) in late onset AD. Indeed, for deterministic 
mutations, the outcome is binary, either the mutation is present and the disease will unequivocally 
develop at some point in future, or the mutation is absent and the early onset form of AD will not 
develop. In contrast, the presence of a risk allele for a susceptibility risk  gene will result in a life time 
risk probability score for developing the disease in future and cannot be used to estimate a binary 
outcome as for deterministic genes 216. In most situations, this multigenic risk confers only a genetic 
susceptibility that will be modulated in a favourable or unfavourable way by gene-gene and gene-
environment interactions.  
  
Ethical concerns of genetic testing 
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Despite the similarities of AD with other neurodegenerative diseases such as Huntington disease, early 
diagnosis of a disease whose symptoms may appear years afterwards and for which no treatment is 
available raises important ethical issues that need to be anticipated.  Performing clinical or prevention 
trials in presymptomatic individuals with autosomal-dominant mutations or in asymptomatic 
individuals at risk of developing AD raises ethical questions, as genetic testing will disclose to the 
individual participating in the trial his or her AD risk status.  
Some ethical concerns have been addressed in clinical trials that examined the impact of APOE genetic 
susceptibility testing on asymptomatic individuals, The Risk Evaluation and Education for Alzheimer’s 
Disease (REVEAL) Studies 217. Results of REVEAL trials demonstrate that disclosure of APOE genetic 
results by trained professionals using appropriate educational approaches does not generally result in 
short term adverse psychological effects. REVEAL studies were not fully representative of a typical 
clinical setting. The individuals recruited were a preselected (having a parent with AD), volunteering 
highly educated group, generally female, receiving a free of charge testing whose results were not 
included in their medical record. However, these studies provide insight into what we have to expect 
from the various all-in-one personal genomic services delivering scores of health conditions which 
usually includes results on AD susceptibility genes. Finally, early identification of presymptomatic 
individuals might have major psychological effects for the individual and other consequences  218,219 
both for the individual and for his/her family members, who might be indirectly informed of their own 
risk. 220,221  
 
The way forward in genetics 
 
Genetics and genomic discoveries are a major entry point in AD research by offering new research 
leads through non-hypothesis driven approaches. Already in 1991, the discovery of a causative 
mutation in early onset autosomal dominant AD gave support to the amyloid cascade hypothesis. Less 
than 20 years later, the intense development of genomics allows expansion of the research landscape 
thanks to a non-hypothesis driven approach based on whole genome screening. The 40 genes and 
susceptibility loci, confirmed or suspected, identified to date, offer insight into the high level of 
complexity hidden behind the brain pathology of amyloid plaques and neurofibrillary tangles in AD. 
However, the genetic discoveries must now be brought forward. We have entered a post-GWAS era 
that will need to integrate all the research tools that are available today in biological and computer 
sciences: bioinformatics, “omics” technologies, system biology, epigenetics, molecular and cellular 
studies, animal models, risk factor assessments and social and health care research (Figure 4). The 
future is transdisciplinary and will require well planned and target-oriented development of databases 
and biobanks which can harbour information from all areas of research and health care, including 
population based studies, clinical data, and experimental research results.   
In 2012, the US launched a major sequencing programme in the context of their National Alzheimer 
Plan, aimed at sequencing 10 000 whole exomes and 600 whole genomes in selected AD patients and 
controls. Similar European initiatives have been launched in the context of research calls through the 
European Union Joint Programme on Neurodegenerative disease (EU-JPND). Following the example of 
the GWAS consortia, sequencing consortia are now arising that will share data. However, the 
dimension of the information collected will require big data handling infrastructures.  
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In parallel, the use of genomics in clinical research must be reinforced.  Ready-to-use tools allowing 
rapid identification of genetic markers in patients attending memory clinics can be developed. These 
tools could be used to facilitate differential diagnoses in dementia and other neurodegenerative 
disorders. These tools would allow physicians and patients to be prepared and educated to the next 
revolution associated with precision medicine. In this context, and as long as we are not able to provide 
efficient treatment for AD (and even after), social and ethical research must be strongly supported to 
help our patients to cope with the concept of an increased AD lifetime risk, and to protect them from 
any negative consequences of early diagnoses developed in the context of clinical research, as a 
possible limitation of access to employment or insurances. To this end greater efforts must be made 
in the European health care systems to facilitate the understanding of the genetic underpinnings of 
neurodegenerative diseases. To achieve this, professionals need to be educated and families and 
patients should have universal access to qualified genetic counselling. In parallel to the progress in AD 
genetics and genomics, genetic research in other neurodegenerative dementias, such as 
frontotemporal dementia, faces similar challenges 222. 
In conclusion, tackling AD is not anymore in the hands of any one researcher, one team or even one 
country. The first pilot JPND research was initiated during the French Presidency of the European Union 
in 2008. Geneticists and epidemiologists began to share data at the international level and, in less than 
5 years, were able to discover more than 20 new AD susceptibility regions. If we want to progress more 
rapidly, this global collaboration must be extended to even more countries as AD does not know any 
borders. In that context, the JPND initiative gathers today 28 different countries beyond the European 
traditional limits, including Canada and Israel (www.jpnd.eu). Moreover, this momentum should also 
support not only academic research but also private research as the Innovative Medicine Initiative 
(www.imi.europa.eu) has brilliantly done. The awareness of this need for global collaborative research 
is progressing as demonstrated by the last G8 summit that was dedicated to dementia, in London in 
2013. The ultimate goal of all this mobilization is to lead to increased global collaboration and data 
sharing for the greatest benefit of our populations and economies. 
 
RECOMMENDATIONS 
Genetics plays a major role in our current understanding of AD and will play an important role in 
implementing prevention and care strategies in future.  
To allow for optimal utilization of genetics in prevention of dementia, pre-symptomatic and early 
diagnoses, and present and future treatment approaches, we need to: 
 Favour data sharing and large scale national/international collaborative studies 
 
 Facilitate clinical and genetic interdisciplinary research to embrace the complex and 
heterogeneous nature of neurodegenerative diseases 
 
 Develop guidelines for health professionals to support the use of new genetic tests 





 Develop a legal framework that regulates the use of personal predictive health information 
by third parties, protects the individual and the family, and facilitates research.  
 
 Increase the societal awareness and knowledge of the use and limitations of genetic 
testing and its ethical concerns 
 
 Provide genetic counselling by appropriately trained personnel in an adapted and 
professional psychological support system (similarly to the genetic counselling provided 
for Huntington disease) 
 
 Develop systematic searches using GWAS and NGS data to identify the biological pathways 
and “causal variants” involved in the disease 
 
 Systematically collect and store DNA and clinical data in clinical settings, as well as in 
clinical trials and prevention studies, for post-hoc research studies and patient 
stratification 
 
 Explore the role of gene-gene interactions and gene-environment interaction in disease 
etiology and progression 
 
 Engage in functional studies to unravel the molecular mechanisms of associated genetic 










Glossary of terms Genetics  
 
Mendelian autosomal dominant transmission: a mode of inheritance of a genetic disease resulting 
from the presence of a disease mutation in one of the two alleles which is located on one of the 22 
autosomes (chromosomes 1 to 22) and which is independent of gender of the parent from which the 
disease mutation was inherited as well as the gender of the offspring who has inherited the mutation. 
Thus diseases with Mendelian autosomal dominant transmission results in a risk of 1 in 2 or 50% in 
children and siblings to an affected mutation carrier.  
Single Nucleotide Polymorphism: a genetic variation in the DNA code (sequence of nucleotide base 
pairs). Generally there are two alleles for each SNP.  
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Allele: a term to describe that there are alternative genetic variants a specific gene or locus. 
Locus:  (plural loci) a specific location or position in the genome or chromosome which could be 
considered as the specific coordinates for a geographical place in a map. 
Co-dominant: meaning that there is an additive increased effect, on the phenotype, of the genetic 
variation with increasing number of alleles, i.e. two copies of the allele result in a more severe 
phenotype than one copy of the allele. 
Attributable fraction of risk: the total number of cases that could be avoided if a risk factor (in this case 
a mutation) could be totally suppressed. 
Minor allele frequency, MAF: the frequency of the less common (usually of two different alleles in a 
SNP) genetic variant (allele) in the population.  
Epigenetic modifications: effects on the genetic make-up which does not include the DNA-code itself 
such as modifications of the DNA (methyl-groups added to the nucleotide cytosine) and modifications 
of proteins (e.g. acetylation) that bind to the DNA in order to make it more or less accessible for 
activation (transcription). 
Somatic mutations: Acquired genetic variations that occur during cell division (mitosis) in the cells of 
the body and that are not transmitted to the next generation (because transgenerational transmission 
requires that the mutation has occurred/ is present in the gonadal cells). 
Precision medicine: also called personalized medicine meaning that individualized choices of treatment 
and prevention can potentially be made based on the specific genetic background of the individual 
when the trait or disease is influenced by the genetic make-up. This concept can be extended to all 
type of –omics information (transcriptomics, proteomics etc) 
 
 
ALZHEIMER’S  DISEASE BIOLOGY  
Summary 
The brain pathology of AD is distinct. Amyloid plaques are made up of deposits of derivates of amyloid-
β precursor protein (APP) and neurofibrillary tangles are due to the abnormal accumulation of another 
protein called tau. Most therapeutic strategies for AD are focused on the direct reduction of these 
protein deposits, or on other proteins and enzymes that regulate their levels in neurons. However, a 
better understanding of the basic biology of AD pathogenesis and how clinical dementia relates to the 
presence of amyloid plaques and tau tangles is urgently required so that prevention and therapy can 
be focused on the proper disease target. 
 
In 1906, Alois Alzheimer described the major changes present in the brain of the first AD patient, 
Auguste D. In the last hundred years, we have gained considerable knowledge in understanding the 
genetical and environmental factors contributing to the disease. However, unfortunately we still do 
not know what triggers the pathology and which are the mechanisms by which the disease progresses.  
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One distinctive feature of AD brain pathology is the accumulation of small (around 0.1 mm) spherical 
structures called amyloid plaques. The plaques are composed of fibrils formed by a protein fragment 
called amyloid A-peptide (A), and are surrounded by dysfunctional neurons. There are different 
variants of A, and it is one of the longest forms, called A42, which is believed to be particularly toxic. 
The other major hallmark of the disease is the accumulation of another protein, called tau, inside the 
neurons, forming fibrillary tangles. Amyloid plaques and Tau pathology are present not only in AD, but 
in several neurodegenerative disorders, which suggest a central role for these proteins in 
neurodegenerative mechanisms. For example, A is accumulated in cerebral amyloid angiopathy 
(CAA)224 and tau in frontotemporal dementia (FTD) or Niemann Pick Disease225.  
In the 90s, studies of early onset familial AD (FAD) identified distinct mutations in some genes that 
cause the disease in some families: the amyloid-precursor protein (APP) and the presenilin (PS) 1 and 
2 genes. The proteins resulting from these 3 genes are involved in the production of Athe majority, 
but not all, of these mutations cause an overproduction of A peptides226, 227. These neuropathological 
and genetic observations led to the proposition of the “amyloid cascade hypothesis” whereby A 
initiates a molecular cascade of toxic effects causing neurodegeneration and subsequently the clinical 
manifestations of dementia192. It is now believed that Aβ forms (1-42 or 1-43) are trigger factors for AD 
228, although which conformational structure (fibrils 229, oligomers 230, soluble forms231, or dimers 232) 
of these peptides drives neurotoxicity is still debated.  
The amyloid hypothesis has dominated the debate about the etiology and pathogenesis of AD, as well 
as guided the efforts to find treatments. Thus, today there is a considerable understanding of the 
mechanisms by which these rare genetic mutations lead to excessive A generation, but the 
precipitating factors that lead to A accumulation in the much more common sporadic forms of AD 
(more than 95% of all cases) are still unknown, although they most probably result from a combination 
of environmental factors and risk genes. Moreover, A plaques are ubiquitous to old-age (>70 years) 
individuals and around 30% of the healthy aged individuals have as much plaque load in their brains as 
in typical cases of AD (reviewed in 233). 
Following the “amyloid cascade hypothesis” a number of explanations have been proposed for the 
mechanistic link between Aβ and Tau pathology (Figure 5). However, the mechanistic relationship is 
not yet clear, as transgenic animals carrying FAD genes and expressing huge amounts of Aβ show no 
or little tangle pathology. Also, a major unmet scientific need in the AD field is to understand the 
biological function(s) of the protein precursor of Aβ, APP, and its metabolites, including Aβ, in the 
healthy individual. Thus, the potential risks of targeting Aβ production (in brain and in the periphery) 
are yet undetermined. The biological role of Aβ is largely unknown. Aβ has been shown to act as 
antioxidant234, have anti-microbial activity 235, activate other signalling proteins236-238 or modulate 
cholesterol transport 239. As β-secretase (BACE1) and -secretase are the enzymatic proteins 
responsible for Aβ generation, efforts have been made to develop inhibitors of these proteins for 
clinical use in AD. However, increasing number of studies reveal their role in the metabolism of multiple 
substrates, which complicates efforts to achieve selectivity to inhibit only Aβ production. Moreover, 
some of these substrates are fundamental for normal cell biology. For example, BACE1 cleaves β 
subunits of voltage-gated sodium channels 240, and neuroregulins. These are crucial molecules for 
neuronal development and myelinization 241,242 processes also important in adult life, particularly for 
the reparation of neuronal damage.  
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Similarly,-secretase is a promiscuous enzyme that cleaves more than 90 protein substrates having 
different structures and localization, and regulates a wide variety of cellular events such as cell fate 
determination, adhesion, migration, neurite outgrowth, axon guidance or formation and maintenance 
of synapses 243. Besides APP, the most studied -secretase substrate is Notch, a signaling molecule 
crucial for development and cell fate determination.  Development of drugs that can inhibit γ-secretase 
has not been an issue, but selectivity to inhibit only APP cleavage is difficult. In addition to decreasing 
the production of Aβ, γ-secretase inhibitors affect many other proteins and the production of other 
functionally important peptides, with potentially toxic consequences. Therefore, new strategies are 
needed to develop agents that will selectively inhibit γ-secretase cleavage of APP without affecting 
other substrates. These efforts received a boost by the recent discovery of modulators that control γ-
secretase cleavage of specific substrates by binding and recruiting them to γ-secretase for processing 
244, which are small molecules capable of reducing A42 production without affecting the generation 
of functionally important γ-secretase products 244. 
Inhibition of the enzymes producing A BACE1 and γ-secretase, has also consequences for the 
metabolism of the Aprecursor, APP, affecting the production of other APP metabolites (e.g., sAPP or 
the cytoplasmic tail, AICD). AICD has more than 20 interacting protein partners which regulate 
important signalling pathways and cell functions, such as transcription, apoptosis and cytoskeletal 
dynamics 245,246. The biological function of APP is partially known, and roles have been described in cell 
migration 247, trafficking and signalling 248, neuronal calcium homeostasis, synaptic transmission and 
neuronal networking 249 and in neurotrophic mechanisms 250. In consequence, targeting APP processing 
to reduce Aβ levels is not an easy task and might have a large number of biological consequences. This 
difficulty has been seen in clinical trials and, as discussed in the section of pharmacological 
interventions, to now all the numerous clinical trials with agents targeting Aβ production have failed 
to reach their primary clinical endpoints and in some cases caused serious side effects. 
An alternative to reducing Aβ levels is to increase Aβ clearance from the brain. Since the absence of 
Aβ does not lead to any loss of physiological function in mice 251, the elimination of this peptide could 
be a safe approach for AD treatment, but it remains to be seen if clearance of this peptide has some 
benefits or slows down the progression of AD. With this aim, some immunotherapy approaches have 
been tried in AD patients, as discussed previously, with disappointing results.  
Consequently, the question of if Aβ (production or clearance) is a good target for AD treatment is still 
unknown, and improved efforts are needed in basic research to understand the limitations and the 
real possibilities of this approach.  
The other distinguishing feature of AD, formation of tau tangles in brain neurons, has historically been 
a secondary player to explain the disease pathology, despite its direct correlation with neuronal death 
and disease progression. In contrast to the APP gene, mutations in tau do not cause AD, but they do 
cause familial frontotemporal dementia 252. In contrast to Aβ, some biological functions of tau are well 
known. Tau regulates microtubules assembly, dynamics and spatial organization, and participates in 
the axonal transport of organelles, and vesicles in the cell 253. The biological activity of tau is regulated 
by its degree of phosphorylation. Tau in neurofibrillary tangles is abnormally hyperphosphorylated 254. 
Hyperphosphorylation of tau converts it from microtubule-stabilizing to microtubule-disrupting 
protein 255. Accumulated data strongly suggest that neurodegeneration is most likely a consequence of 
the loss of biological function of Tau, together with the initiation of toxic events. Hyperphosphorylation 
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promotes the aggregation of tau into paired helical filaments leading to the formation of tangles inside 
the neurons with corresponding impairments of neuronal cytoskeletal organization and of the 
transport of proteins and organelles along the cells. Since basic research has demonstrated that 
excessive tau phosphorylation is crucial to tau pathology, efforts have been done to develop inhibitors 
of the responsible molecules, called tau kinase inhibitors, as potential therapeutics. However, there 
are multiple kinases involved in generating hyperphosphorylated tau, raising the question of whether 
specific or multiple kinase inhibitors will be more effective 256. Other anti-tau based strategies, such as 
tau anti-aggregants or tau immunotherapy are being tested. Then again, as for the Aβ-based 
approaches, the lack of good predictive animal models, good biomarkers for disease progression, and 
well defined target populations in clinical trials are strong difficulties for demonstrating their potential 
benefits against AD. 
As for models based on brain accumulation of Aβ, many treatments have been successful to “cure” 
mice designed to accumulate hyperphosphorylated tau in their brains. Several tau kinase inhibitors, 
mainly glycogen synthase kinase 3β (GSK3β) inhibitors, or lithium, were successful in animal models 
257. However, despite previous encouraging positive effects, the GSK3 inhibitor tideglusib failed to meet 
primary cognitive endpoint in a 26-week Phase IIb trial for the treatment of over 300 mild-to-moderate 
AD patients 258. 
Methylene blue (methylthioninium chloride), a drug identified in 1891, 15 years before the first 
description of AD by Alois Alzheimer, as a possible anti-malaria agent 259, has been recently proposed 
as potential drug for AD treatment. The mechanism of action of this compound is unknown, but it has 
been speculated that it could inhibit Tau aggregation 260.  Phase II clinical trial data suggested slowed 
decline. However, methylene blue colors the urine and eyes, which raises the question of how the 
study was blindly performed. A new version of methylene blue is now heading towards Phase III testing 
in patients with frontotemporal dementia. 
As an alternative to kinase inhibition, activation of phosphatases has also been proposed as a strategy 
for reducing tau phosphorylation. Protein phosphatase 2A (PP2A), the main brain phosphatase 
involved in tau phosphorylation, have received special attention. Treatment of tau transgenic mice 
with the PP2A activator sodium selenate reduced tau hyperphosphorylation and tangle formation, as 
well as improved memory and prevented neurodegeneration 261. However, a problem is that PP2A acts 
in a broad number of molecules and the activation of this enzyme to specifically reduce tau 
phosphorylation is not an easy task. In other words, treating with non-specific enough activators of 
PP2A could result in multiple unwanted side-effects. 
Several other anti-tau treatments were effective in preventing and intervening in the progress of tau 
hyperphosphorylation in animal models, improving neuronal function or cognition, for example 
microtubule-stabilizing agents as davunetide 262. Disappointingly, a 12 week placebo-controlled study 
of intranasal davunetide failed to detect statistically significant benefits in 144 subjects with amnestic 
mild cognitive impairment 263. 
Increasing efforts are being made to design an effective vaccine against tau pathology. Few studies 
regarding passive immunization (transfer ready-made antibodies against at target protein to enhance 
its clearance) against tau protein are currently available 264. Also, several studies suggest that active 
immunization (induction of immunity after exposure to an antigen; the recipient develop antibodies 
that may be stored permanently) may be effective against tau in animal models 258. Very recently, the 
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first in-man active anti-tau immunization studies started (AADvac1; 
http://clinicaltrials.gov/ct2/show/NCT01850238).  
Similarly to the Aβ -based approaches, a number of key questions remain still to be answered in the 
Tau-based immunotherapeutic approaches. Still, we do not know which is the exact species to be 
targeted (aggregation states, fragments, subtypes), or the mechanism of action by which antibodies 
clear target molecules. We will see in the coming years if current anti-tau immunotherapeutic 
approaches are effective or if they will be “lost in translation,” as has seemed to be the case with 
previous strategies.  
The reasons for the lack of successful translation from preclinical to clinical studies in treating AD are 
unknown. It is possible that the use of simple animal models reflecting a single aspect of AD is not 
enough to mimic the disease, and thus, to develop new treatments. Some limitations of the current 
animal models for AD are discussed below. 
 
Animal models for AD 
Transgenic animal models (animals genetically modified by genetic engineering techniques to mimick 
some aspect of the disease) are very important tools in tackling the molecular basis of 
neurodegenerative disorders and in understanding the mechanisms of disease progression. Many 
organisms, including mouse, zebra fish, worms, and fruit flies, have been used to model AD. The vast 
majority of these models are based on the overexpression of one, two or in some cases several human 
mutations that result in the accumulation of A or hyperphosphorylated tau in the brain. Despite many 
promising results in animal experiments, the drugs that have made it to human clinical trials have so 
far failed. Moreover, in some instances the failure was not only in reaching the primary objectives, but 
also due to serious adverse effects in the tested patients. Thus, it could be concluded that animal 
models are highly informative for molecular processing of A and tau, but may not reflect the 
pathophysiology of sporadic AD in humans. Despite some efforts to generate disease-relevant 
experimental animal models 265,266 this issue remains as a critical need area for defeating AD. We should 
bear in mind that there are some inherent problems with transgenic mice: the gene is inserted at 
unknown locations in the genome and other genes could be disrupted, non-natural promoters are used 
and the expression is un-naturally high. Recently, a knock-in mouse has been developed were the 
endogenous mice APP gene has been substituted for a human version carrying a FAD mutation. The 
major advantage of these mice with respect to the previous models is that they show ageing dependent 
amyloid pathology, neuroinflammation, synaptic alterations and memory impairment, all in a more 
AD-like manner. However, they do not develop tau pathology and, although promising models for 
future studies on amyloidosis, still are limited models for AD 267 . 
Since, the use of simple animal models reflecting a single aspect of AD has not been successful for 
developing potential new treatments, to create good animal models for AD is crucial to advance the 
understanding of the basic disease biology (reviewed in 268). New research breakthroughs are needed 
for the development of new models, which optimally should reflect the heterogeneity of the disease. 
Another possibility is that in the majority of the AD cases, Aβ and tau pathologies are end points of 
other disease driving mechanisms. Thus, achieving a successful inhibition of Aβ and tau pathologies 
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might not necessarily mean finding a successful drug for AD.  Considering the heterogeneity of AD, it 
is probable that a multi-target approach will be necessary. 
Mechanisms of Alzheimer disease 
Epidemiological evidence underlines the importance of vascular health and diabetes in the 
development of AD and hypertension and high blood cholesterol levels have been shown to enhance 
the risk for AD in many studies 269. In addition, several other pathways have been identified that can 
contribute to disease development, such as head trauma-traumatic brain injury 270, ischemia and 
hypoxia 271, neuroinflammation 272, environmental toxin -N-methylamino-L-alanine from 
cyanobacteria 273, and metabolic abnormalities involving decreased brain glucose uptake 274.  Although 
at present, using risk indicators only modestly enhances the reliability of predicting who will develop 
AD, their larger importance is that they identify pathways and processes leading to AD. In the recent 
years, large new genome wide association studies (GWAS) and systematic exome sequencing 
approaches have confirmed some of the previously known pathways and have also identified other 
novels. The new loci identified have however modest effects on AD risk (with odds ratios in the 1.1-2.0 
range) 275. These analyses continue with pooling of larger number of samples.  
In broad terms, GWAS identified cholesterol metabolism, innate immune system, and endosomal 
vesicle recycling as important contributors to AD. Before these new genetic studies, a large amount of 
evidence suggested a pathogenic link between disruptions in cholesterol metabolism and AD. The 
strongest known genetic risk factor for sporadic AD is the presence of the E4 allele of the cholesterol 
carrier apolipoprotein E (APOE) 178. Since the discovery of APOE4 as a major risk factor for AD, 
considerable efforts have been made in linking this molecule to Aβ metabolism, aggregation, and 
deposition. An increased plaque deposition has been observed in APOE4 individuals and in animal 
models of brain amyloidosis (accumulation of Aβ in brain tissue) 276. APOE4 can potentiate Aβ toxicity 
in vitro 277,278 and in animal models 279. It has also been suggested that carriers of the APOE4 allele might 
be less efficient in mediating Aβ clearance 280. On the other hand, the contribution of APOE4 to tau 
pathology remains poorly understood. A reduced capacity for neuronal delivery of cholesterol of 
APOE4 allele carriers is believed to have consequences for the development of new synapsis 
(connections between neurons) and for repair mechanisms. Indeed, the brain is the major cholesterol 
containing organ in the body 281 and an efficient cholesterol metabolism is the brain is crucial for 
recovering damaged membranes. Also, neuronal axons are surrounded by cholesterol rich myelin, 
which both protects the axons and facilitates neurotransmission.  Thus, an impaired cholesterol 
synthesis, delivery or metabolism is likely to contribute directly to disease progression 281. This notion 
is supported by GWAS, where genes related to cholesterol synthesis, transport, uptake or metabolism 
were found to be linked to AD (e.g., ABCA7, ABCA1, CLU, CYP46A1) 275. However, new efforts are 
necessary to understand the underlying mechanisms by which APOE4 other cholesterol-related 
molecules contribute to AD pahtology. Also, if experimental manipulation of brain cholesterol 
metabolism has therapeutic potential for AD needs to be clarified. 
Studies in the late 80s already indicated the role of the innate immune system and the complement 
cascade (a part of the immune system that helps the ability of antibodies and phagocytic cells to clear 
toxins or pathogens from an organism) in relation to AD pathogenesis 282. The brain has its own innate 
immune system, which can maintain a low grade, systemic inflammatory reaction. Presumably, the 
innate immune system of brain, as in other tissues, has a protective and defensive role. But it is also 
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probable that a chronic inflammatory process may damage the neuronal cells. AD brains show 
activated immune system cells (microglia/macrophages), as well as a large variety of proteins resulting 
of inflammatory reactions. Proteins of the classical complement cascade may also be of particular 
importance, since studies have shown that they are largely expressed in the cortical pyramidal neurons 
which are severely affected in AD 283. Whether complement-producing neurons are particularly 
vulnerable to immune system attack remains unknown. Inflammation has been recently proposed as 
an early pathogenic event in the disease 284. Lately, GWAS studies have clearly shown that variability 
in the innate immunity confers risk for AD 186,187. The isoform S of the complement receptor type 1 
(CR1) has been associated with AD 189 and it has been hypothesized that is likely associated with 
increased complement activation 285. Indeed, the complement cascade is known to be activated by A
β286 . This would activate phagocytic mechanisms remove the Aβ deposits. If this process fails, a 
persisting complement activation would cause excessive inflammation that could damage the neurons.  
Another AD/inflammation associated gene uncovered by exome sequencing is TREM2 201. TREM2 has 
being shown to suppress inflammatory response in microglial cells 287. Thus, it has been speculated 
that TREM2 could participate in the regulation of phagocytic processes to remove amyloid. 
Consequently, a lack of function of TREM2 could also result in chronic inflammation, and amyloid 
accumulation. Interestingly a very recent report  has identified apoE as a ligand for TREM2 288 , the 
biological consequences of this association and its relation with AD pathology remain to be defined.  
Despite the solid links between inflammatory and immune components to AD pathology the 
mechanisms by which they affect the onset of amyloid deposition and tau phosphorylation need to be 
elucidated. Longitudinal data are missing, and since inflammatory responses can have both beneficial 
and detrimental effects, to understand how to regulate inflammation effectively is an important 
challenge for AD research. 
The recent GWAS studies have also revealed endosomal vesicle recycling as one of the pathways of 
importance for AD pathogenesis 186,187. Endosomes are a dynamic vesicular network that provides an 
environment for material to be sorted before it being degraded. Some material from endosomes is 
recycled to the plasma membrane of cells and SORL1, PICALM and BIN1 are all likely to be relevant 
molecules in this category. Very little is known about the functional implications of this discovery. 
However, it is worth mentioning that some on the metabolism of APP occurs in the endosomal pathway 
289, and it seems plausible that impairment of vesicle recycling would have detrimental consequences 
for important cellular systems such as secretory or autophagy pathways for secretion or degradation. 
In other words, impairments in the machineries to secrete or to degrade unwanted proteins could 
affect the survival of neurons.  
Together, epidemiological and genetic studies of AD individuals have categorized insulin resistance, 
deficits in cholesterol transport, hypertension and neuroinflammation as mechanisms contributing to 
AD275.  
Another hypothesis has proposed that AD is a prion-like pathology. According to this model, Aβ or Tau, 
misfolded or aggregated, are produced in one cell, secreted to the extracellular space, and entered 
gain into neighboring connected cells, where they trigger further Aβ or Tau aggregates.  Thus, Aβ and 
Tau inclusions begin in specific regions of the brain and are spread to other areas (for review, see291,292. 
Intracerebral or intraperitoneal injections of Aβ or extracts from AD brains were shown to induce 
amyloidosis in the brain of in vivo models 291,292More recently, Jaunmuktane et al 293reported an 
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autopsy study of individuals who received human cadaveric supplementary pituitary hormone when 
young, and showed brain Aβ pathology at the age of death (36–51 years). The authors suggest that 
cadaveric pituitary hormone could contain 'seeds' of Aβ that transmitted the pathology. Indeed, 
further research is necessary to clarify the mechanisms and possible risks deriving from transmissible 
Aβ or tau. 
However, it is unclear whether they are upstream or downstream of the amyloid and tau pathways. 
There is a consensus that  aggregation and accumulation is the cause of FAD. However, this view is 
not consensual for the majority of AD cases (without genetic mutations) Indeed Aβ is also important 
in the pathology, but may not be the cause of AD in non-genetic cases. The existence of variant 
pathways to AD is probably reflecting the heterogeneous etiology of the disease. To discern which 
overlapping, intersecting or synergic mechanisms in these pathways induce brain Aβ and Tau pathology 
remains as an important challenge for the future. The identification of patient subtypes with 
homogenous etiology and prognosis will result in more accurate, personalized, treatments. Intensifying 
innovative basic research will also result in the identification of novel biomarkers for subtyping AD, 
which will open possibilities for precise medicinal interventions (Figure 5). 
 
Future  goals and vision  
 
Despite the efforts in the past three decades, we still need to elucidate the causal mechanisms of AD. 
Also, the assumption that the molecular mechanisms mediating the genetically determined forms of 
the disease are identical to those resulting in late-onset AD needs to be demonstrated. Ongoing non-
European Initiatives like the Alzheimer's Prevention Initiative (API) and Dominantly Inherited Alzheimer 
Network (DIAN) studies211 will determine, in the near future, if clearing A from the brain will be 
effective to treat FAD. API is an international public-private consortium established to conduct 
research in a 5,000 member family (the world's largest in which a gene for FAD has been identified) in 
Antioquia, Colombia. DIAN, is an international initiative funded by the National Institute on Aging (NIA) 
tracking participants from families in whom an Alzheimer's-causing mutation has been identified.  A 
possibility is that targeting A will be only successful for the autosomal dominant types of the disease, 
where increased A production occurs from birth. For the majority of AD cases, where amyloid 
accumulation is likely a late event resulting from other metabolic disruptions, the strategy will probably 
not be so simple. We have considerable information on different pathways contributing to the disease. 
To discern the causative forces and the overlapping mechanisms among them, is one of the priorities 
for the future. To determine how these mechanisms result in A accumulation and tau 
hyperphosphorylation will be fundamental to understand the disease.  
The identification of patient subtypes, with homogenous etiology and prognosis, will result in more 
accurate treatments in the future. It is likely that different subtypes, resulting from different causative 
pathways, should be treated differently. Intensifying innovative basic research will also result in the 
identification of novel biomarkers for subtyping AD, which will open possibilities for precise medicinal 





Epidemiological and genetic studies have successfully uncovered risk factors and molecules for AD. 
Now, it is essential to understand the molecular mechanisms behind those factors. It is likely that 
preventive strategies will be successful in delaying a few years the onset of the disease. However, in 
an increasing aging population, the need to find a cure or an effective therapy for AD remains 
imperative.  For that, there is need of ambitious programmes in basic research. Without new 
breakthroughs in understanding AD pathogenesis, the development of a cure seems unachievable. 
 To implement large-scale programmes to support of basic research in AD 
 
 To intensify the identification of novel, “out-of-the-box,” disease modifying strategies. 
 
 To increase efforts in understanding disease mechanisms with emphasis in systems biology, 
vascular research, neuroplasticity and inflammation. 
 
 To develop relevant animal models for AD. Optimally, these models should reflect the 
heterogeneity of the disease. 
 
ALZHEIMER DISEASE DIAGNOSIS AND CLINICAL ASSESSMENTS INCLUDING BIOMARKERS 
 
Summary 
The diagnosis of AD and other dementias is complex, requiring cognitive and functional assessment, 
sometimes with serial evaluations, and exclusion of other morbidities causing dementia. New robust 
and affordable tools are required for AD diagnosis. The use of AD biomarkers, from blood or 
cerebrospinal fluid (CSF) and brain imaging such as MRI or PET scanning, are not yet widespread, except 
in the setting of clinical trials in specialist clinics. Better approaches are needed for both subjective 
cognitive testing and objective diagnostic criteria for AD.  
 
 
What effect does an AD diagnosis have in patients and their families? The consequences of the 
diagnosis of AD for patients and families are complex. Given the background that AD is one of the most 
feared diseases, the disclosure of a dementia diagnosis can result in severe mental distress and there 
is evidence for an increased risk of suicide after the diagnosis has been made 294. However, there is 
also evidence that the adequate disclosure of AD can relief symptoms of anxiety in patients, because 
it clarifies a frightening loss of cognitive capacities 295. At more advance stage of AD, self- reflection is 
often impaired and the meaning of the dementia diagnosis is not understood fully by the patient, which 
prevents severe mental distress. For caregivers, the disclosure of an AD diagnosis is also stressful and 
associated with fears and grief, but can also trigger seeking and receiving help and coping with the 
situation. Overall, the process of providing information on diagnostic procedures and meaning of 
outcomes, applying and interpreting diagnostics, disclosing the diagnosis and providing counselling on 
prognosis and treatment options is very complex and individualized procedure, which is becoming 
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even more complex with earlier diagnosis and the increasing availability of new biomarkers and 
treatment options. This constantly increases the demands on the skills of the physicians and requires 
increased specialist knowledge. If provided in an individualized and highly competent fashion the 
diagnostic process of Alzheimer's disease can be helpful for patients and caregivers. If applied with 
insufficiently or inadequate, it can be devastating and harmful. 
What health services and professionals are usually involved in such diagnosis? There are a wide variety 
of involved services and professionals in different European countries depending on the health care 
system and the reimbursement structure. In many countries, for example Germany, a large proportion 
of patients with AD is only seen by the General Practitioners (GP), where often the diagnosis is not 
firmly established. Other patients are referred to neurologists or psychiatrists in private practice. Only 
a very small proportion of patients is diagnosed in specialized centers, such as memory clinics, which 
are usually linked to large hospitals and universities. There is no specific reimbursement structure for 
guideline based dementia diagnosis. In Germany, there is currently also no defined pathway of care or 
diagnosis for dementia. In the UK, policies to increase recognition of dementia have introduced limited 
screening into hospitals for acute admissions and into some dementia practices. Such introduction of 
policy without prior trial evidence has been controversial and, some would argue, has led to further 
delays in access to diagnostics services because of the large volume of referrals.  
Why is diagnosis relevant? A diagnosis of the dementia syndrome and clinical diagnosis of AD is usually 
the basis for the pharmacological and non-pharmacological treatment and can be a route to access for 
support for the person with dementia and their loved ones. In younger people the differential diagnosis 
of different causes of dementia will be important for treatment decisions and estimation of individual 
prognosis. In older people in whom most dementia is mixed this is arguably less helpful. Rarely are fully 




Increased awareness has led to dementia being the top disease in terms of what individuals most fear. 
This was not necessarily the intention of the awareness campaigns, but may be a consequence. In the 
absence of improvements in quality of life and treatments for people with dementia, there might be 
few incentives for family doctors to pursue a diagnosis of dementia.   
The main challenge for clinical assessment of patients with AD today is the transfer of concepts and 
methods, which were mainly developed for advanced dementia, to the early stages of the disease. The 
focus on early stages, however, is crucial, because future treatment, still to be developed, will most 
likely have to be initiated at those stages to be effective. This transition can be achieved by 
understanding AD as a slowly progressive disorder of cognition starting gradually before full dementia 
is reached. The main aim of the assessments tools for symptoms of AD is identifying and mapping 
individual components of cognitive decline (e.g. memory, attention, language) from the earliest 
disease stage to progressive impairment of function and relate them to biomarkers as indicators of AD 
pathology.  
The identification of very early disease symptoms, of effects of treatment on these symptoms, and of 
predictors of treatment outcomes at the very mild symptomatic stage are urgent priorities. Related to 
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this is a conceptualization of the very early stage of AD as a disorder with distressing impairment of 
memory, which affects individual’s well-being even in the absence of severe impairment in daily 
functioning.  
AD as a neuropathological process is a slowly evolving condition in the brain with a quite long 
preclinical period without symptoms, followed by a prodromal phase with very mild symptoms and 
finally the dementia phase. Currently the clinical diagnosis of AD in clinical care and in the majority of 
clinical trials is made at the stage, where dementia is reached. Overlapping but slightly different criteria 
set for AD dementia are provided by the clinical classification system ICD-10, which is being used in 
Europe and by the US diagnostic manual DSM V, as well as by IWG-2, NINCDS-ADRDA and NIA-AA 
research criteria. These criteria list features to make the clinical diagnosis of typical AD, such as the 
slowly and progressive onset and course and memory deficit as the initial presentation. They also 
acknowledge atypical presentation such as the language variant (logopenic aphasia), the visuo-spatial 
variant (posterior cortical atrophy) and the variant with executive dysfunction (frontal variant). The 
reliability of criteria has been established in the clinical settings (i.e. different physicians agreed 
reasonably well when applying the same set of criteria to the same patients) 296. People with a clinical 
diagnosis of AD when followed to post mortem, however, do not always have Alzheimer type 
pathology, with around 20% suggested to be misclassified during life in one report 297. Also, there are 
many older people who fulfil neuropathological criteria for Alzheimer’s disease, but who are not 
demented when they die, creating a continuing and largely unaddressed conundrum for the field of 
AD and its early detection.  
The two major conceptual changes in recent years have been the introduction of biomarkers in 
combination with the clinical syndrome definitions in new research criteria 298-301 and the introduction 
of criteria for pre-dementia stages of AD, which can be diagnosed based on mild symptoms plus 
biomarkers or even in the absence of symptoms based on biomarkers alone 298-302. These two recent 
approaches are currently applied in research including validation studies and in clinical trials on 
dementia and dementia prevention. They are not used in clinical practice yet.  
Clinical assessments of AD patients need to lead to the detailed description of symptoms, to better 
understand the natural history of the disease in individual patients, including those with atypical 
variants of AD. This knowledge would be helpful for evaluating the variation in disease courses, as well 
as for assessment of efficacy of interventions, stratification in clinical trials, and prediction of cognitive 
and functional decline. 
The standard instruments in clinical care and clinical trials today include comprehensive and detailed 
cognitive test batteries, rating scales of functional impairment, informant-based questionnaires on 
instrumental and basic activities of daily living (IADL and ADL), on neuropsychiatric symptoms, on 
quality of life, on disease related burden and others. The majority of tools have been developed for 
the assessment of patients with dementia between the mild and the severe stage. Even though these 
measurements are widely accepted and understood in terms of their performance in clinical and 
population settings they are acknowledged as relatively insensitive for people with high levels of 
education. Furthermore, such instruments sometimes lack sensitivity for very mild symptoms of the 
disease. Many measurements as applied will have uncertain reliability (i.e. coming to the same result, 






There are three main challenges with regard to improved assessment of cognition. First, it is common 
today in clinical practice and clinical trials to describe the cognitive performance of patients with a 
single global score (e.g. the commonly used Mini-Mental-State Examination Test (MMSE) expresses 
the level of cognitive performance with a single number ranging from 0-30; the standard scale for 
cognitive testing in clinical trials, the Alzheimer’s Disease Assessment Scale, cognitive part -ADAS cog- 
expresses cognitive function by a single number between 0 and 70). This approach needs to be 
extended by measuring individual components of cognition (e.g. memory, attention, language) to 
increase understanding of how these individual components are affected over time by the disease and 
how they individually respond to treatment. Also, this would aid in describing different clinical 
subtypes of AD.  
The second main challenge is detection of earliest symptoms and symptomatic changes below the 
detection threshold of currently used tests. Several studies have described decline in different 
cognitive domains at the preclinical stage of AD in individuals at risk 302. Measures of this change, 
however, have not been standardized and are not applied on a large scale across studies. Also, they 
are not tested in all the different patient groups to which they might be applied to in the future (i.e. 
patients of GP, patients of memory clinics). New tests therefore need to incorporate techniques, which 
allow reliable detection of very subtle early changes in AD.  
Subjective cognitive decline (SCD), defined by the experience of worsening of cognitive abilities, is 
often reported by elderly people 303 . SCD is associated with increased risk of progression to dementia 
in population studies, (e.g. 304,305). Some studies have shown that it adds predictive information with 
regard to the risk of future dementia in an individual, which is of a similar magnitude as impairment in 
performance on a memory test (e.g. 306). There is an increasing number of studies reporting that 
subjects with SCD show evidence for AD pathology by biomarkers, such a Aß42 reduction and Tau 
increase in the CSF 307 or AD typical changes in brain imaging (e.g. 308,309) more often than subjects 
without SCD. Recently, it has been shown that subjects with SCD and evidence for AD pathology 
measured by cerebrospinal fluid (CSF) markers are at increased risk to develop dementia310. According 
to a recent international consensus publication 303, future research should develop improved and 
standardized assessments of SCD, and should investigate the relationship with objective decline in 
cognition as well as with psychiatric conditions such as depression and anxiety 311.  
The third challenge of cognitive testing is improved robustness against intra--and inter-individual 
variance and rater- /rating-related confounds. Intra-individual variance refers to the fact that in some 
tests the performance of one individual is subject to day-to-day changes, for example related to 
different levels of alertness and concentration, and subject to learning effects, when the test is 
repeated (repetition effect). Problematic inter-individual variance can occur for example in the case of 
a verbal recall test, which aims at testing memory, in which individuals with greater language abilities 
may have an advantage over subjects with poorer language abilities. The rater- or rating related 
confounds describes the observation that patients score differently on a test depending on how it is 
administered with regard to task instructions, but also with regard to behaviour of the person who is 
giving the test (the rater). In particular, at the early disease stage (the late asymptomatic at risk stage 
and the very early AD stage) 302, the decline in cognitive performance is small and often cannot be 
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detected, because the normal day-to-day variation in performance on a particular test is larger than 
the subtle decline related to early AD. Thus, there is a strong need to develop tests with less variation. 
These tests require very standardized task instructions to reduce the rater-related confounds and 
should minimize components which increase the inter-individual variance (e.g. being independent of 




Current ADL scales have low sensitivity for early functional changes in the course AD. However, effects 
of early cognitive impairment already affect IADL at the pre-dementia stage of AD and IADL impairment 
actually predicts decline to dementia 306. At present, some diagnostic criteria acknowledge the 
presence of mild IADL impairment and define the cut-point to dementia by a level of impairment which 
interferes with independency. Mild IADL impairment already reflects disease burden for individuals. 
Thus, it is important to improve assessment of IADL and to measure effects of early interventions on 
IADL to establish evidence that a particular intervention have a relevant and meaningful effect for the 
patient. Current scales for IADL impairment in very early AD rely largely on observations reported by 
the informant. Innovation in IADL assessment therefore also includes direct measures of the time 
needed and number of errors in a patient, while performing IADL activities 312,313.  
Closely associated with IADL assessment is the approach of individualized outcomes of treatment This 
refers to defining specific IADL (e.g. using a telephone) which are individually identified with a patients 
as a goal of treatment (goal attainment), as opposed to applying an identical IADL scale to all patients 
314. This approach is appealing as it directly reflects individual patient-related benefit (i.e. the most 
relevant areas of impairment for an individual are defined as opposed to assessing in everybody 
whether for example cooking still works, including those, who never cook). It also mirrors clinical 
practice, where the patients discuss and work on individual goals with the treating physician.  
Standardization of the goal attainment approach for clinical trials, however, is challenging.  
 
Quality of life assessment 
Evidence of effects of treatment on quality of life of patients is increasingly required by decision makers 
on reimbursement in some countries (e.g. in Germany) as a measure of patient-related benefit of an 
intervention. Reliability and validity of most currently used scales for the assessment of Quality of Life 
in AD are very limited 315. Recently developed instruments of refined disease-specific Quality of Life 
assessment in AD, including early disease stages, are being validated and will be increasingly integrated 
in observational studies and clinical trials 316,317.  
 
Post-mortem diagnosis: the need for an increase in autopsy rates 
 
Despite biomarker discoveries in the clinical diagnostics of AD and other neurodegenerative dementias, 
there is still a need for neuropathological confirmation for a definitive diagnosis which requires a 
postmortem examination, to confirm the presence of extracellular deposition of Aβ peptides and 
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intraneuronal aggregates of neurofibrillary tangles in brain tissue (Figure 6) (National Institute on Aging 
(NIA)/Reagan Institute of the Alzheimer Association (AA) Consensus Recommendations for the Post-
mortem Diagnosis of AD or NIA–Reagan Criteria318). Unfortunately, in many European countries and 
the US, the number of autopsies has decreased by at least half since the 1970’s, which can potentially 
mask diagnostic errors. Such diagnostic errors will reduce power in research studies and may thus 
hamper the progress. The reduced autopsy rates will lead to less reliable records of cause of death and 
this is of even greater concern in the aged population with chronic conditions where the individuals 
will have multiple morbidities and the cause of death might be uncertain. The low autopsy rate for 
neurodegenerative diseases is particularly alarming since the reported cause of death for dementia in 
Sweden for example has quadrupled since 1987. Furthermore, in a study on 176 consecutive 
neuropathological examinations of clinically diagnosed patients with dementia, the clinical and 
pathological dementia diagnoses were in agreement in only 49% (86) of cases 215.  
The global decline in autopsy rates underpins the need for collaborative and specific efforts to facilitate 
neuropathological examinations in patients, particularly if included in clinical research studies or 
clinical trials. Indeed, advances in neuropathological characterization of neurodegenerative diseases 
suggest that there is a complex interplay of several pathologies underlying the clinical presentation of 
our most common dementias including AD, 319 which has resulted in new guidelines 320,321. Equally 
important, there is a need for basic research studies on human brain tissue as a complement to in vitro 
and in vivo animal studies, which will be possible only if human brain and spinal cord tissue are 
collected post-mortem. Studies on autopsy rates for other conditions suggest that the rate of autopsy 
is correlated to how effectively physicians recommend it 322.  
Thus one strategy to increase the autopsy rates is to train physicians and health care professional in 
understanding and communicating the value of a neuropathological confirmation of the diagnosis as 
well as the value for researchers to have access to human post mortem tissue for basic research. 
Another strategy is to build and facilitate national and transnational brain biobanking infrastructures 
which would ensure that the tissue is collected using standardized and harmonized protocols such as 
the Brain Net Europe (BNE) Initiative.  
 
The use of biomarkers in Alzheimer’s disease diagnosis  
 
Biomarkers allowing accurate, early and differential diagnosis are being developed and are currently 
in a transitional state between research and clinical practice. Widespread application is being delayed 
by a number of methodological, economic and political factors. Particularly, their practical usefulness 
is questioned at a time when interventions are lacking to significantly delay the progression of 
neurodegeneration. The major methodological factor is related to standardization issues. For CSF 
biomarkers, we need certified reference materials and methods and automated assays to allow for 
uniform measurements and decision limits irrespective of what laboratory performs the 
measurements. Similarly, standardization is an important topic in neuroimaging. The economic and 
political factors relate to costs for sample acquisition and analysis and how the biomarker results 
influence the clinical management of the patient. Validated diagnostic algorithms are currently lacking 
but several have been suggested, most recently in the IWG-2 research diagnostic criteria report 302 
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(Table 10). Another initiative, the NIA-AA criteria has been developed in parallel 323and a comparison 
between these criteria and the IWG criteria is shown in table 11.   
 
Current status 
We have seen a quite dramatic development of several diagnostic biomarkers that can be used to 
detect AD neuropathology even in individuals at preclinical stages of dementia.  Biomarkers can be 
classified into diagnostic markers and progression markers. Diagnostic biomarkers are pathological 
markers, reflecting in vivo pathology. They can be used to detect changes even at asymptomatic stage 
and may not correlate with clinical severity. PET imaging of amyloid plaques in brain and measurement 
of Aβ42 and P-tau in CSF are examples of diagnostic markers (Figure 7, 8). A progression marker may 
have poor disease specificity and may not be present in the early stage of the disease, but will reflect 
clinical severity. PET imaging of cerebral glucose metabolism, CSF T-tau and brain atrophy measured 
by MRI both can be considered as markers for disease progression (9) (Figure 9). 
Brain volume and structure can be investigated by computerized tomography (CT) and magnetic 
resonance imaging (MRI) imaging. The size of certain brain regions as the temporal lobe (hippocampal) 
are used to evaluate brain atrophy 324. In order to study  the functional activity of the brain, imaging 
techniques as positron emission tomography (PET) are used to measure the cerebral  brain glucose 
metabolism and cerebral blood flow,  which both correlates with cognitive function 325. Molecular PET 
imaging also allows detection of AD pathology manifested as amyloid plaque deposition 325. Several 
PET tracers are under development for imaging tau deposition in AD and non-AD dementia disorders 
326. CSF can easily be obtained by lumbar puncture which is a well-established and safe procedure in 
clinical neurology (Peskind ER et al., Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5). A CSF test 
result showing increased levels of CSF T-tau and P-tau levels, and decreased levels of A42 327 indicates 
AD-like neurodegeneration in conjunction with Aβ pathology.  
Amyloid imaging and CSF biomarkers thus allow early detection of AD, and most importantly, 
discrimination of patients with mild cognitive impairment (MCI) that have underlying AD pathology 
and therefore a high risk to progress to AD dementia (prodromal AD) 328,329 (Figure 10). Three amyloid 
PET tracers florbetapir (AmyvidTM), florbetaben (NeurozecTM), flutemetamol (VizamylTM) have during 
2012-2014 been approved by US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) for use in clinical assessment of memory disorders to exclude AD (Lerner AJ Neurology 
2013:81:1108-1109, the International Federation of Clinical Chemistry and Laboratory Medicine and 
the Global Biomarker Standardization Consortium are making progress to create certified reference 
methods and materials to standardise the CSF biomarkers 330,331 and a fully automated assay of CSF 
Aβ42 with very low inter-laboratory coefficients of variation (1-4%) was just described While structural 
imaging is well established in clinical assessment of memory impairment, the use of CSF and PET 
imaging biomarkers for tau and Aβ pathology are starting to become incorporated into clinical routine 
in memory assessment at specialist clinics in many countries in Europe. However, an important 
question in many countries is the reimbursement from health assurance.  
The use of these biomarkers in longitudinal studies of cognitively normal individuals at risk has shown 
that the pathophysiological process of AD begins a decade or more before the appearance of 
symptoms.  A prospective cohort study in healthy controls, AD and MCI patients indicated that the Aß 
deposition is slow and that it takes around 20 years to reach onset of clinical symptoms332. Meta-
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analyses show correlation between amyloid positivity and clinical diagnosis, age and APOE genotype 
333,334. A patient with clinical symptoms of mild AD is already at a stage of the disease with profound 
losses of neurons in specific brain regions, such as the entorhinal cortex 335. Thus, it is not surprising 
that it is extremely difficult to reverse or slow down the symptomatic decline at this disease stage. It is 
likely that disease-modifying approaches will work best in clinical trials aimed at preventing the 
progression of the clinical syndrome in individuals with very mild or no clinical symptoms of AD yet, 
but with a genetic predisposition or positive CSF or radiological AD biomarkers, i.e., with prodromal or 
preclinical AD according to the IWG-2 lexicon 302. As explained above, some trials are already underway 
336. In these studies, AD biomarkers will be evaluated both before and after initiation of treatment to 
ascertain that any drug related clinical benefit correlates with biomarker evidence of a change in the 
underlying disease process. By such an approach, the drug’s effect on the target would be validated, 
and the validity of the biomarkers would be established. This would facilitate the evaluation of the 
overall results of the trials and also help in the design of new trials. Specifically, biomarkers would allow 
for addressing if the results of a negative trial could be explained by a lack of drug effects on the 
intended target or if the intended target changed in the expected direction but without resulting in 
clinical benefit. Similarly, clinical benefit in a positive trial would be a considerably stronger finding if it 
was backed by expected biomarker changes.  
Many AD biomarkers are at present not standardized enough to be applied in clinical routine, but 
standardization initiatives are ongoing337-339. It should also be acknowledged that Europe is not 
homogeneous technology-wise in regards to neuroimaging scanners, laboratory equipment and 
personnel with the necessary expertise; the diagnosis of neurodegenerative diseases in memory clinics 
is at present made mostly on clinical grounds with brain imaging (CT  or MRI) and clinical chemistry 
tests (CSF tau and Aβ) excluding other potential causes of the cognitive decline, such as depression, 
normal pressure hydrocephalus or cerebrovascular changes. Recently proposed diagnostic algorithms 
incorporating AD biomarkers 340,341 are presently being adapted to clinical realities around Europe, for 
example in the EU-JPND BIOMARKAPD project, which is a pan-European network of memory clinics 
and laboratories engaged in the uniform implementation and standardisation of diagnostic algorithms 
in the evaluation of patients seeking medical advice because of cognitive symptoms.. The diagnostic 
use of biomarkers will be dramatically boosted by the availability of treatments proven to be effective 
in pre-dementia disease stages, where biomarker evidence of AD pathology will be essential to allow 
for accurate diagnosis making.  
Proteomic studies on plasma biomarkers have so far been disappointing, with only a few replicated 
positive results342. A recent study on lipid profiles in plasma gave promising results 343, indicating that 
it may be possible to discriminate AD from cognitively healthy older adults by the use of a blood test. 
However, the number of cases was limited and independent replication of the results is necessary 
before any conclusion on the usefulness of such a test can be made. It is possible that a novel approach, 
such as the analysis of the profile of the different sugars (i.e., glycans attached to proteins) in CSF or 
plasma could be helpful. Interestingly, defects in glycosylation of proteins involved in the pathogenesis 
of AD, such as for example tau, have been reported in AD 344. Ideally, patients should be stratified on 
biomarker grounds, e.g., by amyloid and tau PET imaging or by the use of CSF Aβ and tau markers, as 
to whether they have A- or tau-predominant AD. This stratification will most likely be facilitated when 
methods for imaging of tau deposition in brain by PET are available, as well as for additional processes 
such as neuroinflammation or cerebrovascular dysfunction, detected by MRI, PET or CSF markers. The 
aim will be to personalize the selection of drugs to individual patients on objective grounds. If current 
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secondary prevention trials with anti-amyloid therapies are successful, patients may be selected for 
treatment during the preclinical stages of AD based on biomarker detection 336. Such therapies should 
be initiated at specialist clinics until more information on the clinical use of such therapies has been 
obtained. From a safety and cost perspective view, it will also be important to exclude individuals from 
certain treatments; for example an amyloid-negative patient should not be treated with an anti-
amyloid drug. Finally, novel generic markers of neurodegeneration that may be relevant to a broad 
range of neurodegenerative conditions would be helpful to evaluate the effects of disease-modifying 
treatments intended to slow down neurodegeneration, e.g., markers of synaptic dysfunction. Novel 
ultrasensitive measurement techniques have just opened up the possibility to measure such 
biomarkers in serum and plasma 345 
 
What needs to be done 
At a time when an effective treatment is lacking, an accurate appraisal of the societal values and 
utilities associated to knowing the diagnosis seems key for decision makers to allocate public funds to 
relatively expensive diagnostic procedures, but there are virtually no studies addressing this aspect so 
far. Biomarkers can help diagnosis at the preclinical stage of AD and more accurate differential 
diagnosis at the mild to moderate dementia stages 340,341,346 and some biomarkers are quickly gaining 
routine use in memory clinics. Still, guidelines for routine use of biomarkers for diagnosis are lacking, 
which may lead to uncontrolled and poor, non cost-effective use; overuse could lead to the 
identification of AD-related pathological changes with uncertain importance for the symptoms the 
patient presents; underuse could lead to that we misdiagnose AD as depression or other non-
degenerative brain disorders. Data are also scanty on the added diagnostic value of individual 
biomarkers, the optimally cost-effective sequence of biomarker assessment, and the role of key 
variables on patient characteristics such as age, co-morbidities and social factors (e.g., education 
level)347. It is essential to develop and standardize biomarkers into practical and affordable tools for 
clinical use to prepare for the next generation of preventive and disease modifying AD drugs.  
 
RECOMMENDATIONS 
In summary, the diagnostic biomarkers field is under rapid development. The robustness and predictive 
value of biomarkers are under investigation and novel biomarkers are being actively sought.  
 Currently available biomarkers need to be further developed into standardized and affordable 
tools that can be used in clinical routine to select patients for appropriate care and treatments 
as they become available.  
 
 The search for novel biomarkers with higher predictive value at pre-dementia stages of the 
disease needs to be continued, and simple low cost assays (preferably in blood) that could be 
used also in general practice should be developed. 
 
 There is a need to develop tools to measure cognitive characteristics of prodromal AD. The 
tools should be informed by cognitive neuroscience, should be sensitive to minor impairment 
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and changes, and should be robust in application and informative in the populations for whom 
they are intended. 
 
 
PHARMACOLOGICAL TREATMENT AND PRIORITIES TO ACHIEVE NEW EFFECTIVE TREATMENTS 
 
Summary 
An effective therapy for AD is perhaps the greatest unmet need facing modern medicine. To develop 
effective and affordable AD therapies will require an organized and concerted effort among 
governmental agencies, academic researchers and industry. Several drug candidates are currently in 
clinical trials, and a few drugs are approved for symptomatic treatment of dementia, but the overall 
success rate for AD drug development has been poor. New paradigms are required to incorporate 
advances in early diagnosis, genetic factors and epidemiology into the design of clinical trials for new 
drug candidates. Major longterm financial commitment will be required. 
  
In this section, we review the few available drug treatments for Alzheimer’s disease (AD) and 
summarise the symptoms that cannot be currently treated pharmacologically. We then describe drugs 
in development, and discuss the major challenges in developing effective pharmacological treatment. 
Finally, we provide a set of recommendations for policy decision makers. 
Pharmacological treatments for Alzheimer’s disease  
The increasing number of people with AD is leading to markedly more use of pharmacological 
treatment and greater medication costs. For example, in Sweden the total drug costs for people with 
dementia constituted about 1.1% of the societal costs of dementia in 2000, 1.6% in 2005 and 1.8% in 
2012 348.   Although drug costs are a small proportion of the total societal cost of dementia (the major 
cost proportion is within the municipal sector for long term care (about 80%), mainly for long term 
care), it constitutes a significant proportion of health care costs for people with dementia and in 
Sweden, the dementia drug cost proportion as proportion of the costs of dementia care in the health 
sector has increased from 23% in 2000 to 39% in 2012. This trend indicates that the incentives to 
provide treatment may be different from a health care budget viewpoint than from a societal 
viewpoint, since the economic impact of dementia drug costs in the health sector costs of dementia is 
so large. Moreover, the drift in diagnostic boundaries of AD toward earlier diagnosis may lead to 
greater use of marketed drugs even in the absence of efficacy evidence for pre-dementia cognitive 
impairment.  
Marketed drugs 
Approved drugs for marketing in Europe are the acetylcholinesterase inhibitors and memantine.  They 
are indicated for either mild to severe AD or moderately severe to severe AD, respectively.  These 
marketed drugs are approved for the dementia of AD. In addition, rivastigmine is approved for 
Parkinson’s disease (PD) dementia.  No drugs are approved for mild cognitive impairment MCI, 




As all are available as generics, the price has dropped considerably, for example for donepezil:  in 
Sweden by 98%, in UK by 97%, and in Germany by 84%, similar to previous price drops of for example 
enalapril, simvastatin and citalopram. However prescription rates have not necessarily increased 
although total prescriptions have due to the increasing number of people with AD is leading to 
markedly more use of pharmacological treatment perhaps because information campaigns from the 
drug companies have decreased or because the known and approved target population has already 
been reached.   Proprietary formulations of donepezil 23 mg, memantine 28 mg, and higher dose 
rivastigmine patch (transdermal formulation) are being marketed in Europe to compete with the 
generics despite the lack of evidence, as higher doses of proprietary drugs have not been shown to be 
more effective than the lower recommended doses.  
Effectiveness of marketed drugs 
The evidence we present comes from clinical and effectiveness studies of marketed drugs for the 
treatment of Alzheimer’s disease, and does not address other conditions, such as cognitive impairment 
due to mixed AD, LBD, older old.  
Although AD influences many functional domains, the main focus and primary outcome in most AD 
trials has been on cognition. Other potential meaningful outcomes, such as global measures of 
functionality, activities of daily living (ADL) and behaviour are in most studies secondary outcomes, and 
are more relevant in advanced dementia stages than in early phases of the disease. Studies in mild AD 
cases should include outcomes focusing on memory functions, while in later stages of the disease 
effects on ADL, psychiatric and behavioral disturbances are more clinically relevant.   
Efficacy based on cognitive tests and daily activities inventory can be reliably assessed in clinical trials 
of drugs for AD.  The effects for the marketed cholinesterase inhibitors, however, have been 
statistically small and engendered controversy on just how effective, and cost-effective, they are. The 
few RCTs (randomised control trials) where data on resource use and costs have been collected have 
not shown any significant cost savings or cost effectiveness for the brand-name drugs349. However, 
these clinical trials have not been designed for economic evaluations and the duration of these trials 
have been short (6 months to 1 year) in relation to the period where long term cost effectiveness is of 
interest. Thus, several simulation approaches have been applied, where inputs of effectiveness as well 
as data on mortality and costs can be applied on, for example, the expected period of survival350. The 
conclusion from such simulations (largely sponsored by drug companies) is that treatment is cost 
effective 349,351. Notably, these models assume long term use of the drugs over several years even 
though most patients take them shorter term. 
Outcomes from the trials cannot be easily generalised to clinical practice or to effectiveness.  Study 
populations in randomized controlled trials are generally highly selected in terms of inclusion and 
exclusion criteria. Very old people (for example 85+), who constitute a great proportion of the 
population with AD, as well as persons with medical comorbidities (which are common in the oldest 
old) are underrepresented, making generalisations to the clinical practice of dementia care from the 
trials problematic.  Duration of treatment in clinical trials is generally up to six months, with only a few 
trials extending beyond this period.  In clinical trials, cholinesterase inhibitors can be tapered and 
withdrawn without loss of function over 8 weeks. There is no need to substitute memantine.  Most 
patients can be withdrawn when there is uncertainty about its effects352. There is very little unbiased 
information on long term use or safety.  Rather there is a reliance on the medical records from research 
centres, research cohorts, and prescribing data.  
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For policy decision makers and stakeholders, long-term cost effectiveness may be of greater interest 
than efficacy in trials or clinical effectiveness per se. Since such long-term data will be unlikely  available 
from clinical trials, other sources such as economic simulations as mentioned above, registry data or 
results from epidemiological studies may be of interest. From an evidence based viewpoint, these 
alternative sources have lower creditability than randomized clinical trials.  Thus, there is no single 
design that can be used, and a synthesized approach where results from several sources are used may 
be a feasible way.   
Furthermore, instead of focusing on single drugs, combined drug treatment (and combined also with 
various non-pharmacological treatments) in various settings are perhaps better approaches. It is the 
total effect of an intervention package rather than of single interventions that are of interest, as shown 
in the FINGER study 168 
 
Effectiveness of the drugs for disruptive behaviours  
Randomized controlled trials evidence does not show donepezil or memantine to be effective for 
patients with significant behavioural disruption (i.e., agitation or aggression) 353,354. In mild to moderate 
AD patients, measurable changes can be observed on behaviour rating scales but these are in patients 
without marked agitation, and significance of the small mean change is unclear355. 
Effective pharmacological treatment of behavioural symptoms is a challenge. Modest advantages of 
antipsychotics for delusions or aggression are offset by their considerable toxicity, and they should be 
used cautiously or avoided356. Antidepressants have not been demonstrated effective for depression, 
but in some case have shown limited efficacy as, for example, citopram for agitation in dementia357. 
Yet cardiovascular adverse effects and worsening cognition limit their use as well (FDA warning 
citalopram, http://www.fda.gov/Drugs/DrugSafety/ucm297391). Anticonvulsants should not be used. 
Newer drugs with different mechanisms of action might eventually be helpful.  
It is also of importance to combine non-pharmacological and pharmacological treatment, where it is 
the total effect that is of interest, not the effect of a single treatment component per se358.  
 
Inequalities in AD treatment in Europe 
Reimbursement is crucial to the availability of many drugs. There are substantial inequalities in AD 
treatment in Europe despite the existence of common standardised diagnostic and treatment 
procedures. The proportions of people with AD who receive treatment with approved medications and 
treatment durations vary across Europe (Table 12) 359and globally 360. This can be partly explained by 
variations in prescribing practices and reimbursement policies among European countries. In some 
countries reimbursement requires decisions to be made by specialist doctors or in specialist centres 
(Table 13). Some others also require a continuous evaluation of the treatment decision to be made by 
a specialist, see table 13.  Reimbursement may not be made available to people with AD living alone 
or living in nursing homes. Other systems require specific examinations to be carried out prior to a 
reimbursement decision being made. Finally, there are considerable differences between European 
countries in the specified cognitive test scores that limit the initiation and discontinuation of treatment 
(www.alzheimer-europe.org).    
As seen in table 12, the situation varies across Europe, although the drugs are both approved or 




The centralisation of the market authorisation process at the level of the EMA has solved the problem 
of existing delays between the different European countries for marketing drugs for 
neurodegenerative disorders. However, the launch dates of products continue to vary across countries, 
as well as the timing for the integration of approved drugs in the reimbursement system. Thus, 
inequalities in the access to new drugs for AD still exist. The demand for AD social and medical care 
will continue to increase.  Successful future medications need to be introduced such that access to 
them is fair and equitable, that they are priced fairly.  Any effective treatment anticipated for patients 
with presymptomatic or prodromal AD will also increase the size of the market and the numbers should 
be estimated and provided for. 
Long-term effective therapy for cognitive impairment is a major unmet need. A drug that provides even 
one to two years of stable function or quality of life will be useful and cost-effective 361 regardless of 
whether the underlying Alzheimer’s pathology has been affected.  Indeed, current clinical trials for 
drugs in development for mild Alzheimer’s disease and prodromal AD are 18 to 24 months in duration 
in order to demonstrate longer term effects.  
Discussions are ongoing between the European (EMA) and US (FDA) authorities to harmonise the 
rules for drug approvals, since drug trials for approval often are done separately in the US and in 
Europe. 
 
Challenges and recommendations with marketed drugs  
Considerations with regard to current treatment include the diagnosis of AD, patients who will be 
offered treatment, use of evidence-based prescribing standards, and patient-preference-based 
standards to assist in treatment decisions; reimbursements across health care systems that are fair to 
patients, valid, including decisions to start and stop; and more consistent access and reimbursement 
policy across Europe.  Patient- and family-centred standards of pharmacological treatment have yet to 
be developed, the use of current medications needs to be linked to their ability to show better health 
outcomes including better function.  One need is to continue to assess effectiveness, the circumstances 
under which the marketed drugs are most helpful, whether there are groups or individual patients who 
can be recognized and who may particularly benefit.  
 
Drugs in late-stage development 
AD is a complex disease and there are many drug targets under investigation.  Current research 
emphasis is on amyloid-β pathways, tau, and small molecules. Table 14 lists drugs and their 
mechanisms that are in late-stage clinical development, i.e., phase 2 or 3. The diagnostic targets for 
new drugs include mild to moderate AD, prodromal AD 302 (i.e., MCI due to AD, 298), preclinical or 
presymptomatic AD, and treating at-risk populations (prevention). 
 
Drugs directed toward amyloid-β – immunotherapy, β- and γ-secretase inhibitors 
The most active research is taking place in the disruption of the amyloid pathway, as Aβ production or 
clearance are thought to be among the earliest pathological changes and to lead to neurodegeneration.  
These new drugs include vaccines and antibodies to Aβ, and β- and γ-secretase inhibitors, and 
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modulators. The first vaccine removed amyloid plaques, but caused brain toxicity and had no clinically 
significant benefit 362,363 
Current active trials for Aβ immunotherapies are taking place with monoclonal antibodies: 
solanezumab, gantenerumab, crenezumab, aducanumab, and with several Aβ vaccines, including CAD-
106 and ACC-001 (http://www.alzforum.org/therapeutics) 
γ-Secretase cleaves amyloid precursor protein (APP) intracellularly to produce Aβ fragments that are 
thought to be toxic and critical to the pathogenesis of AD; this enzyme was thought to be a valid 
therapeutic target. Unfortunately, clinical trials failed with an unexpected degree of toxicity and 
worsening cognition (avagacestat364, semagacestat365).  Reasons for the failures may have involved off 
target effects, the particular drugs used, and dosing366.  
β-secretase inhibits the β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves APP 
extracellularly to produce β-amyloid peptides (Aβ).  The development of BACE1 inhibitors is being 
avidly pursued and several have entered clinical trials (Table 14), including AZD3293 (AstraZeneca), 
LY3202626 (Lilly), R7129 (Roche), E2609 (Eisai), HPP854 (High Point); and others in preclinical stages.  
The most advanced is MK-8931 (Merck) which is in combination phase 2/3 trials for either mild to 
moderate AD or prodromal AD.  In phase 1 it reduced CSF levels of total and soluble AB by up to 84% 
and 88%. The two latter phase trials will involve approximately 1800 participants each367 treated over 
18 to 24 months. Outcomes and marketing authorization (if successful) are expected in 2018. 
Tau-targeting drugs 
Downregulating tau-related toxicity may reduce the impact of beta-amyloid by reducing the 
pathological hyperphosphorylation of tau protein, and has been demonstrated in vitro for many drugs 
often by inhibiting GSK3b (glycogen kinase3) which may detach tau from neurotubules.  Several 
companies have been developing tau-related approaches, Abbvie Bristol Myers Squibb, Lundbeck, 
Pfizer, Tau Rx (Singapore).  
Merck (Alectos) has aimed at inhibiting O-linked N- acetylglucosamine (O-GlcNAc), which modifies cell 
signalling and is decreased in Alzheimer’s brains, and related to increased tau hyperphosphorylation368.    
Antibodies can target the MAPT gene or tau protein (for example, AC Immune and Genentech and J&J 
programs(http://www.acimmune.com/content/img/pdf/FinancingD_20140109_final.pdf) 
((http://www.alzforum.org/therapeutics/aci-35)(http://www.alzforum.org/news/conference-
coverage/therapies-take-aim-tau). Axon Neuroscience is in a phase 1 study with active vaccination 
against tau369,370. Tau Rx, methylene blue, is based on the view that tau clearance in general must be 
achieved to modify disease progression.  A formulation of methylene blue, LMTX 371-374, is being tested 
in a phase 3 AD trial and a phase 2 frontotemporal dementia trial, with 833 mild-to-moderate patients 
followed for 12 months, and 500 mild patients for 18 months, respectively. Outcomes of both trials are 
expected in 2016. 
 
Alternative targets and therapeutic approaches 
As the targets for AD are not validated and potentially many, there are alternative therapeutic 





Recommendations to advance therapeutic development 
In summary, since the advent of the acetyl cholinesterase inhibitors, drug development for AD has 
been disappointing.  All drugs in phase 2 and 3 have failed.  Pursuit of the amyloid cascade hypothesis 
has not so far been rewarding, and clinical research efforts are now being directed more broadly.  AD 
drug development is moving towards earlier stages of the illness, with prodromal AD and preclinical 
AD RCTs. This raises questions about ethics, cost sustainability, costly diagnostics (biomarkers) and 
analyses, as well as longer durations of trial participation for people with AD and their families.  
In future, if drugs are approved for AD treatment and marketed as disease modifying or as long-term 
treatments, the spectrum for diagnostic work-ups will likely shift from mild and prodromal AD to 
preclinical AD. This shift may have two implications, firstly regarding the validity of early-stage or 
preclinical diagnoses  and secondly regarding the long term cost effectiveness of treatment. 
Biomarkers will be crucial for diagnosis, but have yet to be validated. Even if they were validated, 
available biomarkers would have to have very high levels of sensitivity and specificity (e.g. 95-99%) to 
be clinically useful. There will be challenges in terms of positive predictive values when the prevalence 
in the target population will be (for example 10% instead of 50%, as it may be on memory clinics today). 
The risk for false positive and false negative cases needs to be carefully considered 375 
There is a lack of predictive biomarkers. There is no evidence that a patient with mild memory 
impairment will evolve differently from one with worse impairment, or, for example, that one with a 
small hippocampus or low CSF Aβ levels will respond to treatment better than a patient with a larger 
volume or higher levels. The prognostic value of AD biomarkers such as aβ and tau is unclear in very 
advanced age, and 70% of dementia cases in the general population are people aged 75+. 
As there are difficulties in estimating the long term cost effectiveness of currently available drugs, a 
shift to earlier stage diagnoses, such as to preclinical and prodromal AD, the duration for expected 
effects of treatment will be prolonged by many years. Furthermore, the resource use and costs during 
the predementia period are low, and conventional trials such as RCTs will not be useful for cost-
effectiveness discussions.  Other strategies, such as simulations or the use of registry data will probably 
be better options than conventional trials.  
The ageing of populations is occurring worldwide, led by the demographic transition that has already 
happened in many European countries and Japan. Ageing adds additional challenges in terms of early 
diagnosis because of our unclear understanding of the threshold between age-related and disease-
related cognitive decline. Another critical problem is the multifactorial nature of dementia in old 
individuals (concurrent vascular and different types of neurodegenerative lesions).  
Physical comorbidity is also frequent in advanced age, generally accompanied by poly-
pharmacotherapy, with not optimal use of drugs, and with anticholinergic and sedative effects being 
common in geriatric patients with AD376,377 
These challenges highlight the importance of offering a comprehensive geriatric assessment (GSA) to 
every patient, defined as a multidisciplinary diagnostic and treatment process that could identify 
medical, psychosocial, and functional limitations of a frail elderly person in order to develop a 
coordinated care plan to maximize overall health with aging 378,379. GSA can support both evaluation 
and management of people with dementia, improving pharmacological treatment decisions. Also, 




Existing and future regulatory processes 
The unique challenges in AD and other dementias have driven regulatory policy. Some relevant 
guidance documents from the EMA and FDA in the area of AD and other neurodegenerative diseases: 
EMA “Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer’s 
disease and other dementias”; EMA “Qualification opinion of a novel data driven model of disease 
progression and trial evaluation in mild and moderate Alzheimer’s disease”; FDA “Guidance for 
Industry, Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease”; FDA 
“Guidance for Industry, Expedited Programs for Serious Conditions – Drugs and Biologics”; FDA 




Our conceptual models for age-associated cognitive impairment, dementia syndrome, and AD need 
development, and consideration of their effects on drug development.  The causes of AD remain to be 
elucidated; it is a complex disease; and there are formidable barriers to treatment research. The 
several AD- related clinical diagnoses, including AD (i.e, AD dementia, mild cognitive impairment due 
to AD, prodromal AD) result in biologically and clinically heterogeneous groups of patients.  Patients 
will show various cognitive profiles, severity of early memory impairments, genotypes, and expressions 
of putative biomarkers. This heterogeneity makes drug discovery and development more complicated. 
Furthermore, similar efforts should be made on the range of age-associated cognitive impairment 
conditions and other neurodegenerative conditions beyond AD.  
Diagnostic criteria can very much affect the numbers of affected people and who are treated in clinical 
trials.  The lack of validated drug targets and too many targets lead to ethical challenges in clinical drug 
development. Many drug targets may be applicable to cognitive- or brain- aging as well, not just to AD.  
Thus far, drugs in development for AD have lacked of action on the brain target.  That is, they may 
target and alter one aspect of disease or brain function but then adversely or unpredictably alter 
another aspect.  
There is great difficulty relating mechanisms of drugs to clinical outcomes.  One urgent need is the 
development of efficient clinical trials designs and outcomes.  Clinical trials have been restricted in 
design.  The designs and outcomes tend to be nearly identical from one program to the next, and are 
not necessarily relevant to the modelled action of the drugs.  There is a need to develop targeted 
clinical trials designs to allow individualisation of treatment.  
Another is the need to develop a clinical trials infrastructure.  Delays and barriers to recruitment limit 
trials.  Samples of convenience may not constitute valid trials samples for many purposes.  For example, 
the median onset of dementias and AD is in the early 80s, who also have substantial concomitant 
illnesses, and neuropathology is usually mixed380,381. Clinical trials are done with much younger patients 
in their 70s with little concomitant illness or medications, and attempts are made to exclude other 
causes of cognitive impairment.   
One important challenge is the need to identify the real benefit of anti-Alzheimer drugs for elderly 
patients, taking into account the mixed nature of the brain damage and neurodegeneration causing 
dementia and the impact of other illness, and poly-pharmacotherapy on cognition.  Generalizability of 
clinical trials results is limited when conducted in young older people with no or little comorbidity, to 
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the general population. It is likely that substantial numbers of subgroups of the Alzheimer’s population 
will not be helped by any particular treatment.  
Major barriers to successful drug development are our current translational models and translating the 
way drugs work in the pre-clinical and animal models to humans. It is possible that newer approaches 
to prevention trials, stratified medicine, and smaller phase 2a trials to gain early signals of potential 
efficacy may be helpful.  
The failures of the trials and development programs have led to many explanations, although, the most 
likely explanation for the lack of effective medications is that the drugs do not work.  When truly 
effective drugs are tested, however, their effects will overcome the current inefficiencies in clinical 
development. 
 
Major challenges in drug development   
 The evidence generated so far is limited by the underlying assumptions and theories implicit 
in the generation of the data 
 The decisions on the right drug development, for the relevant groups in society, should not be 
taken before setting the aims that might ultimately be achieved 
 Very long clinical trials using “soft” or uncertain clinical and biological endpoints are obstacles 
to progress. 
 Other factors that can affect the success of clinical trials are the heterogeneity of patient 
populations, the overlap of cognitive impairing conditions, and trial participant samples 
which are not typical of everyday clinical practice.   
 In clinical research, the risk faced by participants is higher in early phases of trials than in late 
phases; – hence, concentration of risk and resources on early phase research is essential. 
 The development of safe therapeutics that can be used for very early intervention to prevent 
dementia in at-risk people 
 Optimisation of clinical outcomes assessments 
 Make all clinical trials data publicly available 
 Drug development as a collaborative rather than competitive effort  
 
Prospects and goals for experimental treatments 
Establishing validated drug targets requires greater understanding of the several neurodegenerative 
illnesses, other age-related cognitive impairment syndromes, cognitive impairment with other 
conditions, and the numerous processes leading to illness.  Advances in basic and clinical science, 
better knowledge and selection of drug targets will drive future drug development.  
Advances in clinical trials and development methods will be incremental and iterative.  AD clinical 
development advances have evolved through the several failures and have improved prospects for 
identifying effective drugs. Predictions of an effective treatment in the near future can be based only 





The clinical development enterprise [MAKE THIS A PANEL] 
 Drugs are needed to both prevent and treat the cognitive and functional symptoms of 
preclinical, prodromal and AD.   
 Plans need to be developed to decide what drug development to support, and to identify the 
determinants of successful translation of drugs to AD treatment.  
 Clinical development should be justified by prior knowledge that would help to determine the 
likelihood for success.  More resources should be provided to early clinical development so 
that more potential treatments can be assessed.  Resources should be directed to areas where 
there is evidence for efficacy. 
 Detailed results and outcomes trials should be broadly available immediately after studies 
have concluded in a manner easily understandable by the general public. Protocols should be 
published.   
 Preclinical drug research and early phase clinical trials need replication before continuing to 
later phases.  Avoid enrolling at-risk and AD patients in trials that should not be performed.  
The emphasis on phase 3 without fulfilling objectives of phase 2 is wasteful and not justifiable 
from a societal perspective, although high-risk, high-rewards business arguments have been 
made for these mega-wagers. 
 Assess whether or not particular clinical research is worth pursuing.  (For example, is an 
expected 1.5 point ADAS-cog effect after 2 years of treatment worthwhile? Might efforts be 
better spent elsewhere?) For example, the capital put into the recently failed bapineuzumab 
and solanezumab phase 3 programs could have funded perhaps 20 focused phase 2 
development programs for a range of compounds with different mechanisms, the outcomes 
of which would have provided more information than the outcomes for just two drugs.  
 There should be consideration for collaborative risk-sharing with governments and industry.  
Drugs or approaches with common mechanisms might be developed collaboratively rather 
than competitively.   
 Failures of very large programmes may have devastating effects.  There is a societal need to 
reduce redundant approaches and competition between similar approaches (See Lancet series 
on waste in clinical trials and drug development). 
 
RECOMMENDATIONS 
Improve the clinical development infrastructure: 
 Increase collaboration between governments, public, and private institutions, Alzheimer’s 
Associations and pharmaceutical industry to facilitate clinical research. There is substantial 
redundant research in AD drug development. 
 Increase drug discovery, development and clinical trial research budgets.  Establish 
international methodology, cohorts, and ethical and regulatory frameworks to facilitate trials.  
Clinical drug development and clinical trials should be coordinated internationally.  Recognize 
and support the different approaches to drug development. 
 Improve public, private, corporate funding such that decisions are based on evidence and 
scientific merit, rather than by advocacy, opinion and persuasion. 
 Strengthen the patients' voice in risk-based approaches to the conduct of early first-in-human 
clinical trials where the pre-clinical evidence base is limited. Options should be discussed for 
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an earlier entry into clinical development allowing the collection of valuable pharmacokinetic 
and pharmacodynamic information from patients. This would help to refine adaptive clinical 
trials and enable early failure 
 Involve more patients in research.  Establish registries of elderly patients with and without 
cognitive impairment to facilitate recruitment into trials.   
 Enable a more synchronised implementation of regulatory processes for clinical trial conduct 
into national laws383,384 
 
NON PHARMACOLOGICAL INTERVENTIONS FOR THE TREATMENT OF PERSONS 
WITH DEMENTIA AND MILD COGNITIVE IMPAIRMENT 
 
Summary 
Non-pharmacological interventions and the active early involvement of caregivers should be an integral 
part of AD treatment strategies. The diagnosis and treatment of associated conditions, 
neuropsychiatric symptoms and psychosocial deterioration are key elements in improving the quality 
of life for AD patients and their families. Lifestyle changes, exercise and nutritional support might play 
a role at all phases of the disease, but more research is needed to guide the implementation of 
significant intervention programs.  
 
Whilst considerable efforts have been made to improve understanding of the neurobiology of 
Alzheimer’s disease and to identify and evaluate candidate disease modifying therapies, far less effort 
has been focussed on developing and implementing non-pharmacological interventions.  This is a vital 
missed opportunity, as establishing effective non-pharmacological interventions for key indications is 
a much more tractable target and effort focussed in this area is likely lead to tangible benefits to help 
people live better with dementia within a much shorter time frame.     
 
Current Status  
 
Cognitive Training and Brain Training games involve teaching individuals strategies to improve 
cognition.  Generally interventions follow one of two approaches, either strategies based on 
theoretical neuropsychological models of cognition and/or learning (eg errorless learning) or  teaching 
skills to try and improve specific aspects of cognition (eg mneumonic strategies to improve new 
learning). These interventions can be delivered to individuals or in groups and can include computer 
based approaches.  A meta-analysis of ten, mainly small, RCTs focussing on healthy older individuals 
(age ranged from 60-76 across the studies) indicated a small but significant benefit (effect size 0·15, 
95% CI, .103 to .194), which was generally limited to the specific cognitive domain targeted by the 
training.385 A common limitation in many of these studies is that the comparison has been “no 
treatment” and the absence of an active control treatment.  In such circumstances where the 
comparison group does not receive any treatment, they will not benefit from the non-specific 
advantages associated with any intervention due to placebo and Hawthorne effects.  The consequence 
is that this may exaggerate the comparative benefits of the intervention being investigated. The largest 
and most extensive study, the ACTIVE trial, followed more than 2500 cognitively healthy older adults 
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of 65 years of age or older (mean age 74) during five years at 6 US sites. Ten groups of participants 
received training focused on attention, memory or reasoning, as well as practice and teaching people 
specific mneumonic (organization, visualization, association) and reasoning (teaching strategies for 
finding the pattern in a letter or word series) strategies in to improve cognitive performance in the 
respective intervention groups. The study reported benefits in the cognitive domain that was the focus 
of the specific training package, with memory training improving memory and attention training 
improving attention. Only reasoning training had the added benefit of more general improvements in 
memory and attention as well as reasoning, and conferred additional benefit on IADL-.386. 
 
Findings from studies investigating benefits of cognitive training in people with memory impairment 
or dementia are more conflicting. In the ACTIVE study, training in memory conferred no benefit to the 
sub-group of individuals with memory impairment (based on a threshold of a 1·5 standard deviation 
below normative values on the Rey Auditory Verbal Learning Test).  Eleven RCTs, mainly with less than 
50 participants, have evaluated cognitive training in RCT designs in people with AD.  Out of eight studies 
evaluated for general cognitive outcomes (MMSE or ADAS COG), three showed significant benefits.  Of 
note however, neither of the trials considered to be high quality by the reviewers reported a significant 
advantage of cognitive training.  A number of studies did report benefits in at least one specific aspect 
of cognition, but without any consistency in cognitive domains across studies.  The authors did not 
undertake a meta-analysis because of the huge variability between studies, so the effect size and 
overall statistical significance has not been elucidated.  The authors concluded that there was sufficient 
evidence of benefit for cognitive training to merit further larger intervention studies387.  
 
Based upon current evidence, cognitive training does appear to have value in healthy old people, but 
further work is needed to examine cost-effectiveness.  There is also a suggestion of benefit in some 
initial studies of cognitive training in people with dementia, but the majority of trials are very 
preliminary and better powered studies are needed. 
 
Many commercial companies have developed and marketed brain training games. Despite the publicity 
surrounding the benefits of brain training games, there is extremely limited evidence to support the 
value of any of the current commercially available products. By far, the largest intervention study of 
brain training is Brain Test Britain, a 6-week online study with 11 430 participants aged between 18 
and 60 years who were randomized to receive brain training in reasoning (with an emphasis on training 
games involving executive function), general brain training (similar to commercially available brain 
training games), or control (Internet search tasks). On average, participants completed 24 training 
sessions during the six weeks of the intervention. Participants showed a large and significant 
improvement in performance in the actual brain training games (Cohen’s d standardized effect size 
0.73 99% CI, 0.68–0.79 and 0.72 99% CI, 0.67–0.78 respectively for the 2 active interventions, but this 
was not translated to significant benefit in standardized cognitive assessments of executive function, 
attention, or working memory.388 More recently, the longer term outcomes have been reported for 
the older participants in the study (6742 adults over 50), indicating significant benefits in reasoning, 
verbal learning and instrumental activities of daily living over 6 months with reasoning training and 
general brain training in comparison to the control treatment, but with significant drop-outs after 12 




The largest study of cognitive rehabilitation RCT evaluated 69 people with AD or mixed AD/vascular 
dementia, who had Mini Mental State Exam (MMSE) scores of more than 18, who were randomized to 
3 arms.  One group received cognitive rehabilitation (n=23) intervention to improve individualized 
outcomes. a second active control group of 24 people received relaxation and stress management and 
a third group of 22 people received no treatment.  All treatments were for eight weeks. The multi-
faceted cognitive rehabilitation approach consisted of weekly individual sessions utilizing teaching 
strategies and techniques for learning new information, maintaining attention and concentration, 
managing stress, and using appropriate aids. The cognitive rehabilitation intervention conferred 
significant benefits in goal performance and satisfaction, compared with both of the other two groups.  
Smaller case series have also demonstrated improvements on global activities of daily living measures 
using interventions based on implicit memory389.  
 
Although the idea of cognitive stimulation for people with dementia is not new, Spector and colleagues 
were the first to develop this approach into a standardized treatment. Their intervention, Cognitive 
Stimulation Therapy (CST), is a group-based approach for people with mild-to moderate dementia 
based on the theoretical concepts of reality orientation and cognitive stimulation. designed as a very 
specific operationalized approach with 14 sessions of themed activities that typically run twice a week 
during a seven-week period390. A single-blind RCT of CST in 201 people with dementia (115 people 
receiving CST and 86 control subjects) reported significant improvements in MMSE (P = 0·04) and the 
Alzheimer Disease Assessment Scale—Cognition (commonly referred to as ADAS-Cog [P = 0·01]) in the 
treatment group relative to the control group, with additional benefits in quality of life.391 These initial 
cognitive improvements following CST were sustained with maintenance CST392. There is also some 
evidence indicating the cost effectiveness of CST based on an RCT in people with mild to moderate 
dementia comparing 91 people receiving CST and 70 people receiving care as usual. Costs were 
calculated for the eight weeks before and the eight weeks after treatment.  Cost effectiveness analyses 
usually calculate the cost of improving quality of life, usually using outcomes such as quality adjusted 
life years.  A health economic analysis indicated that there were quality of life advantages for those 
receiving CST without the intervention incurring additional cost, suggesting that CST is a cost-effective 
intervention393.  The positive impact of CST on quality of life has been further supported by qualitative 
studies394. Other research groups have adopted a broader definition of cognitive stimulation, and 
developed other intervention approaches which are less operationalized than the original Spector 
intervention. However, the overall evidence base for less operationalized approaches to cognitive 
stimulation is less clear-cut than for the specific package of CST developed by Spector and colleagues 
395 396.   
 
Caregivers and treatment of AD  
Caregivers play critical roles in the treatment of patients with AD and in research studies. For instance, 
caregivers’ reports about their patients’ cognitive impairment correlate better with objective 
neuropsychological evaluations than the patients’ own complaints397.  Furthermore, people with 
presymptomatic Alzheimer’s disease whose caregivers identify that they have cognitive complaints are 
more than twice as likely to progress to dementia than people with caregivers who do not report such 
complaints (OR, 2.2; 99% CI, 1.2-3.9; P < .001), indicating that caregivers can  accurately identify 
significant levels of cognitive dysfunction398. Caregivers generally provide a more accurate longitudinal 
history and information about daily function than can be gleaned from an office consultation. They 
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often can provide proxy consent for treatment and for trials when patients are insufficiently competent 
to give consent themselves. All drug trials for AD require an informant with a specified minimum 
amount of weekly contact. Caregivers can help to ensure compliance, monitor outcomes, and report 
adverse effects.  
As well as being part of the therapeutic team, caregivers can become therapists themselves through 
cognitive stimulation techniques399 and by managing behavioural and psychological symptoms of 
dementia400. Drug treatment for patients with AD can secondarily benefit caregivers in reducing their 
time commitment for supervision and assistance with daily care401-403. 
 
Caregivers often experience significant subjective and objective burden, high levels of stress and mood 
disorder, and are at increased risk of alcohol-related problems and medical co-morbidity.  Supporting 
caregivers is therefore vital for their own wellbeing as well as to enable the best care for people with 
dementia. Non-pharmacological interventions play a key role in reducing stress and improving 
wellbeing in caregivers themselves.  Several small RCTs of group Cognitive Behaviour Therapy and 
educational programmes that include skill training have demonstrated statistically significant 
improvements in mental health and coping skills404,405. Educational interventions without these 
components, carer support groups not utilizing cognitive behaviour therapy, and information provision 
without other key elements have conferred less convincing evidence of benefit406. 
 
Interventions to provide information 
Information is a key part of service provision to people with dementia and those caring for them, and 
the importance of information and signposting is often presented as a key benefit of early diagnosis. 
Information can cover a broad range of topics, including the symptoms and causes of dementia, and 
more detailed information regarding specific symptoms, their treatment and management.  
Information often also covers treatment approaches, including drug therapies; the impact of dementia 
on caregivers, financial information, key legal issues and guidance regarding advanced directives.  A 
number of information sources also address local service provision, charities and local groups to sign 
post caregivers and people with dementia to the support that they need. In a recent systematic 
review,406 thirteen randomised controlled trials were identified which predominantly focused on the 
provision of information, although many did include additional elements such as skills training, 
telephone support, and direct help to navigate the medical and care system.  Two of the three studies 
measuring quality of life indicated modest but statistically significant benefit in people with dementia 
and statistically significant benefits were also evident for neuropsychiatric symptoms.  Surprisingly, a 
meta-analysis of the same 13 studies did not indicate any statistically significant benefit for caregivers 
with respect to caregiver burden.   Whilst this evidence base does provide some support for the value 
of information services, future studies are needed to determine the specific elements that are effective 
and to optimize interventions.  Designing such studies will be challenging, as it would not be ethical to 
deprive individuals of usual information provision.  However, these studies, including a health 
economic component, will be essential to enable international standards to be set for the development 




Treatment of neuropsychiatric symptoms 
There are three main types of difficult-to-manage neuropsychiatric symptoms in patients with 
dementia: agitation, psychosis and mood disorder. Agitation includes symptoms of aggression, 
irritability, restlessness, shouting and pacing, usually in the context of distress or anxiety. The most 
frequent psychotic symptoms are visual hallucinations, auditory hallucinations and persecutory 
delusions. First rank symptoms of schizophrenia almost never occur in individuals with dementia, and, 
in contrast to functional psychoses, the psychotic symptoms seen in dementia are much less complex, 
usually visual or second-person auditory hallucinations of people or animals, and simple persecutory 
delusions such as believing that possessions have been stolen. Mood disorders include depression, 
anxiety and apathy. 
A review of neuropsychiatric symptoms (NPS) in AD took place in 2010 under the auspices of the NPS-
Professional Interest Area of the International Society to Advance Alzheimer’s Research and Treatment 
(ISTAART)407.  The review stated that “treatment development should not be limited to 
pharmacological interventions. Treatment developments must take into consideration neurobiological 
and psychological contexts of the development and manifestations of NPS in AD408-411.  
A recent systematic review412 focusing on the value of personalized psychosocial interventions to 
address behavioural and psychological symptoms in persons with dementia living in care home settings 
highlighted the substantial evidence base supporting the importance of pleasant activities with and 
without social interaction for the treatment of agitation.  The best established interventions include 
the Seattle protocols which focus upon assessing person centred activities and then introducing a care 
plan to ensure that individuals receive at least 60 minutes a week of enjoyable activities, with an 
additional focus on problem solving to maximize implementation 413; and the approach for person 
centred social interaction developed by Cohen-Mansfield and colleagues 414 and the review also 
highlighted  the value of reminiscence therapy to improve mood; a recent meta-analysis of RCTs of 
person-centred care training also demonstrates the value of specific training approaches in improving 
agitation and reducing antipsychotic medication use in people with dementia living in care homes. The 
recent WHELD trial, combining person centred care with person centred activities and exercise, has 
also demonstrated the potential for this intervention to reduce mortality as well as reducing 
antipsychotics use and improving neuropsychiatric outcomes (new ref 2). However,  in the studies so 
far  published, these training interventions did not improve well-being and quality of life for people 
with dementia 415.  Further work is therefore needed to try and optimize training interventions to 
deliver quality of life improvements, perhaps by utilizing specific elements to enable the 
implementation of evidence based non-pharmacological interventions in addition to more generic 
training to promote person centred care.  
 
Well-being and quality of life in nursing home care 
Specific figures of people with dementia living in care homes have not been calculated on a Europe 
wide basis. In the UK approximately 250,000 of the 750,000 people with dementia reside in care homes 
(Alzheimer's Society UK. Dementia UK report. 
https://alzheimers.org.uk/site/scripts/download_info.php?fileID=2. 2007). As the age and 
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dependency characteristics are similar across Europe (Alzheimer's Society UK. Dementia UK report. 
https://alzheimers.org.uk/site/scripts/download_info.php?fileID=2. 2007), it is therefore likely that 
something in the order of 1.6 million European citizens are living with dementia in care homes, with a 
median spend of 1% of GDP on long term care across Europe (European Social Network. Services for 
older people in Europe. http://ec.europa.eu/health/mental_health/docs/services_older.pdf. 2008). 
Admission to a nursing home for old people with AD involves a transition with a reduction in the range 
of life roles, for example people are usually less involved in management of their financial affairs and 
may be less engaged with family, friends and hobbies outside of the care home environment. 
Individuals also may experience diminished engagement in meaningful activities within the care home. 
Life in nursing homes has often been depicted in terms of boredom, loneliness, and a disconnect 
between previous roles and interests and ongoing engagement in meaningful activities, for example a 
large observational study using dementia care mapping indicated that people spent less than 2 minutes 
out of 6 hours during the day engaged in social interaction and spent much of the time withdrawn416. 
Contemporary nursing home care in Europe and North America is often criticised for being task-
oriented and strongly focused on functional and biomedical needs, despite research that suggests that 
best practice nursing home care involves a health-promoting approach also focusing on addressing 
psychosocial and existential needs through resident engagement in individualised meaningful 
activities417-420. Research shows that people with AD and other dementias in nursing homes generally 
have a limited opportunity to participate in individualised meaningful everyday activities 416.  The 
previous section briefly describes the potential benefits of personalized activities as a treatment 
approach for neuropsychiatric symptoms, but there is also a strong body of evidence demonstrating 
beneficial outcomes from interventions promoting engagement in activities adapted to cognitive and 
functional abilities, including improved quality of life and wellbeing, reduction in anxiety, better 
attention and increased alertness418,421-427.   
 
The essence of nursing home care is to compensate for cognitive and functional losses through 
assisting in meeting basic human needs, including active or passive social engagement and 
participation. From an existential perspective, engaging in meaningful activities also helps to represent 
and define individuality, and to support a sense of self. Such engagement can mean passive 
participation in or merely observing familiar and everyday activities, and not necessarily the use of 
wide-ranging activity programmes. Interventions based on promoting activities and increasing 
vocational tasks improve wellbeing and quality of life as well as neuropsychiatric symptoms 417,428-431. 
 
Natural Products and Medical Foods 
Studies on the potential benefits of natural products and medical food on AD have so far not yielded 
positive results. For Gingko Biloba, the most extensively studied product, initial studies indicated 
modest but statistically significant improvements in cognition, but the results were not replicated in 
larger and more robust studies, and the overall evidence does not indicate statistically significant 
benefit432. Intervention studies for vitamin supplements or medical foods containing vitamins have 
generally been disappointing.  
 
Souvenaid is a medical food containing vitamins and other components with the aim of 
neuroprotection.  The primary outcome measure was a composite neuropsychological evaluation 
battery.  Souvenaid did not confer significant benefit on overall cognitive performance, and only had 
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very modest benefits in select areas of cognition, mainly memory.  In addition, Souvenaid did not give 
any benefits compared to placebo in everyday functions433.   The evidence of benefit is therefore very 
limited and would not meet usual standards of a recommended therapy. 
 
The VITACOG study examined vitamin B12, B6 and folate supplementation in people with mild 
cognitive impairment.  In the overall group there was no significant benefit with respect to 
neuropsychological performance or the rate of brain atrophy.  There was however benefit in a post-
hoc analysis focussing on the sub-group of individuals with elevated homocysteine, a homologue of 
the amino acid cysteine, at baseline.  This is biologically plausible as elevated homocysteine is 
associated with low B12 and folate and has been associated with increased risk of vascular damage 
and dementia434. This could still be an important treatment approach, but a further study is needed to 
test and replicate these potential benefits specifically in a group of individuals with presymptomatic 
AD and elevated homocysteine.  
 
The other vitamin based treatment for which there is some clinical trial evidence of potential benefit 
in people with Alzheimer’s disease is vitamin E. The recent TEAM-AD VA study 435 examined the efficacy 
of memantine and vitamin E (2000iu) alone or in combination in people with AD already receiving AchEI. 
A statistically significant and potentially important overall clinical benefit, equivalent to six months of 
natural decline, was demonstrated for vitamin E alone compared to placebo on the primary outcome 
measure, activities of daily living. There was however no benefit in the group receiving both vitamin E 
and memantine, nor was there benefit in any of the secondary measures including cognition.  Previous 
RCTs of vitamin E have produced similar mixed results. A large RCT in people with presymptomatic 
Alzheimer’s disease (diagnosed using MCI criteria without biomarkers) suggested no benefit 436. The 
ADCS study 437 did show significant benefit on the primary outcome, a composite measure of poor 
outcome, in people with moderate to severe AD treated with vitamin E. Bizarrely, there are many 
parallels to be drawn between the ADCS and the new TEAM-AD VA studies. Both reported significant 
benefits in the primary outcome but no benefits in any of the secondary outcome measures [please 
interpret these findings for the unfamiliarised reader]. Additionally, neither study showed benefit in a 
group combining vitamin E with another treatment in comparison to placebo.  The difference between 
this evidence base and the evidence for other vitamins and food additives is that there are 2 well 
conducted RCTs showing benefit in the primary outcome measure. Nevertheless, in the absence of 
specific benefits in cognition or function it is very difficult to interpret or understand what factors may 
be contributing to the global benefit.  There is also a potential safety issue to consider, as the dose of 
vitamin E used in these studies is 10 fold above the dose usually sold as a food additive.  For these 
reasons the current evidence base dos not support the use of vitamin E as a clinical treatment for AD. 
 
Fatty acids have also been a focus of interest.   Two larger multi-centre RCTs each with more than 150 
participants have indicated no statistically significant benefits in cognition, every day activities or global 
outcomes from omega 3 fatty acid-based treatments such as docosahexaenoic acid 438,439. There has 
been media interest in ketogenic treatments such as axona.  The theory is that the product is broken 
down into ketones, which could provide an alternative energy source for the brain, predicated upon 
the unproven assumption that the brain's ability to use glucose is impaired. The only published clinical 
trial, a multi-centre phase II RCT in 152 people with mild to moderate Alzheimer’s disease did not 




In general, there is very little efficacy or safety evidence required to market food additives, which can 
have an unfortunate role in creating false expectations and potentially could lead to unforeseen safety 
issues. For example, there is evidence of increased mortality risk with antioxidants from a recent meta-
analysis 441, and there are specific issues for vitamin E with a meta-analysis of existing evidence 
indicating the potential for increased mortality and an increased risk of haemorrhagic stroke 442  
 
There have also been promising results in cohort studies highlighting the potential benefits of 
Mediterranean diet443, but there is potential for results to be confounded by other elements of “healthy 
living” and a randomized intervention study is needed. 
 
Non-Pharmacological Interventions for people at risk of dementia   
There is a growing body of literature on lifestyle and non-pharmacological interventions to prevent or 
delay the onset of dementia in people with pre-symptomatic AD, most of which have been undertaken 
by identifying people based on amnestic impairments, but without evaluation of AD biomarkers.  
Evidence for the benefit of social activity, weight maintenance, and diet is inconsistent or very 
preliminary444. The pivotal FINGER study168 has demonstrated significant benefit in overall cognitive 
function with the largest benefits seen for attention and executive functions. FINGER is a 2 year RCT 
focussing on people between 60 and 77 years of age for a multi-domain intervention (diet, exercise, 
cognitive training, vascular risk monitoring) in comparison to a control treatment (general health 
advice).  Although it is not clear which elements contributed to the benefits, the study provides key 
proof of concept that multi-domain trials are feasible and can confer cognitive benefit.  The 
intervention did include 3 separate interventions with a total of more than 30 therapy sessions in 
addition to self-directed interventions. Further studies are now needed to understand and improve 
the cost-effctiveness of the intervention. 
There is strong evidence to support smoking cessation444, which is already widely implemented, and 
the effect of cognitive reserve446 although this would need to be implemented as part of educational 
policy across the life course as the development of cognitive reserve is largely based on childhood 
cognition and educational attainment, together with occupation in adult life. 
    
A number of small- and medium-sized trials have investigated the effects of exercise specifically in 
people with subjective memory problems, mild cognitive impairment (MCI) or pre-symptomatic AD.  
The main studies have identified participants based upon amnestic deficits or subjective reports of 
memory difficulties in the absence of Alzheimer’s disease, and did not require the presence of 
alterations in AD biomarkers. The largest trial, conducted in Australia included 170 adults, of whom all 
had subjective memory complaints and 92 had -MCI, demonstrated a significant advantage in cognition 
on the ADAS COG at 6 months follow-u as the primary outcome.  Additional benefits were seen global 
outcome and benefits were maintained for 18 months. The benefits were more pronounced in people 
with MCI447. Several exploratory  trials of aerobic exercise in people with MCI, most of which evaluated 
a range of measures without stipulating a primary outcome, have also reported statistically significant 
improvements in cognition, function, cardiovascular fitness, motor performance, brain plasticity and 
AD biomarker levels 448-451 and a recent systematic review has concurred that there is consistent 




The evidence is already strong but larger and better powered RCTs are now required in people with 
pre-symptomatic AD in order to determine whether exercise can delay “conversion” to symptomatic 
AD and to provide evidence  regarding cost-effectiveness, and to inform practice. Several studies are 
currently examining the potential of multicomponent interventions including exercise to prevent 
dementia in people with cognitive impairment and vascular disease or vascular risk factors (e.g., 
ENLIGHTEN, THINK FIT, AETMCI, POEM, My Buddy).  These trials will provide evidence to add to our 
understanding of cost-effectiveness, the potential additive benefits of multi-component interventions, 
and the specific groups of individuals where this type of intervention may confer optimal benefits. 
However, exercise already has a better evidence base than any other pharmacological or non-
pharmacological intervention for people with presymptomatic AD, and there is a strong case that we 
should be routinely offering exercise interventions as a core part of the clinical management of these 
individuals. To give an indication of the potential public health impact, a recent review calculated that 
a 25% reduction in inactivity could prevent up to one million people developing AD worldwide, based 
upon the relative risk of incident dementia from 16 longitudinal cohort studies96. 
 
Implementation 
One of the most disappointing aspects of non-pharmacological interventions to treat or prevent 
dementia is that they are rarely systematically implemented in clinical and care practice even when 
there is clear evidence of benefit from RCTs. For example, although there may be opportunities to 
further optimize the benefits of person centred care training in nursing homes, there is already clear 
evidence that several specific interventions to improve person centred care (eg FITS, Dementia Care 
Mapping) confer benefits in i neuropsychiatric symptoms and enable a reduction in antipsychotic use.  
Despite this, a recent survey of available person centred care interventions in the  English language 
indicated that only 3 out of 170 (1.8%) interventions were supported by clinical trial evidence of benefit 
415. This is because many training programmes have been developed by private companies, but have 
not been evaluated and there is no evidence of whether they benefit people with dementia.  The 
interventions that are effective all involve a therapist working with care home staff for a period of at 
least 4 months to re-inforce the training.  Although some of the un-evaluated training programmes 
follow good educational principles, they do not generally have this additional component.  Tighter 
criteria are needed to require evidence of benefit for approved training programmes. Further examples 
of failure to implement a non-pharmacological intervention with good clinical trial evidence of benefit 
relate to the promotion of person centred activities for people with dementia in nursing homes and 
interventions to promote aerobic exercise in people with presymptomatic Alzheimer’s disease, where 
general recommendations are often made without attention to detail or structure for implementation. 
A programme to train and support CST therapists has been developed by University College London 
and has enabled some adoption of CST in routine clinical practice within the UK, but further 
development of the training and support is needed to enable full international implementation of CST. 
 
 
Future vision and goals        
 
The G8 UK summit on dementia on December 12, 2013 emphasized the need for non-pharmacologic 
interventions that are effective and safe, and can be used world-wide. The future vision therefore has 
to be a routine implementation of evidence-based effective and cost-effective non-pharmacological 
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therapies for the treatment of cognition, function, neuropsychiatric symptoms and caregiver support 
and a better understanding of the optimal combination of non-pharmacological and pharmacological 
interventions as a routine part of clinical care to more optimally harness the potential of caregivers as 





Further systematic review and international consensus are required to enable a blueprint for current 
best practice and to identify the non-pharmacological interventions that should be routinely available 
as a part of clinical care, and to identify the key research gaps.  The absence of a strong commercial 
interest in the development of non-pharmacological interventions has resulted in a particular  
challenge to obtain funding for RCTs examining the additive benefits of non-pharmacological and 
pharmacological interventions and large adequately powered RCTs of personalized non-
pharmacological interventions are time consuming, expensive and difficult to undertake.  There may 
be opportunities to streamline other non-pharmacological interventions such as cognitive training and 
exercise by utilizing self-directed on-line interventions. In treating neuropsychiatric symptoms, the lack 
of clear research definitions for key symptoms, such as agitations, is an additional challenge, with 
different definitions used in different studies and by different assessment tools.  A working group of 
the International Psychogeriatric Association has been convened to develop an improved international 
consensus.   High placebo response rates in clinical trials of neuropsychiatric symptoms, often higher 
than 40% and contributed to by non-specific benefits, increased interaction and spontaneous 
resolution are an additional challenge which need to be addressed.  Proposed solutions include the 
introduction of a less intense non-pharmacological intervention lead in period for all participants, 
increasing the symptom threshold for entry into trials and utilizing novel approaches such as central 
rating through video links to reduce the number of raters and increase the inter-rater reliability for 
primary outcome measures.   
   
Personalized activities for people with dementia living in nursing homes requires a shift in culture 
from ’doing for’ towards a culture of ’doing with’. The overall philosophy of care as well as 
organisational demands and priorities can facilitate or obstruct resident engagement in activities and 
health promotion.  
 
We need to ensure the widespread availability of good quality information in Europe, but also to learn 
to understand the added components of information and educational interventions that are necessary 





 Systematic reviews are needed and must be supported by an international Delphi consensus 
to agree on evidence-based effective non-pharmacological interventions that should be 




 European recommendations and an infrastructure to enable non-pharmacological 
interventions for which clear evidence of benefit already exists should be put into practice with 
appropriate training, support and maintenance of fidelity.  Examples of such interventions 
include exercise, Cognitive Stimulation Therapy, personalized activities and Person Centred 
Care Training in Care Homes and Activities with or without social interaction for the treatment 
of agitation. 
 
 A European consensus regarding the highest priority non-pharmacological interventions would 
be extremely helpful in guiding reimbursement decisions in individual countries. 
 
 Additional RCTs are needed to address key gaps (eg non pharmacological management of sleep 
disturbance, pain, psychosis, apathy in people with dementia)  
 
 Better models are needed to fund partnerships between public funders and commercial 
organizations to address the funding challenge and to better enable key studies examining the 
combination of key non-pharmacological and pharmacological interventions and to enable 
academic-commercial partnerships.  
 
 Open data access to randomized clinical trials using non-pharmacologic treatments is needed 
to support systematic reviews and meta-analyses based on individual patient data. 
 
 Treatment manuals and programmes should be generally available as part of dissemination for 
effective non-pharmacological interventions.  
 
 Non-pharmacological interventions and activities can have an inherent ethical value in high 
quality care even if it is sometimes difficult to detect measurable group level outcomes. Ethical 
evidence such as observed signs of wellbeing while a personally meaningful activity is ongoing 
needs to be systematically collected, discussed and used in clinical care. 
 
Glossary of terms non-pharma intervention 
 
Implicit memory is an aspect of memory where previous experiences aid the performance of a task 
without conscious awareness of these previous experiences. 
Reality Orientation is a programme designed to improve cognitive function in people with dementia. 
The aim is to use verbal interaction, aids such as calendars and clocks and sensory stimuli such as 
distinctive sights, sounds, and smells to improve orientation and sensory awareness. 
Cognitive Stimulation: The general principle based on the “use it or lose it” philosophy that it is 
beneficial to keep the “minds” of people with dementia active through various pastimes, interactions 
and activities. 
Reminiscence therapy uses tools such as life histories, shared memories and familiar objects of past-
periods to improve wellbeing, usually in a group setting. 
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Mediterranean diet is a modern nutritional recommendation based on the traditional dietary patterns 
of the Mediterranean region.  The key components of the diet include a high consumption of olive oil, 
vegetables and fish, with moderate consumption of dairy products (mostly as cheese and yoghurt) and 
low consumption of meat products 
Cognitive reserve is a concept focusing on the resistance of some individuals to the impact of brain 
damage (including neurodegeneration) based upon education, stimulating work and stimulating social 
interactions. 
Delphi Consensus is a structured method to achieve expert consensus. The experts answer several 
iterations of questions, with a facilitator providing an anonymous summary of the experts’ forecasts 
from the previous round as well as the reasons they provided for their judgments. Through discussion 
and reconsideration of their answers to the stated questions, this enables a consensus to be achieved.  
 
 
FORMAL AND INFORMAL CARE  
 
Summary 
The care of AD patients does not easily fit into typical healthcare delivery systems, especially those that 
rely on active patient involvement. Longterm care of dementia patients often begins at home in a 
collaborative partnership between informal and formal caregivers. Institutional care for severe 
dementia patients is demanding and costly, and little research information is available concerning the 
transition between informal family care and institutional care. Patient autonomy and ethical 
considerations are an ongoing challenge in clinical decision making in dementia care. Worldwide, the 
burden of care often fall on family members, but effective assisted-care and skilled nursing homes will 
become increasingly important, especially in Europe with shifting age demographics. Compassionate 




People with dementia need care and support in many areas of their lives. This might be provided by 
health care, social care, housing, transport, leisure or other sectors. Irrespective of provider, this 
support can be categorized into three main domains: (a) support in basic activities of daily life (ADL), 
(b) support in instrumental ADLs (IADLs) and (c) supervision to safeguard individuals from harm 324. In 
addition to these forms of care and support, individuals with dementia may receive specific medical 
services such as injections, infusions, sore management medications to alleviate dementia symptoms. 
ADLs are dressing, eating, toilet visits, personal care activities, moving around the home or a care 
facility; these are very basic personal activities. IADLs relate to more complex activities with a social 
component: preparing food, shopping, managing money, laundry, cleaning the house, managing public 
transportation and communication, for example using the telephone. One challenge with IADLs is that 
they are influenced by context. Therefore, they are also more closely linked to technical abilities, such 
as the use of mobile phones, use of internet 325, or use of technical equipment in care.  
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Given the multidimensional needs of people with dementia, the care and support they receive often 
spans a number of sectors and does not easily fit into typical health-care delivery structures. It is also 
not always in harmony with traditional ways of organizing and financing formal care into health and 
social care categories.  Traditional health care takes place in hospitals, specialist and primary care 
settings, and is provided by physicians, nurses, physiotherapists, occupational therapists, psychologists, 
and healthcare assistants. Long-term care in nursing homes (or similar) or in the individual’s own home 
can be delivered by either or both health and social care providers.  Similarly, day care can have a focus 
on social activities (“social care”) or physical rehabilitation (“health care”). Care at home is 
conventionally classified as “formal” (delivered by paid staff) or “informal” (delivered by unpaid family 
or other carers), although the meaning and separation of these concepts is changing, as discussed 
below.   
Most people with dementia will receive both formal and informal care during the course of their illness. 
Indeed, there is no health or social care system in the world that would be able to meet the needs of 
people with dementia without these informal care inputs. Consequently, strategic policy discussions, 
case-level planning and evaluations all need to ensure that they fully recognise the considerable 
contributions made by family members and other unpaid carers, and should factor into their thinking 
both the (opportunity) costs for carers and the consequences for their own health and quality of life326.  
An important reason for the blurring of the distinction between paid staff and family and other unpaid 
carers is because the latter are increasingly active in many parts of the care system, not only as 
providers of personal care but also as advocates, participants in care planning and holders of devolved 
(personal) budgets 453. The growth of different forms of self-directed support has been a notable 
feature of many social and health care systems, giving patients and their family members more control 
over their care; personal budgets pass responsibility for managing care resources to the patient or 
carer, often with both effectiveness and cost-effectiveness advantages 454. However, in contrast to 
other chronic disorders, care planning and self-directed support are complicated in the case of 
dementia by the effects of the cognitive decline (mental capacity, lack of insight, legal issues of 
impaired autonomy, and risks of financial abuse). Thus, different ways and strategies of closing the 
gaps between all involved factors and participants  including clear political strategies such as national 
dementia care plans, case management plans, counselling, and education are crucial for quality of care. 
It should also be noted that the needs and demands of patients and their families cannot all be met by 
public sector health and social care agencies alone, even if the public sector tends to be dominant in 
most European countries. Major roles are played by organisations in the voluntary sector (often called 
charitable, non-profit or third sector) and in the private (for-profit) sector. The voluntary and private 
sectors deliver mainstream services as well as engaging in other activities such as information provision, 
lobbying for better care or more research, and case-level brokerage. Some of these activities might be 
funded by government under contract or via (general) grant aid, but many will be funded from 
charitable donations or private market transactions, selling care services directly to people with 
dementia or their families. Dependent on national structures and local conditions, such services could 
serve as either complements to or substitutes for available public sector resources. Whether such 




Formal (paid) care 
Table 15 provides a list of formal care resources and activities, including staff support, aids and 
adaptations, and newer technical support such as alarms and other forms of telecare. For the purposes 
of policy development, local planning and commissioning, and for regulation and monitoring, it is 
important that each activity is measurable and quantifiable in some way (e.g. hours, days or visits). The 
definition of “institution” varies widely. It could be a specialised small group home for six to eight 
people with dementia with staff trained in dementia care providing round-the-clock support, or a 
supervised facility with low staffing ratios, or a large nursing home with several hundreds of people 
with dementia and an emphasis on medical care. The wider concept “long term care” also includes 
comprehensive care at home. The ultimate aim for the high-quality formal care of people with 
dementia is to create an environment in which the individual’s needs are met, and where they are 
respected and can experience dignity, meaningfulness and wellbeing in spite of their difficult 
symptoms and limitations. Care needs to go beyond the provision of basic physical tasks and 
procedures to include the creation and maintenance of a person-centred, positive and welcoming 
climate and the support of relationships. Good formal care should have at least two dimensions: 
completing care tasks, and building meaningful relationships and engagement. However, there is a risk 
that the care tasks are given almost exclusive priority in financially-strained contexts, and that 
organisational decisions are so heavily influenced by financial considerations that only the minimum 
resources are made available to guarantee the most basic physical care tasks. Ethical dimensions also 
need consideration, even if it is difficult to gauge the outcomes of promoting dignity, meaningfulness 
and well-being. Good care for people with dementia means meeting physical, psychosocial and 
existential health needs, as well as promoting a dignified and good life. The processes of planning, 
organising, funding, delivering and evaluating formal dementia care need to acknowledge and support 
the completion of care tasks as well as build meaningful relationships and engagement in order that 
well-being becomes a right and a priority.  
 
Informal (un-paid) care 
Even if the analysis of the circumstances of informal carers is complex (including also for example the 
needs and preferences of carers), a pragmatic and narrowed approach for economic analyses is to 
focus on time spent on care. As mentioned above, it is important to clarify which kinds of activities are 
included in informal care, otherwise comparisons are not possible or meaningful. By using the division 
in three types; ADL, IADL and supervision it is possible to get a good overview of how informal carers´ 
time is used. The quantity of informal care can be measured in different ways. A direct and continuous 
observation timed is the best way since then it can be directly measured, but for practical reasons it is 
useful only in validation and exploration studies 327. Diaries and recall are the most frequently used 
methods to quantify informal care, although recall may overestimate caregiver time 328.  
Instruments for assessing the amount of care may be generic or diagnosis-specific. Data may be also 
collected in different ways: interviews, diaries, medical records, registries, etc. There may be legal and 
ethical aspects involved in how to get access to data that can vary a lot between and within countries. 
In dementia/AD, the Resource utilization in dementia (RUD) instrument 329, 330 and the Client Service 
Receipt Inventory (CSRI) 331 are comprehensive and frequently used instruments to collect data on 
resource utilization. When combined with appropriate unit cost, these instruments aim to calculate 
costs from a societal viewpoint, including use of health and social care resources as well as informal 
care time. Examples of other instruments are the Caregiver Activities Time Survey (CATS) 332, the 
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Caregiver Activity Survey (CAS) 333, and the Resource Use Inventory (RUI) 334.  The CATS captures formal 
and informal caregiver time use across a range of tasks and activities, while the CAS measures caregiver 
time and some aspects of caregiver burden. The RUI from the US asks about resource use in the past 
three months and is designed for AD prevention trials.   
It is not easy to get a view of how formal and informal care resources are used by people with dementia 
worldwide.  Such data are to a great extent available from high-income countries. However, the 
Alzheimer´s Disease International (ADI) with its 10/66 group, Alzheimer´s Association, as well as 
Alzheimer Europe has in recent years broadened the picture. ADI´s World Alzheimer Report 2010 and 
linked publications 1, 4, 335 were based on a very comprehensive review of the use of formal and informal 
resources worldwide. Informal care was very often comprehensive and in low and middle income 
countries the most important form of care. In low income countries, the social care sector (home care, 
nursing homes, day care) was almost non-existent and 90-100% of dementia cases were estimated to 
live at home (about 50-90% were estimated to live at home in high-income countries). Women were 
the most frequent carers, 55-91% with a tendency of a lower female proportion in high income regions 
456. However, in the ADI report it was concluded that the education of women in low and middle income 
countries and their increasing participation in the workforce (which generally should be seen as a 
positive human development indicator), tend to reduce womens´ availability for informal caregiving.  
Spouses were the most common informal caregivers but with considerable variations (daughters or 
daughters in law are in some countries/cultures more frequent as caregivers). Data on formal and 
informal care of people with dementia from Eastern Europe are also rare, but as part of the EuroCoDe 
project (administrated by Alzheimer Europe) 5, 336 data from Hungary were presented and, as part of 
the ICTUS study, 337 similar resource-use figures came from Romania. Although figures from Eastern 
Europe must be judged cautiously due to the limited number of studies, it seems as the contribution 
of informal care is higher in Eastern Europe than Western Europe and in parallel, the proportions of 
people with dementia that are living and cared for in nursing home is lower in Eastern Europe.   
 
Future goals and vision  
For many persons with dementia and their families, the dominant priority is timely access to care. This 
is clearly demonstrated, for example, in the EU-funded projects RightTimePlaceCare 457 and ACTIFCare 
338, which explore how a timely care planning and a timely diagnosis can facilitate care and help patients 
and their families to have control of their situation.  Care that is inadequate and arrives too late is 
ineffective, as well as being very burdensome for some families, while too much care too early can 
create dependency and wasted resources. National strategies for dementia, such as those in France, 
the USA, UK, the Netherlands, Sweden and many other countries 458 all emphasise the need for timely 
diagnosis. More generally, those national policy frameworks aim to set out how to improve care and 
support, including strategies for implementation across health, social care and other sectors.  
One clear need is for better information on the multidimensional needs and related preferences of 
people with dementia and their families. Information and advice can help those individuals gain some 
understanding of the disorder and its consequences, while self-directed support – if it is possible within 
a particular national or local context – can contribute significantly to empower them to be active 
partners in care. Principles of person-centred care, where the individuality of the person with dementia 
76 
 
is acknowledged in all aspects of care and treatment, are vital to improve quality of life both for the 
patients and for their family members339. 
Formal care support for family members and informal caregivers, such as day care 340, respite care 341,  
counselling, 342 as well as various case management programmes 343 (+ new REF) is crucial for better 
quality of life, and can also represent a cost-effective use of resources. Timely diagnosis of dementia 
344,458 is obviously necessary to arrange for timely care. Timely does not necessarily mean as early as 
possible (such as in a preclinical state) and it does not indicate mass screening programmes since there 
may be great problems with false positive cases 345. However, opportunistic screening for dementia 
where people who, for example, are offered a cognitive tests in a primary health center may be an 
alternative option 346. Although care is organized and financed differently across Europe, early 
detection of dementia and timely access to post-diagnostic support demands some kind of care 
infrastructure, including diagnostic resources, support programmes for people living at home, and 
resources for long-term care in (hopefully) home-like institutions with staff available around the clock 
or as needed.  
 
Challenges  
Two of the main challenges are how to organize care in order to achieve the vision of timely care, and 
how to ensure the effectiveness and cost-effectiveness of care systems.  
 
The diagnosis rate of dementia varies within and between countries, but the iceberg metaphor 347 
seems appropriate. It is not only an issue of resources, but also a question of awareness and attitudes 
348. The main arguments for an early diagnosis today are linked to care planning in a narrow context 
(what do we need to do and plan for in the immediate future?) and to planning across the life-course 
in a broader context (what are the long-term consequences of the diagnosis?) 346.  Policy statements 
such as from the G8 summit in London in December 2013, or from the World Health Organization 1 in 
2012 and the European Parliament in 2009 2 are important for raising the profile of dementia and 
ensuring that it is high up on political agenda; while national strategies and local dementia plans are 
obviously important for turning those high-level aspirations into the reality of care and support as 
experienced by individuals with dementia and their families.  One enduring challenge in the diagnostic 
process is accuracy, particularly in the ‘grey zone’ transitions from normal cognition to mild cognitive 
impairment to very early dementia. It is unclear how well today’s diagnostic pathways avoid the 
problems of false positives and false negatives: either of these misdiagnoses could be enormously 
distressing, with negative psychological consequences from a false positive and delayed support and 
care planning from a false negative. 
 
Long-term care of people with dementia is very demanding on staff time and therefore very costly. 
Long-term care refers not only to institutional provision but also support, often quite intensive, in 
community settings459. Most people with dementia, especially as their condition gets more severe, 
need support not only in instrumental ADL but also in basic ADL and more general supervision, and 
overall this can amount to a much heavier need than in other chronic disorders where cognition is not 
affected 460 . As the numbers of people with dementia grows, the funding of long-term care becomes 
a greater challenge, which in turn is forcing national governments to seek new strategies for 
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sustainable long-term care459 . However, there is an obvious tension between the need to contain 
future costs and the desirability of better education and training of care staff in order to improve the 
quality of care. Offering better working conditions and higher salaries in order to attract and retain 
high-quality care staff will push up costs, unless that investment in human resources can reduce the 
risk of expensive admissions into institutions. For example, in a Swedish study on day care for people 
with dementia with special trained staff it was shown that nursing home admissions were reduced 461  
 
Since a high proportion of care at home is already provided by family members, and given the high cost 
of even maintaining current patterns of formal care into the future, another major challenge is to 
ensure the continued availability of unpaid carers. This is especially difficult given recent and expected 
future demographic, social and economic trends that have led to smaller families (and hence fewer 
potential child carers), greater geographical dispersion of those families, and higher employment rates 
for women 462. Informal carers also need to be supported to help them manage the heavy personal 
burden of caring. Encouraging results have emerged from a support programme in England which 
offered a coping intervention to family carers of people with dementia: the intervention improved 
carer mental health and quality of life and was cost-effective 349, 350. The basic components of support 
ought to be reproducible in other country contexts. Counseling programmes have also been shown to 
be effective both in terms of quality of life of carers and to postpone nursing home admission 463. 
 
Despite developments in recent years, research evidence is scarce on the interaction between formal 
and informal care, on the interactions between different elements of health and social care systems, 
on the funding challenges of integrated care, and on how best to ascertain and meet the preferences 
of individuals with dementia and their caregivers.  
 
RECOMMENDATIONS  
National policy strategies and implementation guidelines for dementia care, aiming for a later 
development into EU/global guidelines, are needed in all countries. Such frameworks should include 
at least the following:  
 
 Timely diagnosis of dementia. 
 
 Wider availability of evidence-based post-diagnostic support and information programmes for 
people with dementia, families and other carers. 
 
 Better coordination between health, social care and other relevant sectors (such as welfare 
benefits and housing). 
 
 Development of case management and coordination programmes to help people with 
dementia and carers to access the services they need at the time they need them. 
 




 Action to improve awareness of dementia among health and social care staff, and across 
society more generally. 
 
 Affordable long-term funding plans for dementia care that span health, social care, housing 





Ethical considerations are important in dementia risk assessment, treatment and routine care. The 
inherent loss of patient autonomy and competency that coincides with the clinical progression of AD 
and other dementias is a complicating factor. Ethical considerations can raise important challenges for 
the design of clinical trials, especially in large clinical therapeutic trials where regulatory organizations 
must work hand-in-hand with academic and industry partners. 
 
 
With quickly expanding basic knowledge and ongoing innovation in diagnostic and management 
options in AD, new ethical issues require careful attention to realize improved quality of life and 
wellbeing for this vulnerable patient group. These issues affect both research and patient care in the 
fields of prevention, diagnosis, guidance and treatment, as well as policy making.  
The rapidly growing number of AD patients results in considerable increase in expected health care 
costs, while the growth of health care expenditures has to be limited. The quest for sustainability in 
health care gives an extra urgency to the ethical and societal choices that have to be made for technical 
and psychosocial advances needed in dementia care. This section is focused on the ethical issues 
directly involving patients with AD or prodromal stages, their proxies and the professionals delivering 
dementia care services (Table 16).  These issues are mainly deduced from the internationally accepted 
perspective of Beauchamps and Childress. 464 Their main principles, which are the widest accepted 
tools of reasoning in solving ethical dilemmas in health care, can be abbreviated as: doing well, not 
causing harm, respecting the individual’s autonomy, or striving for justice for all.  
Linking these principles to the widely accepted paradigm of evidence based medicine results in very 
important messages for policy making. The first is that introduction of new diagnostic tools should be 
evaluated on proven net benefit for patients, which extend beyond reaching sufficient added 
diagnostic value to also realising added value by being better informed and improved wellbeing.  The 
second concerns shared decision making and maximising the patient’s autonomy. This has to be based 
on sound assessment of the patient’s competency to consent, which should be a required skill for all 
physicians caring for patients in all stages of cognitive impairment. A diagnosis of dementia does not 
mean that patients are incompetent and patient involvement is desirable in shared decision-making in 
all diagnostic and treatment decisions. Thirdly, advanced care management and advance directives 
should be discussed already at an early stage in the disease regardless of whether patients live in low, 
middle or high income countries. These ethical and public health questions may be a greater challenge 
in low income countries where the number of AD patients will grow most dramatically. 
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Increased international collaboration puts a demand on harmonized ethical committee decisions on a 
higher level, ie national/EU level. 
 
Prevention and early diagnosis:  Ethical considerations 
As mentioned in previous sections, recently some evidence has been delivered on the potential 
beneficial effects of exercise, nutrition and other lifestyle changes 267, 285, 288, 296, 306-09, 465. Moreover, long 
lasting drug trials such as the DIAN study have started to focus on prevention of AD in people at high 
risk. This sort of study raises new ethical questions, some of which were addressed in the section on 
ethical concerns on genetic testing.  
In research studies, Alzheimer’s disease pathology is more and more detected using new biomarkers 
well before dementia is clinically diagnosed and even before symptoms of serious cognitive decline 
occur 298,466in line with the proposed research criteria.  There is currently no evidence that these criteria 
should be used outside the realm of scientific research. Apart fom the lack of knowledge on the 
predictive value of these criteria for the development of clinically overt dementia in an average 
outpatient clinic population, there is currently insufficient evidence that early or “preclinical” diagnosis 
will improve patients’ health and well-being 467,468. The question is whether we should inform persons 
that they are possibly at high risk for developing dementia, for which still no effective  treatment is 
available. To answer this difficult question, individual benefits should be weighed against possible 
disadvantages. Once there is sufficient certainty on the diagnosis,  early disclosure paves the way for 
timely psychosocial interventions ameliorating symptoms in dementia, which may be more effective 
when started early. It may also reduce strain in carers as they may be able to adapt more successfully 
to the cognitive and behavioural changes occurring during the natural course of dementia 469. 
Moreover, knowledge about being at risk for dementia empowers patients and carers to make 
important decisions about future treatment, care and life in general 470,471. On the other hand, the 
decision to enter a diagnostic process may be burdensome and provoke anxiety, and may be harmful 
when it raises false expectations of a potential cure 471. Pre-symptomatic diagnosis might also lead to 
early stigmatization, social and emotional isolation, and have important practical consequences for 
daily life, such as on obtaining insurance and not being allowed to maintain a driving licence 472.  
 
Empirical data on the benefits of early or pre-symptomtic diagnosis are largely lacking. People differ in 
how they cope with perceived cognitive decline, and in their needs and preferences for an early 
diagnosis. General practitioners’ experience is that many patients do not want additional diagnostic 
evaluation when they present themselves with cognitive disorders in primary care 471.  Memory Clinics 
and Alzheimer’s Centres are visited by a selected group of persons, most of whom are highly motivated 
to receive an early diagnosis, and are willing to undergo all diagnostics available. It is the responsibility 
of the clinician to clearly explain which tests add value to the diagnostic process, and which are 
obtained merely for scientific research. The external validity of results from studies in these selected 
populations is  limited by referral bias.  This may result in professionals implicitly assuming this active 
statement to be the preference of all patients with memory complaints, thereby overlooking those 
who prefer a more conservative approach. 
 
 Pepersack and Gauthier propose a framework for diagnostic disclosure to reduce practice variation 
and improve average quality of care472,473, which they divide into three phases. In the ‘before phase,’ 
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key objectives include determining whether the patient and his/her family members wish to know the 
diagnosis, identifying the coping style of the patient (here defined as the ability to develop adaptive 
strategies in the face of emotional distress); the psychological profile of the patient and his/her 
entourage, as well as the time and place where the disclosure will take place, and the words that will 
be used to convey the diagnosis and related information. Important elements for the ‘during phase’ 
include establishing what the patient and his/her family know about AD, using terms such as 
‘‘Alzheimer’s disease, or memory complaints’’ instead of ‘‘senile dementia’’ and avoiding the use of 
words such as ‘‘incurable.’’ In addition, the diagnosis is to be directed first and foremost to the patient, 
with the proviso that, should the disease be in its initial stages, the patient’s family is not to be informed 
of the diagnosis without the patient’s consent. Objectives for the phase following the disclosure 
include ensuring that the information presented is understood by the patient and his/her family; 
providing contact information for psycho-education programmes, and scheduling a follow-up meeting. 
 
For the whole process of diagnosis and disclosure, doctor and patient together should best balance the 
potential benefits and costs required for an early disclosure, before the diagnostic process is started 
or continued with new techniques (e.g., imaging and biomarkers). To arrive at this level, new research 
frameworks for evaluation of diagnostic tests should be applied, in which the value of a diagnostic test 
is not simply measured by its diagnostic accuracy alone, but also on how it affects patients’ health and 
wellbeing 474. In patient care a tailor-made approach is the best way to meet the expectations for both 
patient and family, prevent disappointment about the outcome of diagnostic work-up and subsequent 
treatment. This is not yet standard clinical practice and great inter-doctor, as well as inter-patient 
variability, is present. Awareness of the patients’ needs and expectations is a necessary precondition 
for such shared decision making, and appropriate use of decision aids such as evidence based outcome 
tables support this shared decision making with patient and family 475. Cultural differences in weighing 
doing well, not causing harm, respect for autonomy and giving all persons equal opportunities for good 
dementia care  may lead to different outcomes in shared decision making across countries 476. As long 
as evidence for a net benefit of very early diagnosis is lacking, efforts could be made into the 
development of guidance for optimal decision making around early diagnosis, taking into account the 
point of view of all involved (patient, proxies, clinicians and other professionals). Changes in general 
practice on early diagnosis should be monitored by collecting data on their effects on quality of care, 
quality of life and cost-effectiveness.  
 
Competency to consent 
Clinical assessment of competency to consent requires new consideration as more and more complex 
decisions have to be made on early diagnostic testing, treatments that are potentially harmful, and 
genetic testing, with the latter also affecting family members. This competency requires attention both 
in clinical management options and in recruitment for research, but tools that may be used in these 
different settings have to meet different criteria. Here we focus on the assessment of competency to 
consent in research, as new ethical questions will be met first in experimental contexts. Adequate 
informed consent is the cornerstone of shared decision making at all these stages. It is now well 
accepted that the diagnosis of dementia does not mean that a person is by definition incompetent to 
consent. Therefore, it is crucial to be able to judge the capacity to consent on an individual basis. 
Classically, what is considered necessary at least for competency judgement is: 1) ability to receive and 
understand information, 2) ability to process information, 3) ability to appreciate the situation and its 
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consequences, 4) ability to weigh benefits, risk and alternatives, and 5) ability to make and 
communicate a decision.  
Several instruments are available for the evaluation of competency to consent based on the specific 
research question that motivated assessment of capacity to consent, such as the Aid to Capacity 
Evaluation 477, and the MacArthur Competence Assessment Tool (MacCAT) 478,479.  Other instruments 
are based on vignettes providing a hypothetical description of a research situation, which include 
elements that are in general considered crucial in decision making in dementia treatment, such as 
whether or not injections are given or serious adverse events have taken place. The variety in 
instruments to assess competency to consent reflects the major variation in routine practice on 
informed consent assessment.  On the one hand one can try to make a judgement on capacity to 
consent in general; on the other hand one can aim to judge the ability for a very specific situation. 
General decision making capacity assessment is still often practised, while the mental functions that 
are needed for this competency highly differ depending on the complexity of the question at stake. In 
general, helping the individual to understand specific research information as fully as possible and 
checking whether the individual indeed understood the information (e.g., by some standardized 
questions), are the first prerequisites for a valid assessment of informed consent, which is also the 
basis of the MacCat instrument. Important conditions to reach these goals are: sufficient time for the 
information process, and information which is compatible with the cognitive, visual and hearing 
capacities of the older patients. 
If an individual is judged unable to provide independently informed consent on a certain issue, proxy 
(i.e., family) or double consent (of patient and proxy) are good alternatives. However, simplified 
information for the patient, and asking verbal consent or assent, always remains relevant. The patient’s 
behaviour should be closely monitored and in patients who demonstrate objection or signs of refusal, 
the procedures planned should at least be reconsidered.  Ultimately, application of the best 
competency assessment instrument, which is asking the right questions to check for competency on 
specific issues, should be combined with knowledge of the patient’s personal hopes, beliefs and history. 
Combining these elements will give physicians and researchers the best chances for an ethically 
justified answer on the diagnostic or management questions raised, while maximizing the patient’s 
autonomy.  
A range of complex issues in genetic testing has been mentioned in the genetics section of this paper. 
However, we did not yet refer to the fact that  research projects often also have a major impact  on 
relatives’ self-assessment of their health currently or in the future 480. Currently, relatives do not have 
a role in the standard individualized informed consent procedure of patients with dementia in most 
European countries. However, the question arises whether it should be required to give relatives 
always a voice in the informed consent procedure along with the consent of the research subjects 
themselves, especially when the diagnostic information also has impact on their dementia risk and 
therefore on the lives of these family members 481. In case of clinical genetic diagnostics, mostly an 
investigation of all family members at risk and all patients involved is preferred to realize an overview 
of the familial risk status and the different phenotypes present. This familial investigation should 
directly involve the family in genetic testing, for which each family member has to give informed 
consent. If family members do not consent but patients do, this will result in incomplete data collection. 
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From this short overview it becomes clear that properly addressing informed consent in AD patients is 
a routinely required complex competency, which therefore should be an obligatory part of the training 
of all physicians working with AD patients. It is a first and essential step towards realizing shared 
decision making in the dementia care dilemmas that patient and professionals should try to establish 
at each important step during the disease trajectory. 
 
End of life care 
When AD or dementia syndrome due to other causes is the main health problem at the end of life, 
more and more compelling dementia-specific treatment decisions have to be made in current practice. 
The increased level of autonomy that most patients and families strive for, together with the increased 
societal awareness on dementia, will probably result in an important increase of the ethical, political 
and societal dilemmas around end of life care for AD patients. The weighing of benefits and 
disadvantages of diagnostic and treatment proposals at end-of-life stage is more and more actively 
carried out by patients, family members and caregivers. For physicians it is increasingly relevant to 
personalise end of life care in order to do well, cause no harm and safeguard autonomy as much as 
possible. Here we will mainly discuss the decision-making process in the use of advance directives (see 
e-appendix), as these directives may highly improve the quality of end of life care, and are reasonably 
well evidenced (see E-appendix on systematic review of this topic). For the delicate debate on 
euthanasia and end of life care the reader is referred to other papers 482,483. 
In advanced care planning for patients with advanced AD, a key example of what is often debated as 
appropriate versus unnecessary care is the delivery of artiﬁcial nutrition and hydration. Decisions in 
this area are among the most challenging of the various decisions that confront family members and 
physicians with regards to the medical care of patients with advanced AD 472,484. Family members 
frequently state that the non-initiation of such measures would amount to allowing their relative to 
‘‘starve to death,’’ leaving them with no choice but the placement of a feeding tube. Interestingly, the 
use of feeding tubes has not been shown to prevent or delay death, nor has it been shown to improve 
functional status, quality of life, or life expectancy while being associated with dysphagia, aspiration 
pneumonia, and malnutrition 485. Despite the existing evidence, many physicians still feel that such 
measures beneﬁt patients with advanced AD.  
Given the progressive nature of the decline seen in AD, the completion of advanced directives may 
improve guidance in such decision making from the patients’ perspective. While desirable, in the event 
that advance directives were not drafted, or that they are incomplete, decision-making can be guided 
by a consensus-based approach that incorporates the patient’s preferences, as stated or as determined 
by close family members and others who knew the patient well, with the wishes of family members 
and the opinion of the attending physician 486. In the event of an impasse in this process, ideally clinical 
ethics consultants can be involved, or the local clinical ethics committees to provide counsel and 
assistance. However, in most European countries these services are not available in regular dementia 
care. Finally, it is imperative that end-of-life decisions, whether guided by advance directives or via a 
consensus-based approach, are guided by the principles to minimize harm and maximize comfort of 
the patient.  
As stated in several international surveys, the majority of older subjects consider it relevant and 
desirable to get more information on the health-related scenario’s that can be expected in the course 
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of the disease 487,488. Currently, advance directives are already widespread and routinely documented 
on hospital admissions, and in most nursing home admissions. However, the majority of the elderly in 
the community still do not have an advance directive, while in this population the benefits, for example 
by realizing more control on one’s own future hospital care, probably will be the largest. There is solid 
evidence that in older adults a support service guided by primary care professionals will lead to a 
substantial increase of the number of advance directives realised 489, up until almost full coverage of 
all older subjects in  specific regions in the USA, Canada and Australia with a ten-year tradition of 
advance directive support in primary care 490. It has also been demonstrated that advance directives 
indeed have a large impact on the care supplied. For example the Physician Orders for Life-Sustaining 
Treatment-form (POLST), which is now a legally recognized form in about ten states in the US, proved 
to guide substantially the care in older subjects 491,492. As hospital admission is usually stressful and 
acute or semi-acute, this is not the best moment to start such an advance care assessment, which 
much better can be implemented pro-actively in primary care. However, current practice shows 
important barriers for advance directives support by general practitioners in primary care in Europe, 
which may require national advance directive support services that educates professionals (see E-
appendix) and supplies them with well evidenced facilitators such as information leaflets, and clear 
advance directive forms.  
In The Netherlands up until now 5-10% of all elderly subjects in general practice has a form of an 
advance directive or advance care planning 492. However, in other European countries this figure may 
be much lower. In older subjects with advanced dementia and chronic obstructive pulmonary disease 
or another terminal illness the number of directives rises to 10-40% in The Netherlands 493, but 
internationally the average is probably much lower. Therefore, there still is substantial room for 
improvement. In summary, many advance directives and advance care planning can still be much 
improved as a crucial step towards better end of life management and palliative care in AD. There are 
suggestions that this may not only improve quality of care, but also reduce use of health care resources 
in realizing most appropriate care for dementia patients 494,495.  
 
RECOMMENDATIONS 
 For early diagnostic procedures in very early symptomatic persons with cognitive complaints 
or decline, new research frameworks for evaluation of diagnostic tests should be applied in 
which the overall benefits and disadvantages of a new diagnostic test are evaluated both from 
the biomedical and the patients’ perspective.  
 
 Diagnostic disclosure in all stages of AD should always be based on an accurate diagnosis, and 
be well structured, evidence based, and guided by quality indicators and teaching programmes.  
 
 Assessment of competency to consent cannot be based on a diagnosis, neither on staging or 
neuropsychological testing alone, but requires an individual assessment, specified for the 
decision to be made, performed with the aim to maximise autonomy.  
 
 End of life care in dementia can still be substantially improved by advanced care management 












 E-appendix  
SYSTEMATIC REVIEW on Advance Directives (AdvD), with special focus on AD 
 
We found four systematic reviews of the literature on advance directives over the last ten years (Durbin 
2010, Patel, 2004; Ramsaroop, 2007; Bravo 2008), of which three used meta-analytic techniques to 
address the question whether interventions stimulating the use of AdvDs are effective, and if so what 
kind of interventions are most effective in specific subpopulations (Patel, 2004; Ramsaroop, 2007; 
Bravo 2008). We completed our review of the literature with a search on new trials on AdvD until 
September 2014. 
The reviews together surveyed the literature until 2009 and together analysed 55 prospective studies, 
of which 18 were RCTs, 10 non-randomized comparative studies and 27 non-comparative studies.  
Because of the reported age and in- and exclusion criteria, patients suffering from dementia were 
probably included in these studies, but dementia was not specifically addressed in these reviews. All 
four systematic reviews concluded that interventions stimulating the completion of formal AdvDs are 
effective, especially when interventions incorporated direct interactions between patients and 
healthcare professionals, and best when this is spread over multiple visits. Such interventions reached 
an effect size of 0.50 (95% CI=0.17-0.83), and the average pooled odds ratio for increase of formal 
AdvD completion rates by means of an support intervention varied from 4.0 (CI: 1.6-10.4) across 
randomized trials  to 2.6 (CI: 1.3-5.4) when all comparative studies were included. Expressed differently, 
the trials showed that the increase in the percentage of persons having an AdvD following a support 
intervention varied from 23% to 36% (Bravo, 2008). Age was not a significant effect modifier, however 
over the last decades there is increased readiness to use a formal AdvD (on more issues than just 
resuscitation) in most recent years, and the non-clinical, community based and nursing home 
populations showed the highest success rate (46-49%), when compared with hospitalized inpatients 
(18%), which is only partially explained by the lower percentage of AdvDs at the start. This strongly 
suggests that a pro-active primary care approach probably is more effective than starting an AdvD 
intervention at a major clinical event such as a hospital admission. Only the study of Bravo et al. studied 
selection bias. Both with statistical testing and funnel plots there was little suggestion of selection bias 
in these data sets. These systematic reviews found only one random-control trial (RCT) study focusing 
on cost-effectiveness (Molloy, 2000). Molloy et al. found substantial less resource use after introducing 
and AdvD stimulation plan in a nursing home population in Canada. However, an older systematic 
review on cost effectiveness of AdvD support interventions found no definite evidence for reduced 
health care expenditures in three prospective and three retrospective studies in tertiary hospitals in 
the US (Taylor 1999). Another non-randomized trial on a complex AdvD intervention in America 
confirmed both the success of realizing AdvDs after educating subjects with advanced disease, as part 
of a much broader advanced illness coordination plan, and the compliance to these AdvDs (Engelhardt 
2009). A recently published RCT showed that emotion-focused and an individualized approach, 
facilitated care planning, however these patients were all in in early AD stage(Hilgeman et al., 2104). 
The most recent survey on advanced care planning was carried out on a national base in Canada, which 
showed that only 160 (16%) of the 1021 respondents were aware of the meaning of this term while 
530 (52%) and 105 (10%) discussed it with family or health care providers, respectively (Teixeira et al, 
2013). This resulted in an advanced care plan in 205 patients (20%), but this was general population,   
and did not address the specific issues of AdvD. All these recent data underline that there is still much 
work to be done to reach the level that AdvD is discussed in all AD patients.   
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In our systematic review another four articles on RCTs with AdvD interventions were found but none 
of these was specifically focusing on dementia patients. First, Sudore et al. presented additional 
evidence on the importance of presenting AdvD information in a simple format to meet most (n=205) 
older subjects’ literacy needs, by reaching a high preference rate (N=149) for this simple AdvD format 
and a higher AdvD completion rate (in 39 vs 16 subjects) in an adequately conducted RCT (Sudore, 
2007). However, they studied a multicultural American population in a general medicine clinic (San 
Francisco), not a community based sample.  
Two other hospital-based RCTs on legally competent inpatients from settings in Australia and Thailand 
also proved effectiveness of advanced care planning, and showed improved patient and family 
satisfaction and reduced stress, anxiety, and depression in surviving relatives (Detering 2010; 
Sittisombut 2008). 
In a last RCT among the specific population of homeless subjects of all ages in Minneapolis (USA), AdvD 
completion could also be stimulated both by a simple information based intervention, and by a more 
complex counselling intervention (Song, 2010). 
Additional to the review of literature, we also checked the most frequently used clinical trial databases 
(ClinicalTrials.Gov, Current Controlled Trials and the Cochrane Central Register of Controlled Trials 
(CENTRAL). However, we could not find and RCT planned for (in literature databases, or in trial 
registration databases) testing the cost-effectiveness of an AdvD related intervention. The three most 
relevant planned or ongoing AdvD intervention trials in older subjects are focusing on the concordance 
between the patients’ AdvD and surrogate decision making by a proxy (Bravo, 2012; Trial Registration: 
Isrctn 89993391), and on a more extensive advanced care planning in hospitalized veterans (PI: Sudore: 
ClinicalTrials.gov: NCT01990236). In sum, the eight trials found do not add evidence on AdvDs in 
community based older subjects. 
Concerns have been raised on the potential adverse effects of AdvDs because these might result in less 
quality of care delivered to these subjects from the time onwards that they decided on their AdvD, 
which might even result in worse survival. However a recent prospective observational study in 485 
subjects in Colorado (USA) did not find any difference in survival or harm of the patients with an AdvD 
(Fischer 2011). We must conclude however that the evidence on AdvD specifically for AD patients is 
limited, and much more research is required. 
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G8 TARGETS: NOBLESSE OBLIGE TO REALIZE AN INTERNATIONAL DEMENTIA DATA 
SHARING NETWORK 
One of the main targets, expressed by the recent G8 meeting on dementia is to have researchers work 
together, and share data from the research they are conducting, including sharing initiatives for big 
data 496. This is still a major challenge, as sharing research and clinical data for dementia research still 
faces many huge barriers to safeguard relevant privacy and legal issues, regulate valid and trustworthy 
re-analyses, warrant ethical conduct and transparency for sponsors and last but not least guarantee 
high quality research practice for the subjects who participated in the trials and other research. Still, 
considering the enormous challenges in the dementia health care domain, data sharing is the only way 
forward to really make progress and to meet the promises the G8 made to our aging societies497.  
As such, it can be applauded that the European call for research proposals in the Horizon 2020 
programme also promotes data sharing 498 although the European Union at the same time is steering 
in the direction of effectively hindering secondary data use by requiring the patients’ approval with 
increasingly strict privacy legislation that makes no exception for research use  496. With regard to 
dementia research, however, there are some points, which require specific attention.  
 
Challenges 
The first challenge is how to reach an International Database for Longitudinal Studies on Aging and 
Dementia (IDAD), in which harmonization of the data collection over all domains to be covered is 
sufficiently addressed. As genetic, molecular, imaging, epidemiological, observational, and trial data 
are important, this is a huge undertaking. Adequate description of the data and the characteristics of 
setting in which these are collected (“metadata”) in a standardized way is crucial but not 
straightforward 498.  
The second challenge is how to safeguard proper informed consent for such a broad and gradually 
extending data-application in subjects who already have great problems in being capable to consent 
for the trial in which they participate. Subjects should both be facilitated to contribute to scientific 
progress and have what is called a “Right to innovation”499, which refers to the notion that in principle 
all patients should be able to profit from scientific progress and be allowed to contribute to it, if they 
want to, and at the same time be sufficiently protected if they do not wish to participate. 
The third challenge is to organize quality control and management of such an endeavor 500. Interests 
of participating subjects, researchers, pharma and other companies, universities and research 
institutes, the general public and society should be balanced, by organizing transparency on the parties’ 
interests. This overall quality control is a prerequisite to really be able to conduct high quality and 
reliable research on big data that has the expected impact and value, and which is certainly possible 
as put eloquently by futurist John Naisbitt: “we are drowning in information, but starved for knowledge” 
501. Interests in proprietorship over databases and the competitive demand to increase published 
output also may hinder data sharing, and should be tackled by a smart and transparent management 
structure. 
Fourth, and not the least, the technical process of sharing the data should be made feasible, and safe, 




Despite these challenges, the effort is very much worthwhile and should be supported by the G8 and 
other countries. Data sharing has the potential to trigger positive changes in public health strategies, 
and support and improve the preventive strategies that are very promising already 69, but also in other 
research areas this approach might create breakthroughs. These advantages have become increasingly 
recognised throughout scientific communities, consequently prompting 17 major European funders of 
public health research coordinated by the Wellcome Trust  to draft a joint statement supporting public 
data repositories 501. Importantly, the AD neuroimaging initiative cohort study (ADNI), showed that 
large scale data sharing is possible and if carried out professionally and pre-planned  can be highly 
successful 502. We also addressed potential obstacles in data sharing for the Dutch National Care for 
the Elderly Programme in the TOPICS-MDS (The Older People and Informal Caregivers Survey- 
Minimum DataSet) initiative: a national project on data sharing in 64 research projects  in elderly care 
503. Some lessons learned here are that first, to comply with data protection legislation, external users 
will only be permitted to access a fully anonymised database 504. To circumvent issues related to 
publication rights and to prevent uses of the data for which they are unsuitable, a selected group of 
members from the research consortium evaluate all applications for secondary use for scientific 
feasibility and overlap with the studies that are already being performed or planned for. Rather than 
erecting barriers to secondary use, this brief assessment aims to improve secondary use because it 
tries to identify potential synergies with studies that are already ongoing, tries to connect applicants 
with researchers already on the topic, and tries to optimize the methodology of a proposed study to 
the possibilities offered by TOPICS-MDS. To further protect the interests of external users and to 
guarantee the involvement of patient representatives and to improve societal relevance of the 
requests, a Societal Board was established.  The Societal Board acts as a safeguard against preferential 
release of data and evaluates the societal relevance of proposals.  
Conclusion 
International data sharing in dementia research is challenging, but recent examples show that it is 
possible. However, the development of overarching research data-bases takes time, money, effort, 
and expertise. Therefore, the aim of data sharing would benefit from the establishment of an 
international dementia research network to support the exchange of best practices and experiences 
and to produce international consensus guidelines on the subject. As the G8 countries underlined the 
importance of data sharing in dementia, this noblesse obliges to support financially and organize such 
a unique international dementia data sharing network sets the framework for the ambitious goal of 








SUMMARY AND CONCLUSION 
Alzheimer’s disease (AD) is the leading cause of dementia, and since the primary risk factor for AD is 
old age, the prevalence of the disease is increasing dramatically in most developed countries with aging 
populations.  Even in the developing world, the incidence of AD and other dementias are probably 
grossly underestimated.  Despite recent evidence that the incidence of AD in the “younger old” 
population might be levelling off or declining, possibly due to the results of mitigation of concurrent 
risk factors like cardiovascular disease, the cost of future medical care and associated societal burdens 
related to AD will soon become overwhelming.   
Basic biomedical science has provided significant insights about the underlying pathophysiology of AD 
and other neurodegenerative diseases.  Epidemiological studies have identified many risk factors for 
AD and the quality of care of AD patients has improved due to increase emphasis on early detection 
and integrated team-oriented care and treatment of co-morbid conditions. The pharmaceutical 
industry and government-sponsored research programmes in partnership with multinational academic 
consortia have advanced several promising therapeutic leads, but success has been elusive and overall 
progress has been disappointing.   
At present, there is no therapeutic drug available to treat the underlying pathology of established AD, 
and there is no therapeutic option to delay the inevitable progression of AD.  Human subjects research 
on AD is extremely complex and expensive due to a number of factors, including limitations of study 
design, a lack of accessible early biomarkers and ethical consideration.  Drug development 
programmes now pose unacceptably high financial risks to investors.  Because of the lack of progress 
in developing a cure for AD and due to the increasing financial and societal burden of AD, policy 
decision makers and governments have a powerful incentive to provide more resources to develop AD 
therapeutics.  In fact, the coordination of the additional resources through multinational public-private 
organisations focused on the development of therapeutics should be linked to clinical care 
programmes at multiple levels.  Multiple therapeutic targets and approaches should be pursued in 
parallel to mitigate risk.  Even relatively minor advances to delay progression or ameliorate symptoms 
might have significant financial and societal benefits.   
Unlike many other diseases where survival rates can be used to judge success, the progressive cognitive 
impairment and functional decline of AD patients takes a huge toll on individual autonomy and dignity 
and profoundly affects entire families.  
With this background concerning the challenges of AD, we recommend a dramatic overall increase in 
government and private investment in the care of AD patients and the search for AD therapeutics.  The 
individual sections of this compendium have provided specific recommendations.  Here we summarize 
the key points of the Commission and propose how we recommend that patient care and research 
should be organized in the future.  Given the dramatic advances in information technology, 
bioinformatics, molecular biology and genetics and statistical approaches to analyse mega-data, we 
are optimistic that geometric progress can be made if investment in the relevant clinical science is 
increased substantially and if a long-term commitment (15+ years) can be made to maintain the 
investment.   
The overarching aim of this Commission is to provide information and expert recommendations to 
policy decision makers and political leaders about the growing problem of AD and related dementias 
91 
 
of aging.  Unlike many other medical conditions where patients themselves can be advocates for 
enhanced care and focused research, the progression of AD causes a relentless decline in cognitive 
function and often, family members become overwhelmed as well, so that direct advocacy by those 
directly affected is often not possible.  As the cost of care for AD patients increases, funds must not be 
shunted from basic research, clinical research and drug discovery programmes.  In fact, dramatic 
increases in long-term funding for multidisciplinary research programmes is absolutely essential to 
decrease the burden of individual suffering and society cost from AD.  Only targeted increases in 
investment in AD research will provide any hope of curative therapeutic drugs or other strategies to 
delay the onset or slow the progression of AD.Below, we have summarized some of the most important 
recommendations from the different chapters in this commission paper. 
KEY RECOMMENDATIONS 
 All individuals should have access to reliable and timely diagnosis and treatment, independent 
of social inequalities. Accurate and timely diagnosis is a prerequisite for cost-effective care 
with currently available therapies. The cost-effectiveness of new therapies will be uncertain at 
the time they are introduced and should not be a limiting factor for treatment of this patient 
group. 
 
 There is a need to establish harmonized international databases for existing population-based 
longitudinal studies on ageing and dementia. This will provide powerful resources for further 
understanding the burden (e.g., prevalence, incidence, and mortality), nature history (e.g., 
genetic and clinical markers for early detection), and etiopathogenetic hypotheses (e.g., 
psychosocial stress, nutrition, and frailty) for AD and dementia.  
 Prevention studies need to start early in (mid)life and have a long duration in order to identify 
windows of opportunity for effective interventions. Many modifiable risk factors such as high 
blood pressure, obesity, physical inactivity and unhealthy diet are shared among dementia/AD 
and other major late-life chronic conditions like heart disease and stroke. Public health efforts 
promoting healthier lifestyles have the potential to improve generally health status in 
advanced age.  
 
 Scientific collaborations among research groups in Europe require the development of 
appropriate infrastructures to facilitate more effective use of existing data, and rapid 
recruitment of participants in multinational intervention trials. Increased collaboration among 
governments, public, and private institutions is required to facilitate AD/dementia prevention 
research.  
 
 Genetics plays a major role in current understanding of AD and will play an important role in 
the general prevention and care of the disease in future. To allow for optimal utilization of 
genetics in prevention of dementia, pre-symptomatic and early diagnoses, and present and 
future treatment approaches, there is a need to: 
 
o Systematically collect and store DNA and clinical data from epidemiology, clinical 
settings and clinical trials 
o Develop a legal framework that regulates the use of data for research, as well as 




 Currently available biomarkers need to be validated and standardized. At the same time, the 
search for novel biomarkers with higher predictive value at pre-dementia stages needs to be 
continued. It is also necessary to develop more simple biomarkers (eg in blood) to be used in 
general practice.  
 To find a cure or an effective therapy for AD remains imperative. For that, there is need of 
ambitious programmes in basic research. Without new breakthroughs in understanding AD 
pathogenesis, the development of a cure seems unachievable. 
 
IMPROVE THE CLINICAL DEVELOPMENT INFRASTRUCTURE: 
 Increase collaboration among governments, public, and private institutions is required to 
facilitate clinical research. There is substantial redundant research in AD drug development. 
 
 Increase drug discovery, development and clinical trial research budgets.  Establish 
international methodology, cohorts, and ethical and regulatory frameworks to facilitate trials.  
Clinical drug development and clinical trials should be coordinated internationally.  Recognize 
and support the different approaches to drug development. 
 
 Improve public, private, corporate funding such that decisions are made based on evidence, 
scientific merit, rather than by advocacy, opinion, persuasion. 
 
 Recommendations from authorities and an infra-structure to enable non-pharmacological 
interventions for which clear evidence of benefit already exists should be put into practice with 
appropriate training, support and maintenance of fidelity.   
 
 National policy strategies and implementation guidelines for dementia care are needed in all 
countries. Such frameworks should include e.g.,  
o Better coordination between health, social care and other relevant sectors (such as 
welfare benefits and housing). 
o Affordable long-term funding plans for dementia care that span health, social care, 
housing and other relevant sectors. 
 
  For early diagnostic procedures in asymptomatic AD, new research frameworks for evaluation 
of diagnostic tests should be applied in which the overall benefits and disadvantages of a new 
diagnostic test are evaluated both from the biomedical and the patients’ perspective.  
 
Future European Perspectives  
 
In the field of AD research, Europe suffers from several limitations that constitute bottlenecks:  
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1. Low level of investment and human resources compaired to the rest of the world and to other 
diseases. 
2. Fragmentation and low coordination (in Europe, research policy is carried out by the European 
Commission and by the 28 member states at national level. 
3. Knowledge application: Europe must introduce innovation, metholodogies and processes for 
promoting the application of research results. 
4. European research infrastructures should be strengthened. 
5. Research careers and mobility with full freedom of researchers’ movement needs to be 
improved. 
While it is clear that much more basic biomedical research will be required to understand the biology 
of dementia, it is important to develop and implement new approaches for pharmaceutical research 
and development to target Alzheimer’s disease and other dementias.  In the setting of current 
knowledge, and with currently available resources, it is unlikely that any individual pharmaceutical 
company (or even an alliance of companies), will be able to develop an effective therapy.  Large clinical 
trials of drug candidates will continue to be extremely expensive and complex to plan and administer 
and there is no clear strategy to mitigate risk when a profit motive that emphasizes shareholder return 
predominates.   Therefore, we advocate public-private partnerships in which large consortia of 
pharmaceutical companies and public-governmental agencies can deploy capital resources and share 
risk.  
Only agencies such as the US National Institutes of Health or an alliance of European Union health 
research agencies in partnership with the pharmaceutical industry will be able to assemble the 
required expertise and expend the capital to initiate and advance large-scale drug discovery and 
development programmes.  Essentially all major clinical trial initiatives that target early-onset or 
familial dementia syndromes are US led, with at least partial NIH support.  A complementary European 
strategy should be extremely productive; perhaps to target sporadic cases in which onset of symptoms 
occurs at older average ages.  Such a strategy might be most effective if several approaches are tried 
in parallel, rather than the typical approach of successive linear trials with long individual timelines.   
At the same time, a public health perspective should be systematized and considered as a core principle, 
rather than play second-fiddle to a search for a magic-bullet therapy.  For example, would controlling 
known intrinsic risk factors decrease the incidence or severity of disease?  Do elderly subjects with 
normal cognition and mental function harbour some protective factors like antibodies against amyloid 
protofibrils. These types of questions can be addressed only through complex epidemiological studies 
perhaps in combination with diagnostic testing in the setting of sophisticated public health networks.  
The infrastructure for such studies might only exist currently within the European Union and should be 
exploited to provide solid data that might lead to new approaches to mitigate disease or provide new 
targets for therapy. 
In an environment of increased pressure to reduce public spending, options should be debated in an 
open forum with a well-informed public constituency so that long-term strategic support can be 
assured.  The funding of translational research, drug discovery, and patient-oriented clinical trials will 
need to extend beyond the time horizon of any individual political campaign, and the public should 
understand that long-term commitment is required.  In fact, it is likely if not probably that treatment 
of dementia syndromes might evolve to be multidimensional, with combinations of treatments for a 
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specific diagnosis, or numerous treatment options depending on a particular ”molecular” or genetic 
diagnosis.  As an example, cancer treatment is now often ”patient-specific” and cancer is no longer 
considered to be a single entity, but rather a complex multifactorial constellation of disease, often with 
acute and chronic phases.  Oncology centres have evolved to become clinical research enterprises 
where gene sequencing can be part of routine care.  The future of dementia treatment might be similar, 
and would require systematic public investment to focus scientific biomedical resources, while not 
depleting basic clinical care and support.  Dementia syndromes are insidious, progressive, and chronic, 
and the importance of caring sciences and support cannot be over-emphasized.  Relatively low-cost 
innovations and interventions are likely to have a huge impact on the quality of life for patients and 
their families and caregivers.  
The discovery of informative biomarkers should be a priority and the science of disease biomarkers in 
Alzheimer’s disease and related dementias is still in its infancy. New biomarkers and diagnostic 
strategies to detect synaptic loss and apoptotic cell death in the CNS are urgently needed.  The search 
for biomarkers might take place in large patient cohorts even independent of therapeutic options.  At 
present, in most countries, payment for expensive diagnostic services is linked to the potential for 
treatment.  For example, a diagnostic PET scan might not be indicated at present because the results 
would not be used to direct therapy, but more widespread use of advanced diagnostics, especially in 
the setting of the collection of metadata like blood, CSF and genetic analysis plus advanced memory, 
cognitive and behavioural testing might lead to significant understanding of the natural history of 
disease and the stratification of dementia syndromes for the purposes of effective therapeutic trials.  
Of course, the ethical concerns of clinical trial design, for both diagnostic and therapeutic modalities, 
are paramount when informed consent cannot be readily or reliably obtained from human subjects, at 
least in more advanced stages of the disease.  
In summary, effective strategies to prevent or cure Alzheimer’s disease and other dementias will 
require an urgent reassessment of traditional paradigms of health care practice.  Although basic 
biomedical research as initiated by individual investigators can lead to breakthroughs and discoveries, 
and the pharmaceutical industry has had an unparalleled series of successes over many decades, a 
disease threat as large and complex as Alzheimer’s disease in an aging population cannot be left to 
chance on unfocused research programmes on the one hand, or to the whims of corporate risk-return 
business analysis on the other hand.  A massive large-scale public-private partnership on a 
multinational scale is required, and the European Union is well-positioned due to its excellent health-
care delivery system, basic single-payer model, outstanding research infrastructure, and stung 
pharmaceutical industry base, to take the world lead, in partnership with international organizations, 
to develop new paradigms to prevent or cure dementing illnesses and to provide models of 










Table 1: Costs involved in diagnosing a case with Alzheimer’s disease and a calculation of the 
cumulative costs as each new diagnostic procedure is added. Source: Wimo et al 18 Costs in Swedish 
Kronor (SEK) converted to Euros at 9 SEK/EUR. 
 
Primary care level Unit cost (EUR) Cumulative cost (EUR) 
Visit to family physician 122 122 
Routine blood tests 33 156 
Computed tomography (CT) scan 200 356 
Visit to occupational therapist 144 500 
Specialist care level   
Visit to specialist physician 367 867 
Neuropsychologic testing 422 1289 
Electroencephalogram (EEG) 100 1389 
Cerebrospinal fluid (CSF) tests 622 2011 
Magnetic resonance imaging (MRI) 289 2300 
Single photon emission computed tomography 
(SPECT) 
378 2678 
Position emission tomography (PET) scan 1711 4389 









Table 2. The intangible cost of Alzheimer’s disease and other dementias, by World Bank income level 








Total DALYs (million) 1,523 122 121 452 828 
DALYs due to AD and other 
dementias (million) 
11.16 4.39 1.04 3.73 2.00 
DALYs due to dementia (% of 
total DALYs) 
0,7% 3,6% 0,9% 0,8% 0,2% 
GDP per capita (USD) 0 38,182 7,289 1,924 596 
Intangible cost (billion USD) 
valued at 3xGDP per capita per 
DALY 





Table 3. Population-based surveys and systematic reviews of population surveys on the temporal 
trends of dementia occurrence by continents 
 




Key findings on the trend 
NORTH AMERICA     
Langa et al. 2008 
(USA) 
Repeated surveys 
in the Health and 
Retirement Study  
Age ≥70 for both waves; 
Wave 1 (1993), n=7406 
Wave 2 (2002), n=7104 
Prevalence of cognitive 
impairment (≤10 of 35-
point cognitive scale) 
Prevalence decreased from 
12.2% to 8.7% 
Hall et al. 2009 
(Indiana, USA) 
Repeated cross-
sectional surveys  
African Americans, age ≥70 
Wave 1 (1992), n=1500 
Wave 2 (2001), n=1892 
Prevalence of dementia 
and AD (ICD-10) 
Prevalence was stable for 
dementia (6.75% to 7.45%) 
and AD (5.47% to 6.77%)  




every 3 years 
Cycle 1: age ≥65, n=6158 
All cycles: age ≥65, n=~10000 
Time period: 1997-2008 
Incidence of AD 
(NINCDS-ADRDA) 
Risk of AD was stable over 
time (OR for trend variable 
0.97, 95% CI 0.90-1.04) 
Rocca et al. 2011 
(USA) 
Review Time period: 1993 to 2002 Prevalence or incidence 
of dementia and AD 
Prevalence or incidence of 
dementia or AD was stable  
EUROPE     




Age ≥65 for both waves; 
Wave 1 (1988-1989), n=1080 
Wave 2 (1994-1996), n=3715 
Prevalence of dementia 
(DSM-IV) 
Prevalence was stable in all 
(5.2% to 3.9%); decreased 
in men (5.8% to 2.3%) 
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Age ≥60 for both waves; 
Wave 1 (1990), n=5727 
Wave 2 (2000), n=8384 
Incidence of dementia 
(DSM-III-R) 
Incidence decreased (age-
adjusted IRR: 0.75, 95% CI 
0.56-1.02, p=0.06) 




sectional surveys  
Age ≥75 for both waves;  
Wave 1 (1987-1989), n=1700  
Wave 2 (2001-2004), n=1575 
Prevalence and survival 
of dementia (DSM-III-R) 
Prevalence: stable (17.5% 
to 17.9%); Suggestive 
declining in incidence  





Wave 1 (1976-1977): age=70, 
n=404; age=75, n=303 
Wave 2 (2000-2001): age=70, 
n=579; age=75, n=753         
Prevalence of dementia 
(historical criteria-wave 




Matthews et al. 
2013 (England, UK) 
Repeated cross-
sectional surveys 
Age ≥65 for both waves;  
Wave 1 (1989-1994), n=7635 
Wave 2 (2008-2011), n=7796 
Prevalence of dementia 
(Geriatric Mental State 
scale) 
Prevalence decreased 
(8.3% to 6.5%) 
ASIA     




Age ≥60 for both waves; 
Wave 1 (1986-1989), n=1090 
Wave 2 (1997-1999), n=1593 
Prevalence and 
incidence of dementia 
(ICD-10, DSM-IV) 
Prevalence increased (1.7% 
to 2.5%); Incidence 
increased (0.6% to 0.9%) 
Yu et al. 2012 
(Hong Kong, China) 
Review Age ≥70;  
Time period: 1995 to 2006 
Prevalence of dementia 
(ICD-9, 10) 
Prevalence increased from 
4.5% to 9.3% 
Chan et al. 2013 
(Mainland China) 
Systematic 
review of 75 
cross-sectional 
surveys 
Age ≥55, n=340247;  
Time periods: 1990 to 2010 
Prevalence of dementia 
and AD  
Prevalence increased in all 
age groups 
Wu et al. 2014 
(Mainland China, 
Hong Kong, and 
Taiwan) 
Systematic 




Time periods: 1990 to 2012 
Prevalence of dementia 
by survey years, age 




there is a slight increase 
from 1995 to 2012, and a 
birth cohort effect. 
Sekita et al. 2010 
(Hisayama, Japan) 
Repeated cross-
sectional surveys  
Age ≥65 for all waves; 
Wave 1 (1985): n=887 
Wave 2 (1992): n=1189 
Wave 3 (1998): n=1437 
Wave 4 (2005): n=1566 
Prevalence of all-cause 
dementia and AD 
(DSM-III, DSM-III-R) 
Prevalence increased from 
1985 to 2005 for all-cause 
dementia (6.0% to 8.3%) 
and for AD (1.1% to 3.8%).  
Dodge et al. 2012 
(Japan) 
Systematic 
review of 8 cross-
sectional surveys 
Age ≥65, n=13396  
Time period: 1985 to 2008 
Prevalence of dementia 
(DSM-III, DSM-III-R, 
DSM-IV) 






Table 4. Putative risk and protective factors for late-onset dementia and Alzheimer’s disease 
APP: amyloid precursor protein. APOE: apolipoprotein E. CLU: clusterin. CR1: complement component 
receptor 1. ELF-EMFs:  extremely-low-frequency electromagnetic fields.  PICALM: phosphatidylinositol 
binding clathrin assembly protein. TOMM40: Translocase of outer mitochondrial membrane 40 homolog. 
TREM2:  triggering receptor expressed on myeloid cells 2. 
 
A large number of risk and protective factors for dementia and AD have been investigated, and there are greater 
and lesser degrees of evidence to support these various factors. 
  




APOE ε4 allele 
Different genes (e.g., CR1, PICALM, CLU, TREM2, 
TOMM40) have been proposed (www-alzgene.org) 
 
Vascular and metabolic factors 
Atherosclerosis 
Cerebral macro- and microvascular lesions 
Cardiovascular diseases 
Diabetes mellitus and pre-diabetes 
Midlife hypertension  
Midlife overweight and obesity 





Heavy alcohol consumption 
 






Traumatic brain injury 
Occupational exposure (heavy metals, ELF-EMFs) 
Infectious agents (e.g., herpes simplex virus type I, 
clamydophila pneumoniae, and spirochetes) 
Genetic  
Different genes (e.g. APP, APOE ε2) have been 
proposed (www-alzgene.org) 
 
Psychosocial factors  
High education and socioeconomic status 
High work complexity 





Light-to-moderate alcohol intake 
 
Diets and nutritional factors 
Mediterranean diet 
Polyunsaturated fatty acid and fish-related fats 
Vitamin B6, B12, folate  






Hormone replacement therapy 





Table 5. Characteristics of selected RCTs for prevention of cognitive impairment, dementia and Alzheimer disease based on 
multidomain interventions  
RCT FINGER 505 MAPT 506 PreDIVA 507 HATICE 508 
Sample size 1260 community dwellers, 
from previous population-
based observational cohorts 
1680 community dwellers 3533 community dwellers 
 
4600 community dwellers 
Main inclusion criteria Dementia risk score >6 and 
cognitive performance at the 
mean level or slightly lower 
than expected for age 
Frail elderly individuals 
(subjective memory 
complaint, slow walking 
speed, IADL limitations) 
All elderly without dementia 
in GP practices  
Non-demented older adults 
with increased risk of 
cardiovascular conditions 
and dementia 
Age at enrolment  60–77 yrs ≥70 yrs 70–78 yrs ≥ 65 yrs 
Study design Multicentre, randomized, 
parallel-group controlled trial 
Multicentre, randomized, 







Intervention  Multidomain: nutritional 
guidance, physical activity, 
cognitive training, social 
activity and management of 
vascular risk factors  
Multidomain: vascular care, 
nutritional advice, exercise 
advice, cognitive training 
and/or DHA 800 mg/day 
Multidomain: nurse-led 
vascular care including 
medical treatment of risk 
factors, nutritional advice, 
exercise advice 
Multidomain e-health: 
interactive internet platform 
with nurse-led support to 
optimize management of 
vascular and lifestyle-
related risk factors 
Duration 2 yrs + 5-yrs follow-up 3 yrs + 2-yrs follow-up 6 yrs  1.5 yrs 




cardiovascular events, quality 
of life, health resource use, 
change in AD biomarkers  
Primary: change in cognitive 
function  
Secondary: cognition, 
functional status, depression, 
health resource utilisation, 






Primary: optimization of 
cardiovascular and 
dementia risk management  







Status  Ongoing, completed in 2014 Ongoing, completed in 2014  Ongoing, completed in 
2015 
Ongoing, completed in 
2017 
FINGER: Finnish Geriatric Intervention Study to Prevent Cognitive impairment and Disability, MAPT: Multidomain 








Table 6. CAIDE Dementia Risk Score: Probability of dementia in 20 years according to midlife risk 
score categories. 
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        47-53 years 







> 10 years 
 7-9 years 






























Table 7. List of known genes and loci implicated in Alzheimer disease.  
OR: Odds Ratio;  CI: Confidence Interval; MAF: Minor Allele Frequency; PAF: Population Attributable Fraction  
Chr Gene in the region Transmission OR[95%CI] MAF PAF PAF Type Putative function Possible pathways Ref. 
21 







Rare _ causal 





Aβ pathway Tau 
pathway 
176 




































variant                
0.24, p= 
4.19x10-5 
< 1% _ preventive 















variant                  
4.59 [2.49-
8.46] 
< 1% _ risk 
Homozygous loss-
of-function 
mutations in an 
autosomal recessive 











variant                  
2.10 [1.47-
2.99] 
< 1% _ risk 
Member of the PLD 
superfamily 
Aβ pathway 202 
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Table 8. Classification of the identified loci with genetic association to AD according to their genetic 
impact on risk for AD 
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Table 9. Differences between presymptomatic genetic testing for deterministic monogenic mutations 
and testing for susceptibility loci. 
 
 Deterministic genes Susceptibility loci 
Disease type Rare Common 
Inheritance Mendelian, monogenic Complex, multigenic 
Number of genes involved  Few (one) Many 
Prevalence of risk-variant Very rare (~10-4) From rare  to common 
Test result Highly predictive Probabilistic 
Individual impact Strong Weak 
Family impact High Small 
Potential population impact Low High 
Risk Simple (binary: yes/no) Complex 




TABLE 10. THE LEXICON PROPOSED BY THE IWG  
Alzheimer’s disease:  
 starts with the first specific symptoms, 
 encompasses both the prodromal and dementia phases: 
 AD dementia: phase of AD with an impact on ADL (it corresponds to “AD dementia” in the 
NIA-AA criteria) 
 Prodromal AD: the early symptomatic, predementia phase of AD. This condition corresponds 
to “MCI due to AD”. 
 
Typical AD:  
 common clinical phenotype of AD,  
 characterized by an early amnestic syndrome of the hippocampal type that can be isolated or 
associated with other cognitive/behavioural changes 
 
Atypical AD:  
 less common but well characterized clinical phenotypes: logopenic aphasia, posterior cortical 
atrophy, frontal variant of AD;                                                    




Mixed AD:  
 patients who fulfill the criteria for AD with clinical and biomarkers evidence of other co-
morbid disorders 
 
Preclinical stages of AD 
 they include 2 different conditions in cognitively normal individuals (different from the NIA-
AA criteria): 
 Asymptomatic at risk: cognitively normal individuals with in vivo pathophysiological biomarkers 
of AD 
 Presymptomatic AD: cognitively normal individuals with a proven autosomal dominant 
mutation 
 
Alzheimer’s pathology:  
 neurobiological changes responsible for AD  
 (different from the NIA/AA criteria where the presence of Alzheimer’s pathology defines the 
presence of an Alzheimer’s disease) 
 
Pathophysiological markers:  
 in vivo biological changes that reflect the underlying AD pathology;  
 they consist of CSF Abeta and tau and PET-amyloid;                                         
 they are markers of diagnosis, more targeted at identifying AD. 
 
Topographical biomarkers:  
 downstream markers of neurodegeneration 
 they can be structural (atrophy/MRI) or metabolic (hypometabolism/FDG); 




 now includes individuals who do not meet criteria for prodromal AD.  
 It is also valuable to patients for whom there is no disease clearly identified, including 
individuals who have memory deficit characteristic of prodromal AD but where biomarker 





Table 11. Different stages and classification of AD subtypes across NIA-AA and IWG criteria 
NIA-AA criteria IWG criteria Comments 
Preclinical AD 
Asymptomatic cerebral amyloidosis (ACA) 
ACA + evidence of neuronal injury (NI) 
ACA + NI + subtle cognitive decline 
Asymptomatic at risk with AD 
pathology 1 
  
Preclinical AD 2  
1 Normal cognition with a 
pathophysiological marker 
 
2 Normal ognition with an autosomal 
dominant AD-causing mutation 
MCI due to AD 
MCI due to AD high likelihood 1 
MCI due to AD intermediate likelihood 2 
MCI possibly due to AD 3 




(Prodromal stage) 5 
 
 
1 Biomarkers of amyloidosis and 
neuronal injury are positive  
2 Biomarker of amyloidosis positive or 
biomarker of neuronal injury untested 
3 Biomarker of amyloidosis positive and 
biomarker of neuronal injury are 
untested or give conflicting results 
4 Biomarker of amyloidosis positive and 
biomarker of neuronal injury are 
negative 
5 Episodic memory impairment or 
atypical AD-compatible syndrome with 
one pathophysiological marker (CSF or 
abnormal amyloid imaging) 
Dementia caused by AD 
Probable AD dementia with increased level of 
certainty  
 AD dementia with documented 
clinical decline 
 AD dementia with an autosomal 
dominant AD-causing mutation 
Possible AD dementia 
 AD dementia with an atypical course 
 AD dementia with evidence of mixed 
etiology 
Probable AD dementia with evidence of AD 
pathophysiological process 
 High likelihood of AD etiology 
(biomarkers of amyloid abnormalities 
and neurodegeneration both present) 
 Intermediate likelihood of AD etiology 
(biomarker of amyloid abnormalities 
or neurodegeneration is present) 
Possible AD dementia with evidence of the AD 
pathophysiological process 
 High likelihood of AD etiology 
(biomarkers of amyloid abnormalities 
and neurodegeneration both present) 
 Intermediate likelihood of AD etiology 
(biomarker of amyloid abnormalities 
or neurodegeneration is present) 
Alzheimer’s disease 
(Dementia stage) 1 
 
 
1 Episodic memory impairment or 
atypical AD phenotype with impaired 
activities of daily living 




Pathophysiologically proved AD dementia 
(Clinical phenotype of probable AD with 
neuropathology findings indicative of AD) 
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Table 12. Approval (A) or reimbursement (R.) of the four drugs on the market for Alzheimer´s Disease 
(source:  update of Alzheimer Europe: Dementia in Europe Yearbook 2012 – National Dementia 
Strategies (diagnosis, treatment and research), ISBN-13: 978-2-9599755-8-5, 2012 )  
Country Donepezil Rivastigmine Galantamine Memantine 
  A R A R A R A R 
Austria Yes Yes Yes Yes Yes Yes Yes Yes 
Belgium Yes Yes Yes Yes Yes Yes Yes Yes 
Bulgaria Yes No Yes No Yes No No No 
Croatia Yes No Yes No No No Yes Yes 
Cyprus Yes Yes Yes Yes Yes Yes Yes Yes 
Czech Republic Yes Yes Yes Yes Yes Yes Yes Yes 
Denmark Yes Yes Yes Yes Yes Yes Yes Yes 
Estonia Yes No Yes No Yes Yes Yes Yes 
Finland Yes Yes Yes Yes Yes Yes Yes Yes 
France Yes Yes Yes Yes Yes Yes Yes Yes 
Germany Yes Yes Yes Yes Yes Yes Yes Yes 
Greece Yes Yes Yes Yes Yes Yes Yes Yes 
Hungary Yes Yes Yes Yes No No Yes Yes 
Iceland Yes Yes Yes Yes Yes Yes Yes Yes 
Ireland Yes Yes Yes Yes Yes Yes Yes Yes 
Italy Yes Yes Yes Yes Yes Yes Yes Yes 
Jersey Yes Yes Yes Yes Yes Yes Yes Yes 
Latvia Yes No Yes No Yes No Yes No 
Lithuania Yes Yes No No No No Yes Yes 
Luxembourg Yes Yes Yes Yes Yes Yes Yes Yes 
Malta Yes No Yes No Yes No Yes No 
Netherlands No No Yes Yes Yes Yes Yes Yes 
Norway Yes Yes Yes Yes Yes Yes Yes Yes 
Poland Yes Yes Yes Yes Yes No Yes No 
Portugal Yes Yes Yes Yes Yes Yes Yes Yes 
Romania Yes Yes Yes Yes Yes Yes Yes Yes 
Slovakia Yes Yes Yes Yes Yes Yes Yes Yes 
Slovenia Yes Yes Yes Yes Yes Yes Yes Yes 
Spain Yes Yes Yes Yes Yes Yes Yes Yes 
Sweden Yes Yes Yes Yes Yes Yes Yes Yes 
Switzerland Yes Yes Yes Yes Yes Yes Yes Yes 
Turkey Yes Yes Yes Yes Yes Yes Yes Yes 





Table 13. Prescription regulations of the four drugs on the market for Alzheimer´s Disease: Source 
Alzheimer Europe: Dementia in Europe Yearbook 2012 – National Dementia Strategies (diagnosis, 
treatment and research), ISBN-13: 978-2-9599755-8-5, 2012 ) 
     
 Initial prescription  Initial prescription Continued treatment Continued treatment 
 by specialists by GPs decisions by specialists decisions by GPs 
Austria YES NO YES YES (for 6 months) 
Belgium YES NO YES NO 
Bulgaria NA NA NA NA 
Croatia YES* NO YES* YES* 
Cyprus NA YES NA NA 
Czech Republic YES NO YES NO 
Denmark YES NO YES YES 
Estonia NA NA NA NA 
Finland YES (YES)** YES (YES)** 
France YES NO YES YES 
Germany YES YES YES YES 
Greece YES NO YES YES 
Hungary YES NO YES NO 
Iceland NA NA NA NA 
Ireland YES YES YES YES 
Italy YES NO YES NO 
Jersey NA NA NA NA 
Latvia NA NA NA NA 
Lithuania NA NA NA NA 
Luxembourg YES YES YES YES 
Malta YES YES YES YES 
Netherlands YES*** NO YES*** YES*** 
Norway YES**** YES**** YES**** YES**** 
Poland YES YES YES YES 
Portugal YES NO YES NO 
Romania YES NO YES NO 
Slovakia YES NO YES NO 
Slovenia YES NO YES YES 
Spain YES NO YES NO 
Sweden YES YES YES YES 
Switzerland YES YES YES YES 
Turkey YES NO YES YES 
United Kingdom YES NO YES YES 
     
* Memantine only    
** Support by statement from a specialist   
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*** Not donepezil    
**** Restrictions for donepezil   
 
Table 14 – . Drugs in late-stage clinical development (phase 2, 3 or 4 RCT) for Alzheimer´s disease: 
selected ongoing RCTs. 
Data source: www.clinicaltrials.gov 
 
Drugs tested in subjects at-risk of AD  Ongoing RCTs (examples) 
Drugs targeting amyloid: ↓ production  
Pioglitazone: PPARγ agonist, acts as β-
secretase inhibitor by stimulating PPARγ.  
TOMORROW: phase 3 RCT in 5800 cognitively normal 
seniors (65-83 years) at risk of developing MCI due to 
AD. Risk stratification: algorithm including age and 
TOMM40 and APOE genotype. Subjects with high and 
low risk are included. To be completed by 2020, 
duration is 5 years.3 
 
A blinded long-term extension phase 3 RCT is also 
planned, enrolling participants who will complete the 
TOMORROW RCT and will have a diagnosis of MCI due 
to AD. The RCT is expected to recruit 316 subjects; 
duration is 2 years, and it will be completed in 2021.511 
Drugs targeting amyloid: ↑ clearance 
  Passive immunotherapy 
Solanezumab: anti-amyloid monoclonal 
antibody. 
ADCS-A4: Anti-Amyloid Treatment in Asymptomatic 
AD. Phase 3 RCT enrolling 1150 subjects (500 with 
evidence of brain amyloid accumulation), with normal 
cognition, age 65-85 years. To be completed by 2020 
(3 years + 2 years extended follow-up planned).1 
 
DIAN-TU: Dominantly Inherited Alzheimer Network 
Trial. Phase 2-3 RCT enrolling 210 members of families 
with early-onset AD (age 18-80 years); 105 subjects 
carry a mutation in one of three genes (PSEN1, PSEN2, 
APP) causing autosomal dominant AD. To be 
completed by 2019 (2 years + 3 years extended 
follow-up planned)148 
Crenezumab: anti-amyloid monoclonal 
antibody. 
API-ADAD: Alzheimer’s Prevention Initiative -
Autosomal Dominant AD. Phase 2 RCT in 300 
members of Colombian families, (200 carriers of 
autosomal dominant mutation in the PSEN1 gene 
causing AD, age 30-60 years). To be completed by 
2020 (3 years + 2 years).4 
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Gantenerumab: anti-amyloid monoclonal 
antibody. 
Tested in the DIAN-TU RCT (see above).  
Drugs tested in symptomatic, pre-
dementia stages (prodromal AD, MCI due 
to AD) 
Ongoing RCTs (examples) 
Drugs targeting amyloid: ↓ production 
E2609: BACE1 inhibitor.  Phase 2 RCT in 700 subjects with prodromal AD or 
mild AD dementia (age 50-85 years). 18 months 
duration, to be completed in 2016.20 
AZD3293: BACE1 inhibitor. AMARANTH: Phase 2/3 RCT in 2202 subjects with MCI 
due to AD or mild AD dementia (age 55-85 years). 2 
years duration, to be completed in 2019.22 
Verubecestat (MK-8931, MK-8931-009): 
BACE1 and BACE2 inhibitor. 
APECS: phase 3 RCT in 1500 subjects with prodromal 
AD (age 50-85). Two years duration, to be completed 
in 2018.57 
JNJ-54861911: BACE1 inhibitor. Phase 2 RCT enrolling 100 subjects with early AD (age 
50-85). Ten months duration, to be completed in 
2016.512 
Further, a phase 2 extension study of subjects who 
participated in previous phase 1 and 2 RCTs with the 
drug is also ongoing. It is expected to last 2 years, and 
to enrol 100 subjects with early AD (50-85 years). It 
will be completed in 2024.513 
Drugs targeting amyloid:  ↓ aggregation or oligomerization 
PQ912: glutaminyl cyclase inhibitor, which 
counteract the production of amyloid 
peptides (i.e., pyroglutamate-modified Aß 
peptides) highly prone to aggregation. 
SAPHIR: phase 2 RCT in 110 subjects with MCI or mild 
dementia due to AD (age 50-89). Three months 
duration, to be completed in 2016.514 
Drugs targeting amyloid: ↑ clearance 
  Passive immunotherapy 
Gantenerumab: anti-amyloid monoclonal 
antibody. 
Phase 3 RCT in 799 subjects (50-85 years), 2 years 
duration, to be completed at the end of 2015.515 
BAN2401: anti-amyloid monoclonal 
antibody. 
Phase 2 RCT in 800 subjects (MCI due to AD or mild AD 
dementia, age 50-90 years), 18 months duration, to be 
completed by 2018.6 
Aducanumab (BIIB037): anti-amyloid 
human monoclonal antibody originally 
derived from healthy older adults. 
2 phase 3 RCTs (EMERGE, ENGAGE), in 1700 subjects 
(MCI due to AD or mild AD dementia, age 50-85 
years), about 18 months duration, to be completed in 
2020.145,146  
Intravenous immunoglobulin: derived from 
healthy donors, contain naturally occurring 
polyclonal anti-Aβ antibodies. 
MCI: phase 2 RCT in 50 subjects with MCI (age 50.84). 
two years duration, to be completed in 2017.516 
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Drugs targeting tau: ↓ p-tau production, ↓ fibrillization or ↓ deposition 
Exendin-4 (Exenatide): anti-diabetic agent 
(glucagon-like peptide-1 receptor agonist), 
can restore intracellular transport of tau, 
prevent tau phosphorylation and improve 
insulin signalling. 
Phase 2 RCT in 100 subjects with MCI or mild AD 
dementia (age 60+). About 18 months duration, to be 
completed in 2016.24 
Drugs modulating neurotransmission 
Atomoxetine: licensed drug which acts as 
norepinephrine uptake inhibitor; increases 
noradrenaline brain levels. 
ATX-001: phase 2 RCT in 40 subjects with MCI (age 50-
90 years). Six months duration, to be completed in 
2017.27 
Ladostigil (TV-3326): derivative of 
rasagiline and rivastigmine, acts as an 
AChEI and MAO inhibitor; also has 
antioxidant properties and can modulate 
APP processing and cellular signalling 
pathways. 
Phase 2 RCT enrolling 200 subjects with MCI (age 55-
85 years). Three years duration, to be completed at 
the end of 2015/2016.49 
DAOIB: modulates glutamatergic 
transmission by regulating NMDA 
receptors. 
Phase 2 RCT in subjects with 50 MCI (age 50-90). Six 
months duration, to be completed in 2016.517 
PXT00864: combination of acamprosate 
and baclofen (both licensed drugs), which 
regulates GABAergic transmission. 
PLEODIAL-I: phase 2 RCT in 45 subjects with mild AD 
dementia, aged 60 or older. 12 weeks duration, 
completed in 2015, 24-week open label extension 
started (PLEODIAL-II).50,51  
Drugs with other mechanisms of action 
Benfotiamine: thiamine derivative, 
supports brain glucose metabolism and 
can reduce amyloid accumulation. 
Phase 2 RCT in 76 subjects with MCI or mild AD 
dementia (age 65+). To be completed in 2018, 1 year 
duration.116 
Insulin (including rapid-acting-insulin 
glulisine): regulate glucose metabolism, 
can also counteract amyloid accumulation. 
SNIFF: phase 2/3 RCT testing insulin in 240 subjects 
with MCI or mild AD dementia (age 55-85). 18 months 
duration, to be completed in 2016.26 
 
Another phase 2 RCT is testing glulisine in 90 subjects 
with MCI or mild AD dementia (age 50-90). 6 months 
duration, to be completed in 2017.38 
Cilostazol: phosphodiesterase III inhibitor 
licensed as antiplatelet drug, can reduce 
amyloid toxicity  
Phase 2 RCT in 200 subjects with MCI (age 55-84). 
About 2 years duration, to be completed in 2018.33 
BI 409306 (SUB 166499): 
phosphodiesterase 9 inhibitor, can 
Two phase 2 RCTs in 624 subjects with MCI due to AD 
(age 55+ years). Twelve weeks duration, to be 
completed in 2016.518,519  
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enhance synaptic plasticity and reduce 
amyloid toxicity. 
 
Simvastatin: licensed cholesterol lowering 
drug, can lower Aβ brain production and 
reduce 
Aβ-mediated neurotoxicity, as well as 
having antioxidant and anti-inflammatory 
properties. 
SIMaMCI: phase 4 RCT in 52o subjects with MCI (age 
55-90). Two years duration, to be completed in 
2018.19 
VX-745: inhibitor of p38a mitogen-
activated protein kinase, modulates 
inflammation. 
2 phase 2 RCTs in subjects with MCI due to AD or mild 
AD dementia (32 participants in total, age 60-85 
years). Duration from 6 to 12 weeks, to be completed 
in 201636,37 
Drugs tested in subjects with dementia 
due to AD 
Ongoing RCTs (examples) 
Drugs targeting amyloid: ↓ production 
E2609: BACE1 inhibitor. Tested in a RCT including subjects with mild AD 
dementia or prodromal AD (see above). 
AZD3293: BACE1 inhibitor. Tested in a RCT (AMARANTH) including subjects with 
mild AD dementia or MCI due to AD (see above). 
Verubecestat (MK-8931, MK-8931-009) 
BACE1 and BACE2 inhibitor. 
EPOCH: phase 2-3 RCT enrolling 1960 subjects with 
mild to moderate dementia due to AD (age 55-85). 18 
months duration followed by double-blind extension 
phase (additional 5 years); the first phase will be 
completed in 2017.520 
Bryostatin-1: macrocyclic lactone that has 
already been investigated as an 
antineoplastic drug; it can stimulate α-
secretase and reduce brain amyloid 
burden. 
Phase 2 RCT enrolling 150 subjects with moderate to 
severe dementia due to AD (age 55-85). Seven months 
duration, to be completed in 2017.521 
Drugs targeting amyloid:  ↓ aggregation or oligomerization 
Carvedilol: nonselective ß-adrenergic 
receptor blocker, approved for the 
treatment of congestive heart failure and 
hypertension. It can prevent formation of 
amyloid oligomers. 
Phase 4 RCT in 50 subjects with mild dementia due to 
AD. Six months duration, to be completed in 2016.522 
PQ912: glutaminyl cyclase inhibitor, which 
counteract the production of amyloid 
peptides (i.e., pyroglutamate-modified Aß 
peptides) highly prone to aggregation. 
Tested in a RCT including subjects with mild AD 
dementia or MCI due to AD (see above) 
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Drugs targeting amyloid: ↑ clearance 
Passive immunotherapy 
Solanezumab: anti-amyloid monoclonal 
antibody. 
EXPEDITION-3: a phase 3 RCT enrolling 2100 cases of 
mild AD dementia, 18 months duration, to be 
completed in 2018.7 
 
EXPEDITION-EXT: phase 3, open-label extension study 
to evaluate safety in 1275 subjects with dementia due 
to AD (age 55+) who previously participated in Phase 3 
RCTs with Solanezumab. Two years duration, to be 
completed in 2018.523 
 
Also tested in subjects at risk of AD (ADCS-A4, DIAN-
TU, see above). 
Gantenerumab: anti-amyloid monoclonal 
antibody. 
Phase 3 RCT in 1000 patients with mild AD dementia, 
age 50-90 years. About 2 years duration, to be 
completed in 2018.144 
Tested also in subjects at risk (DIAN-TU) and patients 
with prodromal AD (see above) 
BAN2401: anti-amyloid monoclonal 
antibody. 
Tested in a RCT including also MCI due to AD(see 
above).6  
Aducanumab (BIIB037): anti-amyloid 
human monoclonal antibody originally 
derived from healthy older adults. 
Tested in 2 RCTs including also MCI due to AD (see 
above).145,146 
Crenezumab: anti-amyloid monoclonal 
antibody. 
Phase 2 long-term, open-label safety extension study 
in 360 subjects with mild to moderate dementia due 
to AD who previously participated in phase 2 RCTs 
testing the antibody. About 2 years duration, to be 
completed in 2017.524 
Albumin and Immunoglobulin associated 
with plasmapheresis. 
AMBAR: phase 2/3 RCT in 350 subjects with mild to 
moderate AD dementia (age 55-85 years). 14 months 
duration, to be completed in 2016.46 
Drugs targeting tau: ↓ p-tau production, ↓ fibrillization or ↓ deposition 
TRx0237: inhibitor of tau aggregation  2 phase 3 RCTs in about 1533 patients with mild to 
moderate AD dementia, age <90 years. About 18 
months duration, to be completed in 2016.124,147  
Exendin-4 (Exenatide): anti-diabetic agent 
(glucagon-like peptide-1 receptor agonist), 
can restore intracellular transport of tau, 




prevent tau phosphorylation and improve 
insulin signalling in the brain. 
Liraglutide: glucagon-like peptide-1 
receptor agonist, approved for the 
treatment of diabetes mellitus type 2. It 
improves insulin brain signalling and can 
prevent tau hyperphosphorylation. 
ELAD: phase 2 RCT enrolling 206 subjects with mild 
dementia due to AD (age 50-85). Twelve months 
duration, to be completed in 2017.525 
Drugs modulating neurotransmission  
Donepezil. AchEI already approved for the 
treatment of dementia due to AD. 
3 phase 4 post-marketing surveillance studies 
evaluating safety and effectiveness in 1600 subjects 
with AD dementia from mild to severe. Up to 4 year 
duration, to be completed between 2015 and 2016.526-
528 
Encenicline (MT-4666, EVP-6124): agonist 
of the nicotinic α7 receptor, increases 
cholinergic transmission. 
4 RCTs (Phase 2 and 3) in 1930 subjects with mild to 
moderate AD dementia (age 50-85 years). Duration is 
from six months (phase 2 and 3) to one year (phase 3), 
to be completed in 2016529 and 201725,530,531 
 
A 6-months extension phase 3 RCT is also planned for 
subjects participating in the RCTs mentioned above. It 
is expected to recruit 1000 participants and it will be 
completed in 2017.532 
MK-7622: it is hypothesized to act as 
allosteric modulator of muscarinic 
receptors, enhancing the response to 
AchEIs.  
Phase 2 RCT in 830 subjects with mild to moderate 
dementia due to AD (age 55-85). Duration is up to one 
year, and the RCT will be completed by 2020.533 
Rasagiline: MAOB inhibitor licensed for the 
treatment of Parkinson disease. 
R2: phase 2 RCT including 50 subjects with mild to 
moderate dementia due to AD (age 50-90). Six months 
duration, to be completed in 2016.534 
RG1577 (RO4602522): acts as MAOB 
inhibitor. 
Phase 2 RCT enrolling 544 subjects with moderate AD 
dementia (age 50-90 years). One year duration, to be 
completed in 2015535 
Idalopirdine (Lu AE58054, SGS 518): 
serotonin 6 (5-HT6) receptor antagonist, 
can enhance cholinergic, glutamatergic, 
noradrenergic, and dopaminergic 
neurotransmission. 
STARSHINE, STARBEAM, STARBRIGHT, STAR Extension: 
4 phase 3 RCTs in 2490 subjects with mild to 
moderate AD (1770 subjects enrolled for STAR 
Extension) aged 50+ years. Six months duration (then 
additional 8 months for subjects recruited in the 
extension study), to be completed between end of 
2015 and 2016.35,52-54 
Riluzole: modulator of the glutamatergic 
transmission. 
Phase 2 RCT in 48 subjects with mild dementia due to 




DAOIB: modulates glutamatergic 
transmission by regulating NMDA 
receptors. 
Phase 2 RCT enrolling 90 subjects with AD or vascular 
dementia from mild to moderate-severe stage (age 
50+). Six weeks duration, to be completed in 2016.537  
Methylphenidate: licensed drug acting as a 
dopamine-norepinephrine reuptake 
inhibitor, promotes dopaminergic and 
noradrenergic transmission, thus acting as 
stimulant. 
ADMET 2: phase 3 RCT in 200 subjects with mild to 
moderate AD dementia and apathy. Six months 
duration, to be completed in 2019.48 
Formoterol: drug approved for the 
treatment of asthma and chronic 
obstructive pulmonary disease. This 
compound act as long-acting agonist of 
adrenergic receptors ß2, which can 
improve synaptic plasticity and reduce 
amyloid burden 
Phase 2 RCT in 60 subjects with mild to moderate 
dementia due to AD (age 50-85). One year duration, 
to be completed in 2016.538 
Drugs with other mechanisms of action 
Sagramostim: licensed synthetic form of 
the hematopoietic growth factor 
granulocyte-macrophage colony-
stimulating factor (GM-CSF); can promote 
amyloid removal by stimulating 
phagocytosis.  
Phase 2 RCT in 40 subjects with mild to moderate AD 
dementia (age 55-85). 6 months duration, to be 
completed in 2016.115  
Benfotiamine: thiamine derivative, 
supports brain glucose metabolism and 
can reduce amyloid accumulation. 
Tested also in subjects with MCI (see above). 
Adenosine triphosphate (ATP): small 
molecule enhancing metabolism, can 
protect against amyloid-mediated 
cytotoxicity. 
 
Phase 2 RCT in 20 subjects with moderate to severe 
AD dementia (age 55-85). 3 months duration, to be 
completed in 2016.539 
Azeraligon (PF-04494700 , TTP488): small 
molecule acting as RAGE inhibitor, can 
counteract amyloid brain accumulation 
and modulate inflammation. 
Phase 3 RCT in 800 subjects with mild AD dementia 
(age 50+). 18 months duration, to be completed in 
2018.117 
T-817MA: small molecule showing 
neurotrophic and neuroprotective 
properties related to protection against 
amyloid and tau-mediated toxicity. 
Phase 2 RCT 450 In subjects with mild to moderate AD 
dementia (age 55-85). About one year duration, to be 
completed in 201639 
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Cerebrolysin: peptide mixture with 
neurotrophic-like properties related to the 
regulation of cell signalling, control of 
amyloid metabolism and anti-apoptotic 
effects mediated by expression of 
endogenous neurotrophic factors. A meta-
analysis of 6 RCTs suggested beneficial 
symptomatic effects in subjects with mild 
to moderate dementia due to AD.540 
 
DAT: phase 4 RCT in 510 subjects with mild to 
moderate dementia due to AD (age 50+). Six months 
duration, to be completed in 2016.541   
Nilvadipine: licensed anti-hypertensive 
drug, is a dihydropyridine calcium channel 
blocker. Can enhance brain circulation, 
and also prevent amyloid 
accumulation/increase its clearance. 
NIVALD: phase 3 RCT enrolling 500 subjects (age 50+) 
with mild to moderate AD dementia. 18 months 
duration, to be completed in 2017.21 
Insulin (including rapid-acting-insulin 
glulisine): regulate glucose metabolism, 
can also counteract amyloid accumulation 
Phase 2/3 RCTs including also subjects with MCI (see 
above). 
AZD0530 (Saracatinib): inhibitor of Fyn-
kinase, can attenuate amyloid and tau-
mediated neuronal damage.  
Phase 2 in 152 subjects with mild AD dementia (age 
55-85). One year duration, to be completed in 2016.542 
Masitinib (AB1010): selective tyrosine 
kinase inhibitor, can modulate 
neuroinflammation by regulating mast 
cells activity. It can also promote 
neuroprotection by targeting Fyn-kinase. 
Phase 3 RCT in 396 subjects with mild to moderate AD 
dementia (age 50+). Six months duration, to be 
completed in 2016.543 
VX-745: inhibitor of p38a mitogen-
activated protein kinase, modulates 
inflammation. 
2 phase 2 RCTs including also subjects with MCI due to 
AD (see above). 
 
Abbreviations: AChEI: acetylcholinesterase inhibitor; AD: Alzheimer´s disease; APOE: Apolipoprotein 
E; APP: amyloid precursor protein; BACE1: Β-site APP-cleaving enzyme; MAO: monoamine oxidase 
inhibitor; MCI: mild cognitive impairment; NMDA: N-Methyl-D-aspartate; PPARγ: peroxisome-
proliferator activated receptor γ; PSEN1: Presenilin 1; PSEN2: Presenilin 2; RAGE: receptor for 






Table 15. Formal Resources of interest to analyse in economic evaluations of dementia care 
Formal care 
Living situation (at home, institutions) 
Respite care 
Home social care visits 
Home medical care visits 
Home rehabilitation care visits 
Visits to clinics: physicians: specialist 
Visits to clinics: GP (similar) 
Visits to clinics: registered nurses (similar) 
Visits to clinics: rehabilitation (similar) 
Hospital care (various specialities/departments) 
Day Hospital care (such as day surgery) 
Day Care special for dementia 
Day Care (non-specified) 
Use of drugs 
Technical device/equipment 









Table 16. Ethical questions in dementia care, currently most important for patients, proxies and 
professionals. 
Domain Patients Proxies/Caregivers Professionals 
Prevention Is lifelong medication and 
lifestyle change beneficial? 
Should recommendations be 
targeted for those at risk or be 
promulgated to the population 
at large? 
 
What may be the effects of early 
risk assessment (genetic, 
vascular, Alzheimer biomarkers) 
for dementia with respect to 
changes in work, family 
planning, behaviour of relatives, 
insurances? 
 
How long, extensive and 
rigorous can prevention trials 
be? 
How can health care providers 
be encouraged to advocate 




What is the benefit of early 
biomarker and/or genetic 
testing? Should the whole 
family be tested genetically? 
Whether or not to participate in 
prevention trials? 
Should a patient with a 
prodromal AD diagnosis without 
symptoms be treated as a 
patient by his/her proxies or 
not? 
Should relatives also be tested 
for risk factors? 
What is the added value of a 
pre-dementia diagnosis based 
on biomarkers? 
How to realize shared 
decision making on the 
preferred diagnostic route? 
Diagnostic 
disclosure 
What are the pros and cons of 
knowing versus not knowing 
the dementia diagnosis? 
Truth telling versus 
paternalistic protectiveness? 
Is there evidence that earlier 
diagnosis is beneficial? 
To tell or not to tell the 
diagnosis to relatives and other 
family members, especially in 
prodromal AD? 
How to balance   advantages 
and disadvantages of 
predementia AD disclosure, 
and minimize stigma of an 
early diagnosis? 
Management Whether or not to participate in 
drug trials? What to do 
independently, and what not 
(e.g. driving), and how to 
balance own versus societal 
interests?   
Whether or not to give 
informed consent by proxy? 
 
How to assess competency to 
consent? 
End of life care How and when to realize 
advance directives? Whether or 
not to have advance directives, 
and limit use of health services? 
How active to be at and of life 
planning? 
How to maximize autonomy at 
home and following 
institutionalization? 
When to stop active and 
supportive treatments? How to 
assist good quality of dying? 
How strictly to adhere to 
advance directives? When to 
stop active and supportive 
treatments? How to assist 










Figure 2. Prevalence of dementia by regions and major countries in the world (Source: Fratiglioni L and 
































Figure 3. Mean survival time and years of life lost due to dementia, cardiovascular disease (CVD), and 





Figure 4. Starting from the genetic and genomic discoveries, future research studies need to integrate 
data from all research areas in order to make intelligible interpretations of the functional 
consequences of the known AD associated genes and loci. These integrated analyses will lead the 





Figure 5. Pathways to Alzheimer disease. Epidemiological and genetic studies of AD individuals have 
categorized mechanism resulting in brain Aβ accumulation, neuronal tau hyperphosphorylation and 
synaptic deficits and leading to non-genetically inherited AD (sporadic AD). In Familial AD (FAD), AD 
begins with Aβ pathology. It is likely that different causing pathways would result in different disease 
subtypes, which should be treated differently. The identification of patient subtypes, with 





Figure 6. Neuropathology (Bielschowsky silver staining of frontal cortex of a patient with Alzheimer 
disease illustrating the presence of a neuritic amyloid plaque (arrow: consisting of aggregated 
extracellular Aβ-amyloid fibrils) and intraneuronal neurofibrillary tangles (arrow-heads: consisting of 






Figure 7. Schematic representation of a neuron showing the pathological changes that the three core 
cerebrospinal fluid (CSF) biomarkers for AD reflect: total tau (T-tau), axonal degeneration; 
phosphorylated tau (P-tau), neurofibrillary tangles; the 42 amino acid form of amyloid β (Aβ42), senile 

















Figure 8. Fusion images from co-registered PET and MRI scans. Deposition of fibrillar amyloid plaques 
measured with 11C-PIB PET in two patients with MCI and one patient AD. The fusion images are 
presented in transverse (left panel), coronal (middle panel) and sagittal (left panel) sections. The MCI 
patients were clinically longitudinally followed. The MCI patient with low PIB retention (PIB negative) 
remained as MCI while the MCI patient with high PIB retention (PIB +) converted to AD. Standard 
uptake values (SUV) in relation to cerebellum are expressed in colour scale.  
Abbreviations:  MCI =mild cognitive impairment; AD= Alzheimer´s disease; PIB=Pittsburgh Compound 








Figure 9. (From Kadir A et al.544) Upper row illustrates the positron emission tomography (PET) images 
of the regional glucose metabolism (umol/mi/100g) as measured by 18F-fluorodeoxyglucose (18F-
FDG)in an AD patients at age of  53(A),56 (B) and 58 (C) years. The red colour indicates high, yellow 
medium and blue low 18F-FDG uptake. Lower row illustrates the 3D brain rendering representation of 
statistical parameters mapping 18F-FDG- PET images. Areas of red depict areas in which the regional 
cerebral glucose metabolism was significantly decreased in the patients with Alzheimer´s disease 
during the progression of the disease compared with a group of healthy control subjects (P=0,001). 







Figure 10. (From Carter et al.545). High Astrocytosis measured by 11C-d-deprenyl and  PET in brain of  
MCI patients with high amyloid plaque load in brain measured with PIB (PIB positive)(prodromal AD 
according to Dubois et al 2014) compared to MCI with no amyloid plaques (PIB negative) and AD 
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